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Introduction 
1. GLUCOCORTICOIDS 
1.1 The adrenal glands and steroid hormone biosynthesis. 
The adrenal glands are paired organs localized superomedially to the kidneys. Each gland is 
composed of a cortex and a medulla which are embryologically and functionally distinct. The 
cells in the medulla are the principal site of adrenaline production in the body. In the adrenal 
cortex, the adrenal steroids are synthesized. The cortex is composed of three histologically 
different zones, the zona glomemlosa, which is the outermost portion, the zona fasciculata and 
the zona reticularis, which is the innermost part. The adrenal cortex produces aldosterone, 
which is the principal mineralocorticoid, the glucocorticoid cortisol and the adrenal androgens. 
All steroid honnones produced by the adrenal cortex, are derived from cholesterol. About 80% 
of the cholesterol used for steroid synthesis is provided by circulating plasma lipoproteins (1-
3). The cells of steroidogenic tissues can also synthesize cholesterol de novo from acetate or 
mobilize intracellular cholesteryl ester pools (1-3). A series of enzymatic steps convert 
cholesterol into steroids with glucocorticoid, mineralocorticoid or androgen activity. The 
biosynthetic pathways for adrenal steroidogenesis are shown in Figure I. 
17.20L! • 17.20t! • 
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FJgure 1. Diagram of the biosynthetic pathways and enzymes involved in the synthesis of glucocorticoids, 
mineraiooorticoids and adrenal androgens from cholesterol. 
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1.2. Regulation of glucocorticoid secretion; The Hypothalamo-Pituitary-Adrenal-axis. 
Glucocorticoid (Ge) secretion is regulated by hormonal interactions between the 
hypothalamus, the pituitary, and the adrenal glands by neural and other stimuli (4-6). In 
response to neural stimuli from the brain (e.g.stress), corticotropin releasing hornlOne (CRR) 
and arginine vasopressin (A VP) are released from the paraventricular nuclei of the 
hypothalamus into the hypophysial portal system (6). They are carried to the pituitary where 
the corticotropic cell is stimulated to synthesize and secrete corticotropin (ACTH) into the 
systemic blood (5). CRR is probably the most potent ACTH secretagogue (7). A VP is a weak 
stimulator of ACTH secretion, but it potentiates the action of CRH (8). ACTH is synthesized 
as part of a large precursor, the pro-opiomelanocortin (POMC) molecule (9), which is 
posttranslationally processed to form different biologically active peptides, among which are 
ACTH and ct- melanocyte stimulating hornlone (<l-MSH) (9). ACTH in its tum stimulates the 
adrenal cortex to systhesize cortisol. To increase the cortisol secretion, ACTH primary acts by 
increasing cortisol synthesis because intra-adrenal cortisol storage is minimal (10). Apart from 
stimulation of cortisol secretion, ACTH stimulates the synthesis and secretion of adrenal 
androgens and mineralocarticoids as well (II). Adrenal growth stimulation is another effect of 
ACTH. Longterm supraphysiological plasma ACTH concentrations result in adrenocortical 
hypertrophy and hyperplasia (12). 
On the other hand, GCs have an inhibitory effect on hormone synthesis and secretion at both 
the hypothalamic and the pituitary level, which completes a negative feedback loop. In the 
corticotropic cell, GCs inhibit both POMC gene transcription and ACTH secretion (9). To a 
lesser extent, GCs also decrease CRR and A VP mRNA levels in the hypothalamic 
paraventricular nuclei (13-15). Finally, GCs block the stimulatory effect of CRR on POMC 
gene transcription (9). A simplified model ofthe HP A axis is shown in Figure 2. 
The activity of the HP A axis is under the influence of an endogenous pacemaker that generates 
a circadian rhythm. The timing of the circadian rhythm is synchronized with the solar day by 
dark-light shifts, which normally are a reflection of the habitual sleep-wake pattern (16-18). 
Plasma ACTH and cortisol concentrations are the highest at about the time of waking in the 
morning) are low in the late afternoon and in the evening and reach a nadir about an hour or 
two after sleep begins. 
14 
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In addition, severe illness, infections, trauma, anesthesia, and surgery but also psychological 
stress are accompanied by activation of the HP A axis, as demonstrated by increased serum 
ACTH and cortisol concentrations (4, 19-26). This activation is an essential component of the 
general adaptation to stress and contributes to the maintenance of homeostasis (4, 26). 
circadian rhythm stress 
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Figure 2. A simplified model ortbe BPA-axis: The activity of the axis is lmder the influence of a circadian rbythm 
and different fomls of stress. CRH and A VP arc secreted into the hypophysial portal system thus increasing the 
ACTH concentration. In reaction, the adrenal glands increase the secrelion of cortisol along with the other adrenal 
steroids with androgen and mineralocorticoid activity. Cortisol has a negative feedback action at both the 
hyotilalamic and pituitary level to complete a negative feedback loop. III tbis way, a perfect balance between cortisol 
requirement and secretion can be achieved. 
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1.3. Effect. of glucocorticoid. 
GCs serve a variety of important functions in cells and tissues including mediation of the stress 
response, induction of gluconeogenesis in the liver, regulation of fat metabolism, and effects on 
the immune- and central nervous systems as well as on the development and function of 
numerous organs (20). FurthemlOre, cortisol has a vital supportive role in the maintenance of 
vascular tone, endothelial integrity, vascular permeability and the distribution of total body 
water within the vascular compartment in cases of severe illness or trauma (26). In the next 
section, several functions of GCs will be discussed in more detail. 
Effects all gillcose alld lipid metabolism 
The overall effect of GCs on glucose metabolism is to reduce glucose utilisation and to 
increase glucose production (27-29) (Figure 3). GCs inhibit glycogenolysis in order to maintain 
hepatic glycogen stores by activating the enzyme glycogen synthetase and inactivating the 
glycogen mobilising enzyme glycogen phosphorylase (27,28). Furthermore, GCs increase 
hepatic glucose production (gluconeogenesis) by increasing substrate availability (lactate and 
pyruvate) and stimulating the release ofglucogenic amino acids from peripheral tissues such as 
skeletal muscle (29). GCs also directly activate hepatic gluconeogenetic enzymes like glucose-
6-phosphatase and phosphoenol pyruvate carboxy kinase (29).Other gluconeogenic hormones 
such as glucagon and adrenaline are ineffective without the permissive effect of GCs (29,30). 
Finally, GCs inhibit glucose uptake and utilisation by peripheral tissues, partly by a direct 
inhibition of glucose transport into the cell, causing insulin resistance (31,32). 
GCs acutely activate lipolysis in adipose tissue, thus providing free fatty acids as energy supply 
for gluconeogenesis (33,34). GCs also have chronic effects on lipid metabolism. After 
longterm GC excess, there is a striking redistribution of fat, with marked depositions of 
adipose tissue on the abdomen and the trunck (35) (see further section 3.2.). 
16 
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Figure 3, GC effect on hepatic glucose metabolism and peripheral tissue metabolism of protein and fat. Stimulation 
by GCs is indicated by a plus sign. inhibition by a minus sign. 
Effec/s all illjlamma/ory processes alld illllllllll%gica/ jllllc/ioll. 
Although GCs are well known for their anti-inflammatory and immunosuppressive activities, 
many of these probably reflect pharmacological effects (4, 25). Indeed, many of the effects of 
GCs have been evaluated under supraphysiological concentrations of these steroids. Despite 
the importance of GC therapy in modern medicine, the physiological effect of endogenous GCs 
on the immune system is poorly understood. TillS might be a consequence of the fact that GC 
therapy was extensively used long before the mechanisms that regulate glucocorticoid receptor 
activation and gene regulation (see section 2.1) were determined (36). 
Inhibition of chemotaxis and bactericidal activity in neutroplllis and monocytes, lymphopenia, 
decreased macrophage function and disturbed complement function are well known effects of 
GC administration (25). On the other hand, several circulating mediators of inflammation have 
17 
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a major role in activating the HPA-axis (4).Three cytokines, tumor necrosis factor a (TNF-a), 
interleukin -I (IL-I) and interleukin-6 (IL-6), account for most of the HP A-axis stimulating 
activity in plasma during inflammation. TNF-a appears first, followed by secretion of IL-I and 
IL-6 (37-39). TNF-a, IL-I and IL-6 stimulate the HPA-axis independently, but in combination, 
their effects are synergistical. All three cytokines stimulate their own secretion (4). Most of the 
GC effects on the immune system are thought to be mediated via interference with 
transcription of the genes encoding for these and other cytokines. The inhibition of IL-I and 
IL-6 synthesis in monocytes and macrophages (40) but also the inhibition of IL-2 synthesis in 
T-Iymphocytes (41,42) are major sites ofGC action. These paradoxial effect ofGCs on the 
immune system (the system is challenged, the defence is suppressed) have been suggested to be 
necessary to protect the orgarusm against overreaction of the immune system (4,26). 
Effects all bOlle mid milleralmetabolism. 
One of the most important side effects in patients treated with GCs is the appearance of 
osteopo·rosis. GCs enhance bone resorption and decrease bone formation. Consequently they 
decrease bone mass and increase the risk offtactures (43). 
The increased bone resorption is the result of direct effects of GCs on the skeleton, probably 
through increased osteoclast function, in combination with a decrease of intestinal calcium 
resorption and an increased urinary calcium excretion (43). Parathyroidectomy prevents the 
excessive bone resorption which is associated with GC, suggesting that ill vivo PTH might 
enhance GC-induced bone resorption. Although increased PTH serum levels have been 
observed during GC therapy, other investigators found them to be in the normal range (45), 
suggesting a transient serum PTH increase or an increment of PTH activity as other possible 
mechanisms for the enhancement of bone resorption during steroid therapy (43). 
Finally, the decreased bone formation is mostly the result of direct inhibitory effects of GCs on 
cells of the osteoblastic lineage (43). 
Developmental effects 
Supraphysiological concentrations of exogenous or endogenous GCs inlubit linear skeletal 
growth in children (46, 47). The mechanism of this effect ofGCs is unknown: growth hormone 
18 
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levels are usually within the normal range and IGF-I concentrations are not decreased (48). 
Growth arrest is probably due to indirect effects of GCs on bone and cOl1llective tissue (49-
51). 
GCs stimulate the differentiation of many cell types. In the lung, GCs induce the production of 
surfactant by pneumocytes type II. This normal developmental process is accelerated by 
pharmacological amounts of exogenous GCs (50). 
19 
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2. SYSTEMIC GLUCOCORTICOID SENSITIVITY 
There is a considerable variability in the sensitivity to GCs within the normal population. As is 
true for the anti-inflammatory actions of GCs, the majority of our knowledge about variability 
in GC sensitivity in the normal population has been collected by observations in patients, who 
received phannacological amounts ofGCs in order to treat non-endocrine diseases, Exogenous 
GCs playa major role in the acute and chronic therapy of a number of immune diseases such as 
asthma and rheumatoid arthritis, and contribute considerably to the prevention of allograft 
rejection after organ transplantation (53). Nevertheless, some disadvantages of GC therapy 
have reduced the enthousiasm to use these agents. The first disadvantage is the unpredictable 
occurrance of side effects during (chronic) therapy (54-56). Although plasma concentrations 
can be measured, it is currently impossible to define a safe GC dose for a given patient which 
provides a maximal beneficial effect with as little side effects as possible. Another disadvantage 
is the unpredictable efficacy of GC therapy in chronic immune disease. There is clinical and 
laboratory evidence that patients can be divided into steroid sensitive and steroid resistant 
groups (56). These differences have been documented in the treatment of asthma and 
rheumatoid artritis as well as in renal grafts recipients, and can be observed every day in 
clinical settings. Little is known about the role of the structure and function of the 
glucocorticoid receptor in these circumstances. On the other hand, also little is known about 
the "iisslble role for GC catabolism. The processes that regulate the physiological actions of 
steroids in target tissues are not completely known (57, 58). But catabolism of the biological 
active hormone to inactive forms in the liver is one of the ways this can be achieved. A number 
offactors like hormonal factors (59), intercurrent disease states (60), obesity (61) and several 
drugs(62, 63), however, may alter the usual hepatic metabolism of cortisol and other GCs. It is 
therefore conceivable that differences in GC catabolism might play a role in the different 
reactions of patients to GC therapy. Nevertheless, all effects of GCs, endogenous or 
exogenously administered, are mediated via the glucocorticoid receptor. Therefore, it is 
anticipated that alterations in GR structure or function might at least in part account for 
differences in GC sensitivity. The next section will discuss the structure and function of the 
GR, followed by several molecular determinants which could influence GC sensitivity. 
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2.1. The Glucocorticoid receptor 
GCs exert their action on target cells via the glucocorticoid receptor (GR). The GR is a 
member of the intracellular steroid hormone receptor superfamily. Other members of this 
.family include the receptors for mineralocorticoids, sex steroids, retinoic acid, vitamin D and 
thyroid hormone (65). These cytoplasmic receptors have a common structure which consists of 
a characteristic three domain structure: A poorly conserved aminotenninal region contains the 
transactivation domains responsible for gene activation. In the central part, two highly 
conserved "zinc-fingers" constitute the DNA-binding domain (66-69). This central region also 
participates in receptor dimerization (70), nuclear translocation and transactivation (71, 72) 
(see below). Finally, the relatively well conserved carboxy terminal domain is important for 
hormone binding. It contains sequences for heat shock protein binding (73-75), nuclear 
translocation (76), dimerisation (77) and transactivation (78-81). For a schematic structure of 
the GR protein see Figure 4 (69). 
Human GR gene 
5' _q':l_~' ,,;::,-;O-;f~'<':',:--"~3i_f:r _l6:-~La;'_(l''--''$-';-. .r:'- ---.c-l)~ci-""'-' : -'-;-':'tnr~ -.,....3.!. 
DBD 
HBD 
TAD. • • • 
• 
• 
. . 
F"'T,- ," __ ",,: ._"C _'_ ,-•. ~--,,_"O--:t~-,,: 
OR fl pi"otetn (742 amino acIds) 
Figure 4. Schematic structure of the human GR-gene. mRNA and receptor protein. Exon 2 codes for the 
transactivation domain (TAD), exons 3 and 4 for the DNA·binding domain (DBD) and exollS 5·9 for the hormone 
binding domain (HBD), 
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The stmcture of the GR gene, located on chromosome 5, consists of 10 different exons, one of 
which (exon 2) codes for the transactivation domain, two exons (3 and 4) code for the DNA 
binding domain and four exons (5-9) code for the honnone binding domain (Figure 4). The GR 
eDNA sequence predicts two fonns of the receptor protein, a more abundant 777 antino acid" 
form and a 742 antino acid P form (Figure 4, ) (69). 
The inactivated (unliganded) receptor is present in the cytosol as a multiprotein complex with a 
molecular mass of about 320 kDa (82). The activated (hormone-bound) receptor has a 
molecular mass of 90 kDa, wltich means that GR activation involves dissociation of a large 
multiprotein complex. Using antibodies against the GR it was found that the 320 kDa complex 
contained only one GR molecule (83). The current understanding is that the complex consists 
of the receptor, two molecules of heat shock protein (hsp) 90, one molecule each of hsp 70 
and hsp 56, and an inmmnophillin of the FK 506 and rapamycin binding class (69). Binding of 
hsp90 with the GR is secured by sites in the GR steroid binding domain, and tltis special 
interaction seems to facilitate the ligand binding to the receptor protein (84). 
The first step in the cascade leading to induction of gene expression by GCs is binding of the 
hormone to the receptor which is present in the cytoplasm of the target cell (Figure 6) (69). 
Since the steroid is a lipophilic substance, it is thought to enter the cell by passive diffusion 
(85). After binding of the GC to the GR-complex, the complex dissociates, hsp90 is released 
and the domains responsible for nuclear localisation, DNA binding and transactivation are 
unmasked (73). Furthermore, the partially phosphorylated receptor protein becomes 
hyperphosphorylated (86-88). The activated GR molecules form homodimers as a result of the 
interaction of dimerization sequences present in the ligand and DNA binding domains (89). 
After dimerization, the GR molecules translocate to the nucleus. 
Inside the nucleus the activated GR-dimers can act in two ways. The first way represents the 
classic model for GR action (69). The receptor homodimer binds to short, palindromically 
arranged DNA sequences in the promoter region ofthe GC responsive genes, which are called 
glucocorticoid responsive elements (GREs). The receptor homodimers bind to DNA using 
their "zinc fingers" (64). These stmctures of the DNA binding domains form a finger-like loop 
stmcture of 12 antino-acids anchored at the base by a zinc ion chelated by two pairs of cysteine 
residues. These finger-like stmctures presumably interact with the coils of the DNA double 
22 
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helix (64), When bound to the GRE, the receptor homodimer can interact with the basic 
transcription cascade in several ways. One possibility is a direct interaction via contact between 
the GR transactivation domains and transcription factors (84), Furthermore, binding of the GR 
homodimer to the GRE can induce a chromatin structure rearrangement allowing other 
transcription factors to bind to the previously inaccessable DNA (90), In some promoters, the 
POMe promoter being a prototype example, binding of the activated GR to the GRE induces 
transcription inhibition rather than activation, These GRE's therefore are called negative GREs 
(nGREs) (69), 
The second way in which activated GR might mediate its function is through direct protein-
protein interaction, Many effects of GCs are achieved via inhibition rather than activation, TillS 
is especially apparent in the anti-inflammatory actions of GCs willch involve negative 
transcription regulation of genes, coding for different kinds of inununoregulatory cytokines 
(69), These genes do not contain a nGRE in their promoter regions, It is well known that these 
genes are positively regulated by activating protein I (AP-I), which is a transcription factor 
that consists of dimers of the Fos and Jun protein family (69, 91, 92), Within responsive 
promoters, AP-I binds to specific sequences (93), It is postulated that GR interacts directly 
with AP-I, thus preventing its activating action, Although AP-I is the transcription factor that 
has been studied most extensively, probably many other transcription factors are regulated by 
the activated GR in this way of direct protein-protein interaction, A similar pattern of GR 
mediated transrepression has been reported for the transcription factor nuclear factor KB (NF-
KB), NF-KB was first identified as a regulator ofthe expression of the kappa light chain gene in 
murine B lymphocytes, but has subsequently been found in many different cells (94), The 
activated form of NF-KB is a heterodimer which consists of two proteins, a p65 (also called 
relA) subunit and a p50 subunit. The GR mediated transrepression of NF-KB is caused by 
physical interaction with the p65 subunit of NF-KB , In addition, GR suppresses NF-KB activity 
by induction of the IKB inhibitory protein, willch traps NF-KB in inactive cytoplasmic 
complexes (94), In Figure 5 the processes involved in the signal transduction of Gcs from the 
outside of the cell to the target genes are schematically shown, 
23 
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GRE AP-1 site 
Figure 5. Simplified model of OR-mediated transcriptional modulation. Ligand binding causes dissociation of the 
GR-hsp mulfiprotein ooDlplex, dimerizaliou orlbe OR and nuclear translocation. The activated OR-OR complex can 
either bind to OREs (left side) or inhibit transcription via direct protein-protein interaction (left side). 
2.2. Molecular determinants of glucocorticoid sensitivity 
All GC effects are mediated by the GR. Therefore, all different steps in the cascade of events 
from the unliganded silent receptor to the transcription activation or repression of GC 
responsive genes may be determinants of tissue sensitivity to GCs. Moreover. also post-
receptor effects may playa role in the eventual sensitivity to GCs. The next section describes in 
short the most obvious molecular detennin.nts of GC sensitivity. 
GR expression level 
It is known th.t the number of intracellular GRs per cell is closely correlated with the eventual 
biological GC response by that cell (95). A striking example of this is described in a family with 
a point mutation in the GR gene, leading to the expression of onJy one GR allele (96). This 
f.mily showed signs and symptoms of the syndrome of glucocorticoid resistance (see below), 
24 
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as they were not able to adequately compensate for the lack of hormone binding capacity. On 
the other hand, there is no consensus in the literature about the question whether in man there 
is a receptor up or down regulation under the influence ofGCs. Many studies (97-100) show a 
definite receptor down regulation in reaction to high concentrations of GCs in vitro. On the 
other hand it is clear that patients from the above mentioned family (96) showed only 50 % of 
the normal receptor number per cell. Apparently they were not able to compensate for the lack 
of GR expression with an increased transcription from the intact allele of the GR gene. 
Moreover, the compensation was achieved by re-setting the HP A-axis at a higher set point 
rather than up-regulation the receptor number. For a more detailed description ofthis topic see 
section 3.3 of this chapter 
Hormone hind/ng affinity 
The potency of the GR also closely correlates with the hormone binding affinity. It has been 
well established that point mutations in the hormone binding domain of the GR gene give rise 
to the clinical syndrome of cortisol resistance (see below) (101-102). 
One of the important functions of the GR-hsp complex is to keep the GR in a "hormone 
friendly" conformation. As a result, low hsp expression levels or mutated hsp can negatively 
influence GR ligand binding affinity (103-\04). On the other hand high levels of hsp were 
found in target tissues that are very sensitive to GCs (105). 
Ligand induced GR cOliformafion change, dissociation ./rom hsp, phosphorylation and 
nuclear transformatio1J. 
Possibly the most important consequence of GC binding to the silent GR complex is a GR 
conformation change which causes the dissociation from hsp (116). The exact mechanism of 
this event is not clear yet. Shortly after or possibly at the time ofGR dissociation from hsp, the 
receptor becomes hyperphosphorylated. It is well known whether phosphorylation influences 
GR function. It is obvious that these steps in GR activation are influenced by many factors, 
which all can cause differences in GR sensitivity. The same is true for the factors and 
mechanisms leading to translocation of the activated GR homodimer to the nucleus. 
25 
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DNA billdillg 
Once within the nucleus, the activated GR binds to the DNA at specific GREs. It is now 
known that several proteins assist the GR in DNA binding (\07, \08), and that the ability of 
the GR to bind to DNA can be negatively regulated as well. 
It might be predicted that mutations, deletions or insertions in the DNA binding domain of the 
GR receptor gene can cause an impaired binding ability of the GR to DNA. However, up till 
now no such alterations in the human GR gene have been described. Differences in GC 
sensitivity could also be explained by alterations in the GREs in GC responsive cells, but again, 
this has never been described. 
lllleraclioll with other III1c1ear faclors 
The final interaction with the transcriptional machinery of the GR responsive cell or interaction 
with other transcriptional activators or repressors (\09) is the last step in GR mediated effects. 
Many different factors like the exact arrangement of the promoter, the arrangement of 
chromatin and the presence of other unknown factors may influence the interaction between 
the GR and nuclear proteins. It is not known, however, how various known mutations in the 
GR gene affect the interaction with transcription factors such as AP-l and NF-KB. It has been 
suggested that cytokines affect the transcription of proinflammatory genes through interaction 
with cell surface receptors leading to increased transcription of AP-l and NF-KB. 
26 
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2.3. Generalized Glucocorticoid Resistance. 
The differences in GC sensitivity in the normal population are probably relatively minor as they 
become only apparent when supraphysiological doses of GC are administered as a therapy for 
non-endocrinological diseases. An extreme example of decreased sensitivity to GCs is 
hereditary (generalized) cortisol resistance (CR) in winch the relative insensitivity of target 
tissues to the effects of GCs leads to clinical signs and symptoms. CR was described for the 
first time in 1976 by Vingerhoeds et al (110), who reported a patient with hypercortisolism 
without signs and symptoms of Cushing's disease. 
The secretion of cortisol by the adrenal gland is regulated by the components of the HP A-axis 
(4) (see section 1.2.). Of principal importance in this system is the ability of GCs to exert a 
negative feedback action at both the hypothalamic and the pituitary level, in order to keep a 
perfect balance between cortisol requirement and cortisol secretion. In cases of generalized 
CR, patients present with increased cortisol concentrations compared to the normal 
population. Keeping the structure of the HP A axis in mind, it is clear that in patients with 
generalized CR, the negative GC feedback on both CRH and ACTH secretion is reduced as a 
consequence of diminished sensitivity to GC (Ill, 112). As a result, the HPA axis is set at a 
higher level: CRH and ACTH secretion increase resulting in higher serum cortisol 
concentrations. In this way, the body tries to achieve a balance between cortisol requirement 
and cortisol secretion (II). The increased cortisol concentrations appear to compensate 
adequately for the reduced sensitivity. It is therefore clear that patients suffering from CR do 
not show any signs or symptoms of cortisol excess, because they simply need these increased 
serum cortisol concentrations. Not only at the hypothalantic and the pituitary level, but also at 
the peripheral target tissue level the sensitivity to GCs is diminished. The clinical symptoms 
seen in patients with CR are therefore not due to GC excess, but secondary to the activation of 
the HP A axis, which results in an increased production of ACTH, resulting in the stimulation 
of ntineralocorticoid and androgen secretion. So in case of CR, the increased ACTH secretion 
will lead to a secondary adrenal overproduction of hormones with mineralocorticoid activity, 
such as deoxycorticosterone, and with androgen activity such as androstenedione, 
dehydroepiandrosterone and dehydroepiandrosterone sulfate (11,111,112). The 
pathophysiologic mechanisms of CR are summarized in Figure 6. 
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Figure 6, Schematic model for the pathophysiological mecbanims in cortisol resistance. As a rcsull of generalized 
decreased sensitivity to GCs, the HPA-axis is sel at a higher level, resulling in adrenal overproduction of cortisol, 
androgens and mincralocortisoids. The increased GC level has a beneficial effect in patients because it compensates 
for Ihe GC resistance; Ihe overproduction of androgens and mineralQC(lrticoids leads to the signs and symptoms of 
the clinical syndrome of CR. 
2. 3.1.Clillica/ presellialioll. 
CR is a rare disease, which has been described in only about 30 patients and (a)symptomatic 
family members since the first description in 1976 by Vingerhoeds et al (110-121). The clinical 
presentation of the patients is variable. A summary of the different clinical pictures and 
references is given in Table I. Generally, symptoms of GC deficiency were not seen in the 
patients, indicating that they all could compensate adequately for their GC insensitivity by 
activation of the HP A axis. Moreover, most of the "patients" evaluated in the context of 
family studies (i.e. affected family members) were asymptomatic despite increased peripheral 
GC levels. The only complaint of members of one particular affected family (116), however, 
was chronic fatigue, wltich ntight indicate that there was an insufficient compensation by 
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increased GC secretion in certain target tissues, like for example the central nervous system. 
As a result of the increased secretion of steroids with mineralocorticoid activity, patients may 
present with hypertension or even hypokalemic alkalosis (110, 112). In women with CR, the 
secondary overproduction of adrenal androgens was reported to result in acne, hirsutism, male 
pattern baldness (geheimratsecken), and manifestations affecting the reproductive system like 
oligomenorrhoea and infertility (Ill, 112). Malchoff and colleagues described a seriously 
affected boy, who presented with precocious puberty resulting trom adrenal androgen 
overproduction (120). 
As mentioned before, the clinical presentation of CR is diverse. The manifestations described 
were·not present in all symptomatic patients, several biochemically diagnosed patients were 
asymptomatic, and even within families, clinical presentation varied. A possible explanation 
might be that there are different degrees of resistance to cortisol among patients, resulting in 
different degrees of overproduction of mineralocorticoid and androgens. Moreover, the 
sensitivity of target tissues to mineralocorticoids and androgens might differ among patients, 
resulting in variable responses between individuals to the same concentrations of steroids (II). 
2.3.2.Diagnoslic evalualion 
Biochemically, the disease is characterized by increased concentrations of plasma cortisol and 
increased 24 hour urinary tree cortisol excretion, a normal circadian pattern of ACTH and 
cortisol secretion and resistance to adrenal suppression by dexamethasone (DEX), without 
signs or symptoms of Cushing's syndrome. In the 1 mg overnight DEX suppression test 
(DST), the patient is given one mg of DE X at 11.00 pm. DEX, which is a powerful synthetic 
corticosteroid, suppresses endogenous cortisol secretion almost completely by negative 
feedback action on the HPA axis. In cases ofCR, the negative feedback of DE X is diminished, 
so the endogenous cortisol concentration remains high compared to that in controls. It is 
known that in cases of Cushing's syndrome, resistance to adrenal suppression by DEX exists 
as well (122). Therefore, clinical evaluation for signs and symptoms of Cushing's syndrome is 
of crucial diagnostic importance once hypercortisolism has been biochemically established. 
Nevertheless, in most patients with hypercortisolaemia due to Cuslting's syndrome, the 
circadian pattern of cortisol secretion is lost, which therefore is another important differential 
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diagnostic parameter. Because the effects of GCs are exerted by the OR, the next step in the 
diagnostic evaluation of patients with hypercortisolism without Cushing's syndrome is the 
evaluation of the OR in these patients. As described above, ligand binding capacity and affinity 
are important determinants of GC sensitivity. OR characteristics can be adequately determined 
in whole mononuclear leukocytes as described by Lamberts et al (112). Furthermore, ill vitro 
bioassays determining the GC induced inhibition of ['H)-thymidine incorporation in activated 
mononuclear leukocytes give an impression of OC sensitivity (112). Table 1 sununarizes the 
OR characteristics and outcomes of bioassays il.l all patients with clinical and biochemical CR 
reported up till now. 
Apart from generalized (hereditary) CR, in which clinical symptoms are related to the 
secondary overproduction ofmineralocorticoids and androgens, Norbiato et al (123) described 
a number of aquired immuno deficiency syndrome (AIDS) patients, who presented with signs 
of hypocortisolism despite elevated cortisol serum concentrations. It appeared that the OR in 
these patients had a lowered affinity for cortisol, whereas the number of receptors per cell was 
elevated. Despite this increment in receptor number, there seemed to be insufficient 
compensation for the diminished ligand affinity with the clinical picture of hypocortisolism as a 
result. These cases probably represent a form of acquired, generalised CR. Another example of 
CR without the classical stigmata was described by Sher, who reported two patients with 
severe asthma which did not respond to steroid therapy (124). The patients were asymptomatic 
with respect to the classical syndrome of CR, but seemed to be resistant to GC therapy. On a 
biochemical level, it became apparent that these patients had a decreased receptor number per 
cell. This probably generalized CR, presenting as steroid resistant astiuna, should be separated 
from a form of steroid resistant asthma which is induced by local cytokine production (see 
section 3.1) 
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Table 1. Clinical presentation, receptor alterations and molecular characterization in generalized CR 
Authors year patients clinical features receptor alterations molecular characterization 
Vingerhoeds 1976 father and son hypertension. hypokalemic alkalosis, asymptomatic not determined D641V 
Cbrousos 1982 ten affected family members asymptomatic decreased affinity 
!ida 1985 mother and son mild hypertension decreased number 
Br6nnegard 1986 mother and son fatigue thermolability 
Lamberts 1986 one sister, three brothers hyperandrogenism, asymptomatic decreased number 4 base pair deletion in intron 
flanking exon 6 
Nawata 1987 woman asymptomatic decreased affinity. 
decreased DNA binding 
Jaursch-Hancke 1989 woman hyperandrogenism decreased number 
Vercei 1989 woman mild hypertension. hyperandrogenism not determined 
Malchoff 1990 boy isosex1l3! precocity decreased affinity V7291 
Lamberts 1992 two men. three women. unrelated mild hypertension. hyperandrogenism decreased numba\ 
decreased affinity 
Werner 1992 six women,. unrelated fatigue, hyperandrogenism.. obesity decreased number. 
decreased affinity. 
thermolability 
Norbiato 1992 nine mY patients hypocortisoJism decreased affinity. 
increased number 
Sher 1994 two asthma patients steroid resistant asthma decreased number 
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2. 3. 3.MoJecliJar characterizatioll 
As early as 1980, it was suggested that CR was the result of a defect in the intracellular 
cascade of events from the entrance of GCs into the cell to their final effect on cellular 
function. Even before the structure of the GR was known, studies performed in patients with 
CR showed alterations in receptor number or ligand binding affinity of the GR. Following 
cloning of the GR gene and subsequent studies of the genomic structure (125), PCR 
amplification and sequencing of genomic DNA have been possible. This strategy has revealed 
point-mutations and/or microdeletions in the GR gene in patients with familial CR (96, 101, 
102). Circulating peripheral mononuclear leukocytes from affected members from a family 
previously described by Lamberts et al (Ill), had only 50 % of the normal number of 
receptors. The proband of this kindred, a 26 years old woman, presented with hirsutism, male 
pattern baldness and menstrual irregularities. She had no hypertension and nonnal serum 
potassium concentrations. It appeared that the patient had marked elevated levels of adrenal 
androgens, explaining the clinical symptoms. Furthermore, she had greatly elevated plasma 
cortisol levels, which were insufficiently suppressed in a I mg overnight DEX suppression test. 
The father and two of the brothers of the patient had elevated basal plasma cortisol levels, 
which were insufficiently suppressed by I mg overnight DEX suppression, but they were 
clinically unaffected with normal blood pressllre and normal serum potassium levels. In 
contrast to the proband of this family, the father and affected brothers had normal androgen 
concentration. Tllis was to be expected because of the much higher gonadal androgen 
production in males compared to females. Therefore, the overproduction of adrenal androgens 
gives rise to signs of hyperandrogenism in females only, and is mostly asymptomatic in males. 
Karl and colleagues (96) identified a 4 base pair deletion at the 3' boundary of exon and intron 
6. Mutations or deletions involving the first two nucleotides of an intron disrupt normal 
splicing (II), generating aberrant mRNA variants. These variants are probably more 
susceptible to nuclease digestion, which precludes the production of mature mRNA, and may 
therefore exclude the expression of the encoded protein. Tllis could explain why the receptor 
number on peripheral mononuclear leukocytes was reduced by 50 % in the affected members 
of this family.Vingerhoeds et al (110) described CR in 1976 for the first time in a father (and 
an asymptomatic son) who presented with severe hypertension and hypokalenlia. In the 
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biochemical analysis, it appeared that the ligand affinity of OR in peripheral mononuclear 
leukocytes of this patient was decreased by a factor three. Molecular analysis revealed a 
homozygous (father) and heterozygous (son) aspartic acid to valine change at codon 641 of 
the GR. An amino acid change like this in the hormone binding domain of the OR might 
explain the lowered ligand affinity of the receptor in these patients. Finally, Malchoff described 
a young boy who presented with isosexual precocity, caused by increased adrenal androgen 
production associated with CR (102, 120). Biochemical analysis showed a two fold higher 
dissociation constant for the OR in peripheral mononuclear leukocytes of the boy. Molecular 
analysis of the OR gene revealed a homozygous valine to isoleucine change at codon 729 of 
the GR protein. In Table 1 and Figure 7, these three different previously described molecular 
abnormalities are summarised. The molecular basis of the only patient ever described with 
cortisol hypersensitivity (126) has not been elucidated yet. 
GR GENE 
.6.4BP 
GR PROTEIN 
D641V vn91 
t::::::::::::::::::::][~[I:r::::::'~::::'~'j" NH2 -j OBO HBD J-COOH 
Figure 7. Schematic model of GR gene mutations in patients with heriditary OR. DBD: DNA binding domain. 
HBD: honnone binding domain. 
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3. TISSUE SPECIFIC GLUCOCORTICOID SENSITIVITY 
3.1 Transient and /01' acquired glucocorticoid resistance 
In most cases, tissue specific CR becomes clinically apparent, because it is not compensated for 
by increased cortisol concentrations. This type of resistance is thought to occur in 
inflammatory diseases such as asthma or rheumatoid arthritis, because GCs cannot exert their 
physiological antiinflammatory actions. CR in asthma and rheumatoid arthritis has been 
reported to be accompanied by a reduction in the number of GRs in circulating leukocytes 
(127), and lor a reversible decrease in the ligand affinity of GR in T-Iymphocytes (124), 
respectively. GCs are known to be powerfull suppressors of the activity of the immune system. 
Inhibition of chemotaxis and bactericidal activity in neutrophils and monocytes, lymphopenia, 
decreased macrophage function and disturbed complement function are well known effects of 
GC administration (25). Most effects of GCs on the immune system are thought to be 
mediated via inhibition of transcription of various cytokine genes, particularly those coding for 
IL-I and IL-6 in macrophages (128) and IL-2 in lymphocytes (41, 42). However, during 
inflammation, higher concentrations of cytokines, especially IL-2, antagonize the suppressive 
effects of GCs in a dose dependent manner, thus counteracting these transcriptional effects 
(129). The balance between GC actions and the production of interleukins in mitogen-
stimulated immune cells is in favor of the actions of GCs in most cases, resulting in suppression 
of the activity of the immune cells. In contrast, the results of a number of studies suggest that 
in cases of rheumatoid arthritis, asthma and sepsis, high local concentrations of cytokines in 
fact induce a localized CR at the site of inflammation, which camlOt be overcome by excess 
exogenous GCs (124, 129-131). This reversible cytokine-induced form of CR should be 
differentiated from the situation in the patients with steroid resistant asthma described by Sher 
et al (124), which was due to an irreversible (probably generalized) reduction in GR number 
(see also Table \.). 
GCs are, in combination with chemotherapy, widely used in the therapeutic regimen of 
hematologic malignancies, because of their apoptotic effect on lymphoid cells. One of the best 
known examples of acquired CR is seen in neoplastic cells of human hematologic malignancies, 
which fail to respond to these apoptotic effects. The sensitivity of the malignant cells to the 
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apoptotic effect of GCs plays an important role in the ultimate prognosis of patients with acute 
leukemia or malignant lymphomas. GR alterations as wei as post-receptor abnormalities have 
been described as possible explanations for the CR seen in these cells (132-134). 
As described before, in some patients with AIDS, GRs in peripheral leukocytes show a marked 
decrease in their affinity for cortisol (123). These patients are clinically characterized by 
features that mimic an Addisonian picture in combination with increased serum and urinary 
cortisol concentrations. So in some cases of AIDS, a form of aquired CR might be the cause of 
this clinical picture. The molecular basis of the decreased ligand affinity of the GR has not been 
elucidated yet. 
Finally, ectopic tumors secreting ACTH and pituitary corticotropinomas form a very 
interesting group of tumors demonstrating localized CR. The following section will focus on 
the clinical, biochemical and molecular biological aspects of Cushing's disease and ACTH 
producing tumors. 
3.2 Cushing's Disease 
In 1912 Harvey Cushing described a woman with a syndrome of painfull obesity, 
hypertrichosis and amenorrhoea. Twenty years later, he brought together a series of 12 patients 
with a similar "polyglandular syndrome". Six of these patients had proven pituitary adenomas, 
and Cushing suggested the pituitary dependence of the disease that now bears his name (135). 
The clinical manifestations of chronic cortisol excess irrespective of its cause, are referred to as 
Cushing's syndrome (135). In classical cases, the clinical features of Cushing's syndrome are 
the triad of hypertension, obesity and diabetes mellitus (122). Weight gain is the most common 
presenting feature, and classically, the patient develops a fat redistribution to the trunk and 
abdominal, supraclavicular, and cervicodorsal (buffalo hump) regions, with a round "moon-
face". Over time, the extremities become thinner, and the thigh and shoulder musculature 
becomes weaker. The skin gets thin and easily bruised, and poor wound healing may occur. 
Thinning of facial skin with increased visibility of the underlying blood vessels in combination 
with an increased hemoglobin concentration contribute to the red or plethoric facial 
appearance often seen in patients suffering from tlus disease. More than half of the patients 
develop wide, red striae, which should be distinguished from the milder, paler "stretch marks" 
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seen in obese people and pregnant women. Increased adrenal androgen production may lead to 
acne and folliculitis in both sexes, and to hirsutism and menstrual irregularities in women (122). 
Administration of exogenous GCs is the most frequent cause of Cushing's syndrome. 
Spontaneous Cushing's syndrome due to the overproduction of endogenous cortisol occurs in 
three distinct pathogenetic states: 1. Excessive pituitary ACTH secretion (Cushing's disease), 
2. Autonomous cortisol production by adrenal tumors. 3. Ectopic ACTH production by a 
variety of extra-hypophyseal tumors. Cushing's disease accounts for about two thirds of all 
cases of endogenous hypercortisolism (135). 
Cushing's disease is characterized by hypercortisolism caused by semiautonomous ACTH 
secretion by a pituitary corticotropinoma, in most cases a microadenoma.Corticotropinomas 
are characterized by a decreased sensitivity of the tumor cells to the negative feedback action 
of cortisol on ACTH secretion (136, 137), which is mediated by the GR. As described in 
section 2.1, hormone-bound GRs regulate the expression of glucocorticoid responsive genes 
by activating or repressing the transcription of glucocorticoid regulated genes after binding to 
"positive" or "negative" glucocorticoid response elements (GREs or nGREs) (138). The 
POMC gene has been shown to contain a nGRE. With respect to the diminished sensitivity to 
the inhibitory feedback action of cortisol in corticotrophinomas, in combination with excess 
cortisol secretion resulting in deleterious effects on the target tissues, Cushing'S disease can 
be seen as a localized. acquired form of cortisol resistance. Also most tumors producing and 
secreting ACTH ectopically (eg small cell lung carcinomas), are characterized by a high degree 
of CR. This has been demonstrated to be accompanied by a reduction in the number of GR in 
several human small cell lung cancer cell lines (139). However, up till now, the molecular 
background of this form of CR has not been elucidated. Another example in this setting is the 
Nelson tumor, which is a fast growing ACTH producing pituitary adenoma that appears in 
30% of the patients who underwent bilateral adrenalectomy for Cushing's disease (140). These 
tumors also are relatively insensitive to the negative feedback action of cortisol on ACTH 
secretion. Cells of one expanding, infiltrating Nelson tumor have been demonstrated to have a 
somatic frame shift mutation in the GR gene, thus explaining their GC insensitivity (140). Little 
is known about alterations in the GR in ACTH producing adenomas in Cushing's disease. 
Dahia et al (141) studied ACTH secreting tumors with respect to GR isoforms and mutations 
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in the GR gene. They found no significant abnormalities in the relative expression of the two 
main GR isoforms in these tumors. Moreover, mutations of critical regions of the GR gene did 
not seem to be a frequent event in studied adenomas. 
3.3. Adaptation to hypercortisolemia 
It has been well established that the ability of GCs to act on target tissues requires the presence 
of sufficient numbers of intact GRs (96). With respect to regulation of GC action. many 
studies investigating GR number were perfomled, hypothesizing that receptor down-regulation 
might be an additional form of negative feedback, protecting the cell from the continued signal 
elicited by the ligand in cases of hypercortisolism or other forms of GC excess (142). A 
number of studies demonstrated a direct correlation between GR number and the cell's 
sensitivity to GCs (95). Furthermore, a receptor down-regulation in reaction to GC therapy 
was demonstrated in cell cultures and animals including humans (100, 143). However, the 
possible mechanism of receptor down regulation is poorly understood. There is evidence for an 
enhancement of receptor degradation (144, 145), but these are ill vitro data, and nothing is 
known about accelerated GR turnover in vivo. Furthermore, many investigations were 
performed on GR mRNA levels (98). There is evidence that GC treatment modulates GR 
expression levels in a number of tissues and cell types, and that down-regulation occurs at both 
transcriptional, post-transcriptional and/or post-translational levels (97-99). Most of the data 
available at present concern ill vitro data or ill vivo data obtained after the administration of 
pharmacological amounts of exogenously Gc. Little is known about the physiological actions 
of GC on receptor number or affinity. An elegant example in this respect would be the 
syndrome of generalized GC resistance. It is striking that in all patients described up till now, 
the HP A-axis was set at a higher level, resulting in higher ACTH and cortisol concentrations. 
In none of these patients a receptor up-regulation was demonstrated, especially not in the 
patient with only half the number of receptors as a result of a splice site deletion (96). In these 
cases, it can be concluded that receptor up-regulation is not an additional feedback system in 
cases of relative cortisol shortage. Another question that could be asked with respect to 
receptor down regulation, is why people with any form of GC excess develop Cushing's 
syndrome. It could be imagined that a sufficient receptor down-regulation should protect a 
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patient from developing side-effects. Nevertheless, many patients treated with GC have serious 
adverse effects. Up till now, GR characteristics in patients with Cushing's syndrome have not 
been studied. 
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4. SCOPE OF THIS THESIS. 
Within the normal population, there is a considerable variability in the sensitivity to GCs. On 
the other hand, little is known about the individual stability of cortisol concentrations. In 
Chapter 2 a study on the reproducibility of cortisol concentrations and their relation to the 
feed back sensitivity of the HPA axis to a low dose of DE X is described. 
In extreme cases the abnormal GC sensitivity may lead to clinical syndromes like cortisol 
resistance or the cortisol hyperreactivity syndrome. Ever since the first description 1979, only 
about 20 patients and (asymptomatic) family members with CR have been described. Up till 
now, the molecular basis for CR has been elucidated in only three patients and affected family 
members. In all three cases, mutations in the hormone binding domain of the GR gene were 
responsible for the clinical manifestation of cortisol resistance. Recent reports of a substantial 
prevalence of abnomlalities in the GR in patients attending the endocrine clinic for 
hypokalemia, hypertension, acne, hirsutism and menstrual disorders (I 12, 120), prompted us to 
carry out a cross sectional study on the prevalence of GR abnormalities in the normal 
population. This study is described in Chap tel' 3. It was hypothesised that point mutations or 
polymorphisms in the GR gene might be reponsible for the differences in sensitivity to GCs in 
the normal population. Chapter 4 describes a polymorphism in the GR gene that seems to be 
associated with increased sensitivity to GC in vivo. Moreover, as it became apparent that CR 
might be a less rare disease than previously thought,6 patients attending the endocrine clinic 
for a broad spectrum of complaints were thouroughly investigated with respect to GC 
sensitivity and GR characteristics. Chapter 5 describes their variable clinical histories in 
combination with endocrine testing and biochemical- and molecular characterisation of the GR 
in these patients and their family members. 
Chapter 6 provides the extensive history of a patient with severe cortisol resistance, who 
finally developed Cushing's disease. It was investigated which molecular defects were the 
cause of this complicated clinical case. On basis of the findings described in Chapter 6 it was 
hypothesised that point mutations in the GR gene could playa role in the pathogenesis of 
Cushing's disease, or that point mutations in the OR gene in corticotropinomas were 
responsible for the relative CR observed in these tumors. Chapter 7 describes the results of a 
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study on the prevalence of point mutations in the GR gene in corticotropinomas, and provides 
a model for the development of these tumors. 
Chapter 8 describes the possible adaptation of glucocorticoid receptors in peripheral 
mononuclear leukocytes in patients with Cushing's disease as a reaction to hypercortisolism. 
Finally, Chapter 9 provides the general discussion of the data obtained from this thesis. 
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CHAPTER 2 
INTER-PERSON VARIABILITY, BUT INTRA-PERSON STABILITY OF 
BASELINE PLASMA CORTISOL CONCENTRATIONS AND THEIR 
RELATION TO THE FEEDBACK SENSITIVITY OF THE 
HYPOTHALAMO-PITUITARY-ADRENAL-AXIS TO A LOW DOSE OF 
DEXAMETHASONE IN ELDERLY INDIVIDUALS, 
Nannette A.T.M. Huizenga, Jan W. Koper, Pieter de Lange, Huibert A.P. Pols, Ronald P. 
Stalk, Diederick E. Grobbee, Frauk H. de Jong and Steven W.J. Lamberts. 
(Journal o/Clillical Elldocrillology alld Metabolism, 1998;83:,/7-5./) 
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ABSTRACT 
In the present study, we investigated whether the negative feedback action of glucocorticoids 
(GCs) upon the HPA-axis changes with age. We performed a I mg dexamethasone 
suppression test (DST) in 216 healthy elderly individuals. In order to investigate individual 
variability offeedback sensitivity in more detail, two and a half years later a 0.25 mg DST was 
carried out in 164 of them. It was investigated whether there was an effect of age or gender on 
both basal and post dexamethasone (DEX) cortisol levels, as well as on the concentration of 
DEX. Furthermore it was examined whether the reactions to the two doses of DEX differed, 
and whether indications for an intraperson stability of baseline cortisol levels could be found. 
Neither the pre- nor the post- 1 mg DEX plasma cortisol concentrations showed a correlation 
with age, while there were no differences between men and women. The same was true for the 
pre- and post 0.25 mg DEX cortisol concentrations. 
In reaction to I mg DEX, over 90% of the subjects investigated showed a cortisol suppression 
to levels below 50 nmoUl. After the administration of 0.25 mg DEX, there was a much wider 
range in post DEX cortisol concentrations. After the administration of 1 mg DEX there was a 
significant correlation between liver function parameters and plasma DEX concentrations in 
males, while there was a correlation between body mass index (BMI) and plasma DEX 
concentration in females. Plasma DEX concentrations after the administration of 1.00 and after 
0.25 mg DEX were closely correlated within subjects (P<O.OOI). 
There was an intra-individual stability of serum cortisol levels, determined at an interval of two 
and a half years. Furthermore, the individuals with the highest baseline cortisol concentrations 
also had the highest post 0.25 mg DEX cortisol concentrations, indicating a close relationship 
between basal cortisol levels and the feedback sensitivity of the HP A-axis to a low dose of 
DEX. These observations suggest a genetic influence on the setpoint of the HP A-axis. Aging 
does not seem to lead to a change in HPA activity as measured by early morning total cortisol 
levels. Also, no changes in the sensitivity of the feedback system to DEX were observed with 
age. DEX metabolism is influenced by liver function (in males) and by BM! (in females). 
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INTRODUCTION 
Glucocorticoids (GCs) are necessary for the normal functioning of most tissues. Even small 
changes in the concentrations of circulating GCs may result in a wide spectrum of 
physiological and biochemical changes throughout the body. Under basal conditions, the 
concentration of plasma cortisol and the secretion of pituitary ACTH constitute a negative 
feedback system. Because of the diurnal rhythm in the rate of ACTH secretion, plasma cortisol 
levels are higher in the morning than at night. Both negative feedback and diurnal rhythm may 
be overcome by stress which causes increases in ACTH output resulting in plasma cortisol 
levels considerably above those found in basal conditions. 
Basal concentrations of plasma cortisol exhibit a wide variation between normal subjects (1). 
Little is known concerning the question whether cortisol levels are stable within subjects. 
Interperson variation and intra person stability of plasma cortisol levels have not been 
extensively investigated. For the intraperson constancy, as reported in twins, genetic factors 
may be of importance (2, 3). The variation in hypothalamo-pituitary-adrenal (lIP A) activity 
between persons is thought to be a function of many influences including the individual 
feedback sensitivity, circadian rhythm and episodic secretion, whereas cortisol binding globulin 
(CBG) levels also affect cortisol concentrations (3). Over the years the effects of age and 
gender on the function of the pituitary-adrenocortical axis have been extensively investigated. 
These studies, however, have resulted in contradictory results. Both circadian patterns of 
cortisol and ACTH secretion and random morning plasma cortisol concentrations were 
reported to be unaltered in the elderly (4-7). On the other hand, an age-related trend towards 
increased levels of evening plasma cortisol was reported (8), and increased mean cortisol levels 
derived /Tom 24-h frequent sampling were found in elderly men but not in women (9). Finally, 
Waltman et al (10) reported that aging in humans is not accompanied by a significant increase 
in spontaneous ACTH or cortisol secretion or by a decrease in HP A sensitivity to GC feedback 
suppression. 
Another controversy in the literature concerns the influence of age and gender on the 
dexamethasone (DEX) suppression test (DST). The I mg overnight DST is a convenient 
screening procedure for patients with Cushing's syndrome. Administration of I mg of DE X at 
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11.00 pm to normal subjects suppresses the nocturnal surge in ACTH production and as a 
consequence, cortisol levels are low when measured the next morning (II). In patients 
suffering from endogenous Cushing's syndrome of any etiology, cortisol levels are less 
sensitive to DEX. Another application for this test was found in depressed patients, who may 
show an insufficient cortisol suppression in reaction to the I mg DST as well (12). To interpret 
this test in geriatric patients, many studies were done to investigate the effect of age per se on 
the duration and pattern of cortisol suppression by DEX Also, many dmgs and medical 
conditions may affect the outcome of the DST (13). In some studies (14, 15) there were 
significant correlations between age and post DEX cortisol concentrations whereas in other 
studies no such correlations could be demonstrated (16, 17). Irrespective of psychiatric 
disturbances, a decreased sensitivity to GC feedback may be prevalent in the very elderly (>80 
years) (18). 
In the present study we investigated whether the autoregulatory negative feedback action of 
GCs upon the HPA-axis changes with age. We performed a I mg DST in 216 healthy elderly 
individuals, and two and a half years later a 0.25 mg DST was carried out in 164 out of these 
216 subjects. In addition, it was investigated whether there was an effect of age or gender on 
basal and post DEX cortisol, as well as on the metabolism of DEX Furthermore it was 
examined whether there were differences in response to the two doses of DEX administered, 
and whether the suppression of cortisol was related to baseline cortisol levels. Finally, the two 
baseline cortisol concentrations in the 164 individuals who underwent two examinations were 
compared, in order to get an impression concerning the intra person stability of these 
concentrations. 
SUBJECTS, METHODS AND MATERIALS. 
For the present study, a sample of participants from the Rotterdam Study was invited for an 
additional examination. The Rotterdam study is a population-based cohort study of the 
determinants of chronic disabeling diseases in the elderly. All approximately 10,000 inhibitants 
of a suburb of Rotterdam, aged 55 years and over were invited to participate as described 
elsewere (19). The popUlation for the present study included 216 persons aged 55 to 80 years 
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(102 men and 114 women with mean ages of 67.7 ± 5.6 and 65.8 ± 6.1 years, respectively) 
who had completed the baseline visit for the Rotterdam Study not more than six month earlier. 
Subjects with acute, psychiatric or endocrine diseases, including diabetes mellitus treated with 
medication, were not invited. Three of the patients used anti epileptic drugs, whereas one, who 
showed the lowest pre-dexamethasone cortisol concentration, was treated with 
glucocorticoids. None of them was treated with estrogens. Compared to the other participants 
of the Rotterdam Study of the same age without diabetes mellitus, there were no differences in 
age and gender distribution. From all subjects written informed consent was obtained and the 
study was approved by the medical ethics committee of the Erasmus University Medical 
School. 
1 mg dexamethasone suppression test. 
Participants were seen at the research centre after an overnight fast. Between 8.00 and 9.00 
am. blood was drawn by venapuncture in order to determine the serum cortisol concentrations 
(pre DEX concentrations), using RIA-kits obtained from DPC (Los Angeles, CAl. Intra- and 
interassay variations were below 8.0% and 9.5%. Also, serum concentrations of the liver 
enzymes alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT) and ganuna 
glutamyitransferase (yOT) were determined, using standard methods. At the same time, the 
body weight and height of the volunteers were measured, and the body mass index 
(BMI,kglm') was calculated to be 26.4±0.29 for the men and 26.4±0.39 for the women 
(mean±SE). 
In the evening following the first visit to the research centre a I mg DST was carried out. 
Participants were given a tablet of LOO mg of dexamethasone (DEX) and instructed to ingest 
these at 11.00 pm. The next morning, fasting blood samples were obtained by venapuncture at 
the same time as the previous morning. In these samples, cortisol and DEX concentrations 
were measured. DEX levels were estimated by RIA using an anti serum supplied by IgO 
Corporation (Nashville, TN) and [3Hl-DEX from Amersham (Little Chalfont, UK). Intra- and 
interassay variations were below 8.5 and 14.2%, respectively. Sensitivity of this assay defined 
as mean result of assay of non-DE X containing plasma + 3SD was 0.13 nmol/L 
56 
Illterpersoll variability, illtrapersoll stability 
0.25 mg dexamethasolle slIppressiolltest (DS7). 
In order to get more insight into individual variability offeedback sensitivity to GC's, all 216 
participants were invited for a second DST two and a half years later. Out of this original 
group, 11 subjects had died and 6 subjects could not be reached. Eventually, 164 individuals 
(76 men and 88 women with mean ages of 69.1 ± 5.9 and 67.6 ± 5.6, respectively), agreed to 
participate in a second test. The same procedures were used as described for the 1 mg DST, 
now using 0.25 mg of DEX, The samples obtained from the first and the second baseline visit 
as well as the pre- and post 1 and 0.25 mg DEX samples were determined in separate assays. 
To investigate possible differences in cortisol concentrations due to interassay variation, 
baseline samples obtained at the first and the second examination from 20 randomly selected 
subjects were determined in a single cortisol assay. 
0.25, 0.50 alld I mg DST ill healthy laboratory persollel 
A group of9 healthy laboratory workers (aged 26 - 49 years) agreed to participate in a series 
of DEX suppression tests with increasing doses of DEX. At intervals of two weeks to ensure 
the absence of interference with DEX effects from the previous test, we performed three DEX 
suppression tests, using 0.25, 0.50 and 1 mg of DEX as described above. None of these 
individuals were using medication or oral contraceptives. 
Statistical allaiysis 
All results are reported as the mean ± SE. Serum cortisol concentrations in men and women 
were compared using the two sample Wilcoxon rank-sum test. The Wilcoxon matched pairs 
signed rank sum test was used to compare serum cortisol concentrations before and after DEX 
administration and between the two examinations in each person. 
To assess the relationships between cortisol and age, and between DEX and liver enzymes, 
BMI and age, linear regression analysis was used. To calculate the degree of association 
between these parameters, the Pearson correlation coefficient r was calculated. Partial 
correlation coefficients were used in order to adjust for several parameters. 
Spearman's rank correlation coefficient 1'1 was used to assess the association between the DEX 
concentrations after the administration of the two different doses and between basal cortisol 
concentrations at the two examinations. 
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RESULTS 
Baseline hormone determina/iolls. 
Table I shows the baseline concentrations of serum cortisol in the whole group of 216 elderly 
subjects, and in males and females separately. There was no difference in cortisol 
concentrations between men and women. Using linear regression analysis, no significant 
correlation could be demonstrated between the baseline serum cortisol concentration and age 
(P>0.2). 
Table 1. Cortisol concentations (nmolll) before and after the administration of I mg of 
DEX in 216 elderly individuals (114 females and 102 males). 
before DEX 
after DEX 
total 
mean SE 
521.7 10.4 
35.5 4.40 
females 
mean SE 
524.8 14.5 
32.0 4.70 
• Test for the difference between males and females. 
J mg dexamethasone suppression/est 
males 
mean SE 
517.4 15.4 
38.9 8.1 
P-value* 
0.89 
0.55 
Figure IA shows the distribution of cortisol concentrations before and after I mg of DE X. Out 
of the 216 healthy individuals, 196 (90.7%) showed a post DEX cortisol concentration below 
50 nmolll. Only five individuals (2.3%) had post DEX cortisol concentrations above 140 
nmolll, which is the cut-off point for a normal test result when the DST is used as a screening 
procedure for Cushing's syndrome in our clinic (20). These five individuals have been further 
investigated for cortisol resistance and are reported separately (21) 
As shown in table I there was no difference between men and women with regard to their post 
DEX cortisol concentrations. There was no correlation between post DEX cortisol 
concentration and age. 
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Figure 1. Cortisol concentrations before and after dexamethasone administration. 
(A) The relative distribution of cortisol concentrations before (open bars) and after (black bars) I mg of DE X in 216 
healthy elderly individuals. (B) The relative distribution of cortisol concentrations before (open bars) and after 
(black bars) 0.25 Illg of DEX in 164 healthy elderly individuals. mood samples were dramt between 8.00-9.00 
a.m, after 1 or 0.25 mg of DEX was administered at 11.00 p.llI. the previous night. The period between the two 
doses was approximately two and a balfyears. 
Figure 2A shows the distribution of the early morning plasma DEX concentrations after the 
administration of I mg DEX. None of the individuals investigated had an unmeasurably low 
circulating DEX level, indicating that all participants indeed had ingested the DEX tablets. Six 
individuals had DEX concentrations below 1.8 nmoVI. Three of them were using anti-epileptic 
drugs. 
Table 2 shows the results of the linear regression analysis for the relationship between DEX 
and several factors which might influence the metabolism of DEX. In males, there was a 
positive correlation between concentrations of DEX and the liver enzymes ALAT, ASAT and 
yGT. After deletion of the results of the 35 men, who had suprenormallevels of at least one of 
the enzymes, the relationship was no longer significant. In females, these correlations were not 
significant, despite the fact that in 21 of them increased levels of at least one of the enzymes 
was found. In women there was a significant correlation between DEX concentrations and 
BMI which was not present in men. Neither in men nor in women there was a relation between 
the DEX concentration and age. Baseline cortisol concentrations were not correlated with liver 
function tests in either sex. 
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Table 2. Relations between DEX concentrations and liver enzymes, BM! and age. 
total 
r P-value 
ALAT(UII) 0.19 <0.01 
ASAT(UII) 0.22 <0.01 
yGT(UII) 0.06 0.36 
BM!(kglm') 0.12 0.07 
age(years) 0.09 0.15 
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Figure 2. DEX cone<:ntrations after 1 or 0.25 mg ofDEX. 
females males 
r 
0.08 
0.14 
-0.1 
0.24 
0.14 
P-value r P-value 
0.38 0.28 <0.01 
0.13 0.25 <0.02 
0.33 0.24 <0.02 
<0.01 -0.03 0.78 
0.14 O.oJ 0.78 
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(A) Distribution of DE X concentralions after 1 rug (0=216, black bars) or 0.25 mg (0=164. open bars) of DE X . 
(B) Relationship between between DEX concentrations after I rug and 0.25 mg ofDEX. r,:=O.66, P<O.OOl, in 164 
subjects in whom both doses were tested. Blood samples were dra\m between 8.00-9.00 a.m. after 1 or 0.25 rug of 
DEX were administered at 11.00 p.m. the previolls night. The period between the two doses was approximately two 
and a half years. 
There was no significant relation between cortisol concentrations before and after I mg DEX 
(P>O.I). The post DEX cortisol concentration and the DEX concentration itself demonstrated 
a low but significant negative relationship (p-0.17, P<O.O I). This was due to the six 
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individuals with the lowest DEX concentrations «1.8 nmoVI); when these individuals were 
excluded from the analysis, the association was no longer significant. Also, there was no 
significant relationship 
between the decrease in cortisol concentrations in reaction to DEX administration (ll cortisol) 
and the DEX concentration (P>O.4). 
0.25, 0.50 alld 1 mg DST ill healthy laboratory persollel 
From the results of the 1 mg DST, it became clear that more than 90% of the subjects 
investigated demonstrated a suppression of cortisol to levels below 50 nmoVL. Therefore 1 mg 
of DE X might be too high a suppressive dose to allow the detection of individual differences in 
sensitivity of the lIP A-axis to glucocorticoids. A pilot study with several doses of DEX was 
subsequently carried out among 9 healthy volunteers. Figure 3A shows the cortisol and DEX 
levels after the administration of 0.25, 0.50 and I mg of DE X. 
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Figure 3. Effects of various doses of DE X on cortisol suppression. 
(A) The cortisol (open bars) and DEX (black bars) concentrations after the administralion of 0.25, 0.50 and Img of 
DEX in 9 healthy individuals. Blood samples were dranu between 8.00·9.00 a.m. 0.25, 0.50 or rug of DEX were 
administered at 11.00 pm. the previous night at intervals of two weeks. Data arc means and SD of the concentrations 
in 9 the individuals. (B) Individual relations betwecn the logarithm of the cortisol concentration and the DEX 
concentration. 
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There was a considerable variability in baseline senun cortisol concentrations, The 
administration of increasing doses of DEX, resulted in a dose dependent increase in mean 
circulating DEX levels and in a dose dependent decrease of cortisol levels. The administration 
of 0.25 mg of DE X even enlarged the range of serum cortisol levels: in one subject the serum 
cortisol level was suppressed to a level below 50 nmolll, whereas in three individuals post 
DEX cortisol levels remained above 200 nmolll. After 0.50 mg of DE X the range became more 
narrow and after the administration of I mg of DEX, all persons had a cortisol concentration 
below 50 nmolll. 
As shown in Figure 3B, there was a considerable individual variability in cortisol suppression in 
reaction to a given DEX concentration. This variability was not due to individual differences in 
CBG concentrations (data not shown). Using linear regression analysis, there was no 
significant relationship between the individual DEX concentrations and the individual degree of 
cortisol suppression or the actual post DEX cortisol levels (all P-values > 0.8). This suggests 
that different individuals suppress the HP A-axis to a variable degree in reaction to similar 
circulating DEX concentrations. 
0.25 mg dexamethasone suppression (est 
Anticipating that a lower dose of DEX would indeed allow a better insight in the individual 
variability of the feedback sensitivity of the HP A-axis, all subjects who originally participated 
in the I mg DST were invited to join in a 0.25 mg DST approximately two and a half years 
later. 
Table 3 
before DEX 
after DEX 
Cortisol concentrations (nmolll) before and after the administration of 0.25 mg 
of DE X in 164 elderly individuals (88 females and 76 males). 
mean 
547.8 
260.5 
total 
SE 
10.9 
10.9 
females 
mean 
568.4 
243.5 
SE 
14.2 
15.2 
males 
mean SE 
523.6 17.2 
281.3 16.0 
P-value* 
<0.04 
0.08 
• Test for the difference between males and females 
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Table 3 shows the mean baseline levels of serum cortisol in 164 elderly subjects. The second 
baseline mean serum cortisol concentrations turned out to be significantly higher than those 
before the 1 mg DST. The original cortisol levels of these 164 subjects amounted to 503.0 ± 
11.3, while the follow up baseline cortisol levels were 547.8 ± 1.9 (P<O.OOI). Furthermore, in 
these 164 individuals, there was a significant difference in cortisol levels between men and 
women (P<0.04). Linear regression analysis for baseline cortisol levels and age showed no 
significant correlation (P>0.06). Random samples from 20 individuals out of both groups of 
baseline samples were determined in a single assay. Mean cortisol concentrations in both 
groups were identical and there was no difference between the sexes (data not shown). This 
suggests that there was no age-related change in cortisol concentrations, but that the 
differences found should be explained by the inter-assay variation. 
Figure 1B shows the distribution of cortisol concentrations before and after 0.25 mg DEX. 
There was a much wider range in post DEX cortisol concentrations than observed after 1 mg 
DEX (cf. figure IA). A small number of individuals suppressed their cortisol levels to below a 
level of 140 mnoVi (n~34, 20.7%), while only 9 individuals (5.5%) suppressed to levels below 
50 mnoVi. 
Table 3 shows the serum cortisol concentrations after the administration of 0.25 mg of DE X. 
There are no differences between men and women. 
The distribution of DE X concentrations after 0.25 mg DEX is shown in Figure 2A. Mean DEX 
concentrations after this low dose of DEX were significantly lower than after 1 mg DEX 
(P<O.OOI). On the other hand, as shown in Figure 2B, subjects who showed the highest DEX 
concentrations after the administration of I mg DEX, also showed the highest levels after the 
administration of 0.25 mg DEX (r,~0.66, P<O.OOI). Figure 2B shows only 2 out of the six 
individuals with DEX concentrations below 1.8 nmoVl, because 4 of those showing the lowest 
DEX concentrations after I mg DEX did not participate in the 0.25 mg DST. 
Figures 4A and 4B show the linear regression analysis for the relationship between pre- and 
post 0.25 mg DEX cortisol concentrations (pO.39, P<O.OOI), and the DEX concentration and 
the post DEX cortisol concentrations (p-0.24, P<0.002). Adjusting the relationship between 
pre- and post DEX cortisol concentrations for the DEX concentration gives rise to a partial 
correlation coefficient of 0.43, P<O.OOI. 
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Figure 4. Rclalionships between oortisol and DEX concentrations in the 0.25 rug dexamethasone suppression test. 
(A) Linear regression analysis for the relationship behyeen pre- and post 0,25 rug DEX cortisol concentrations in 
164 elderly subjects. t=O.39, P<O.OOI. (D) Linear regression analysis for the relalionship between DEX 
concentrations and the post 0.25 Olg DEX wrfisoi concentrations in 164 elderly subjects. 1=-0.24, P<O.002. (C) 
Linear regression analysis for the relationship between the DEX concentrations and the change in cortisol 
concentration in response to the administralion of 0.25 rug DEX in 164 elderly subjecls. r=O.31, P<O.OO I. 
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This indicates that those individuals with the highest baseline cortisol levels have also higher 
post 0.25 mg DEX cortisol levels in response to a given DEX concentration. Figure 4C shows 
the linear regression analysis for the DEX concentration and 6. cortisol (decrease in cortisol 
concentration after 0.25 mg of DEX), (P=30.7, FO.31, P<O.OOI). Although there was no 
correlation between delta cortisol and the DEX concentration in the pilot study (n=9), there 
was an association between these parameters in this much larger group of individuals. The 
finding of a regression coefficient of 30.7 confirms that the biological activity of DEX is about 
30 times higher than the biological activity of cortisol. Figure 4C also shows that in 4 subjects 
there is a low delta cortisol «230 mnoUI), at DEX levels above 7 nmoUI. All 4 subjects 
showed post I mg DEX cortisol concentrations below 50 nmoili. This indicates again that the 
0.25 mg DST gives indeed a better insight into individual sensitivity to GCs than the I mg 
DST. 
Illdividual stability oj Ser/II/I cortisol alld CBG cOllcelltratiolls 
In order to investigate wether plasma cortisol concentrations were stable within each person 
after an interval of two and a half years, Spearman's rank correlation coefficient r$ was 
calculated for the baseline cortisol concentrations that were obtained at the two examinations. 
Table 4 shows that there are highly significant correlations between the concentrations 
determined at an interval of two and a half years in both sexes. It can be concluded that 
subjects with high cortisol levels at the first examination, also had a high level two and a half 
years later. The small size of the coefficient is probably due to the inter assay variation. The 
coefficient within the 20 samples measured in one assay was much larger (r,=0.59).Therefore 
there is indeed an intra-person stability in the baseline early morning concentrations of these 
parameters. 
Table 4. Spearman's rank correlation coefficient between cortisol concentrations 
detennined at an interval oftwo and a half years. 
total females males 
r, P-value r, r, 
cortisol (nmol/l) 0.45 <0.001 0.34 
P-value 
<0.001 0.53 <0.001 
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DISCUSSION 
Individual feedback sensitivity of the HPA-axis 
J mg DST 
In man, the major circulating glucocorticoid hormone is cortisol. Cortisol production in an 
unstressed individual follows a nycthemeral rhytlun with peak cortisol concentrations shortly 
before waking and a decline through the day reaching a nadir at bedtime. Large individual 
variations both in baseline and stimulated cortisol levels have been reported (1). One of the 
goals of the present study was to get more insights in the inter-individual variability of 
feedback sensitivity of the HPA-axis, as well as in the intra-individual stability of circulating 
cortisol values. In 216 healthy elderly individuals, a I mg overnight DST was carried out in 
order to investigate the variability in feedback sensitivity. Only five out of the 216 individuals 
(2.3 %) showed post DEX cortisol concentrations above 140 nmollI, which is the cut-off point 
for a normal test result in our clinic when the DST is used as a screenings procedure for 
Cushing's syndrome (20). These results are in accordance with previous studies where 000-
suppression was reported in 4, 9.1 and 5%, respectively (14, 16, 17). Our data demonstrate 
that I mg of DEX is too high a dose to delect individual differences in feedback sensitiviIy 
within a normal population, as near total suppression of cortisol levels was observed in most 
individuals. 
Another aspect of tIllS study was to get more insight in the role of the metabolism of DEX in 
its suppressive effects on the HPA-axis. Synthetic steroid hormones are metabolized in the 
liver before being elinlinated from the organism (22). It is well known that a number of drugs 
influence the outcome of a DST, by altering the metabolism of DEX: e.g. sodium phenytoin 
induces hepatic enzyme activity, thereby increasing the metabolic clearance of glucocorticoids 
including DEX (23). In our study population, there were six subjects with a DEX 
concentration below 1.8 IllnoVl, three of whom were indeed on anti-epileptic drugs. In the 
other subjects, there was a wide variation in DEX levels (ranging from 2.0 to 18.4 nmollI). 
Also, obesity might influence the outcome of a DST. In a study by Crapo et al.(24), non 
suppression of cortisol after ImgDEX was reported in 1.1% of lean out-patient controls and 
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in 13% of obese controls. Cronin et al (25) reported that the degree of adiposity did not differ 
between patients with false positive responses in a DST and patients with normal responses. 
The data ITom our study show that in males, the capacity of the liver to metabolize DEX is 
related to liver fimction parameters (ALAT, ASAT and yGT). In women, DEX metabolism 
was not related to liver enzyme levels. This sex difference may be caused by the larger 
proportion of men with liver function disturbances, and the larger range of BMI values in 
women. Baseline and post DEX cortisol levels were not related to liver function parameters 
andlor BMI in either sex. Still, the influence of liver function disturbances and BMI on the 
metabolism of DEX might contribute to the occurrence of false positive or false negative 
outcomes of the I mg DST in the endocrine clinic in more severely affected individuals. In 
studies performed by Meikle (26) and by Weiner (27), it was found that plasma DEX 
concentrations of respectively 5.6 nmoUI and 5.1 nmoUI at 8.00h post administration are 
required to reliably suppress HP A function. In another study (28) in psychiatric patients, 
abnormal results of the DST were closely associated with low plasma levels of DEX. In a 
study comparing patients with endogenous depression and normal controls, it was shown that 
serum DEX levels were significantly lower in nonsuppressors than in suppressors (29). 
0.25, 0.50 alld Illig DST ill healthy laboratory persollei 
From the data obtained ITom the I mg DST, it became clear that this dose might suppress the 
HPA-axis too much to allow the detection of individual differences of its feedback regulation. 
A pilot study with 0.25, 0.50 and I mg of DEX in 9 healthy laboratory workers showed that 
these lower doses indeed allowed a better discrimination in HPA-axis feedback sensitivity. The 
broadest range of cortisol concentrations was present after the administration of 0.25 mg 
DEX. This suggests that the 0.25 mg DST may give a good insight into the individual feedback 
sensitivity of the HP A-axis. 
0.25 mg DST. 
Out of the original group of 216 subjects, 164 persons participated in a 0.25 mg DST. The 
results ITom the 0.25 mg DST showed a wide range of post DEX cortisol concentrations from 
14 - 630 nmoill. It also became clear, that there was a close relationship between pre and post 
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DEX cortisol concentrations, a relation which was absent in the I mg DST. The association 
became even stronger when, by calculating a partial correlation coefficient, it was adjusted for 
the actual DEX concentration. These results show that subjects with the highest baseline 
cortisol concentrations also have the highest post 0.25 mg DEX cortisol concentrations for a 
given DEX concentration, and indicate that the sensitivity of the feedback regulation of the 
HPA-axis is related to the baseline cortisol concentration of the individual. This means that the 
"set-point" of the HPA-axis baseline levels is related to its feedback sensitivity. 
Illdividual slability oj corlisol cOllcelllraliolls 
In this study, we were able to measure early morning cortisol concentrations in a large group 
of healthy subjects twice, at an interval of approximately two and a half years. Serum cortisol 
showed an individual stability, indicating that the HP A-axis is set at a stable and reproducible 
set point for a given individual. As described above, it became clear from the data of the 0.25 
mg DST that subjects with the highest baseline cortisol concentrations also had the highest 
post DEX cortisol concentrations. It seems that in one individual, there is a set point for HP A 
activity, which is defined before as well as after a low dose of DE X. A dose of I mg DEX has 
too much suppressive effect to demonstrate this phenomenon, but a dose of 0.25 mg DEX, 
which results in a subtotal suppression of cortisol levels, leaves the influence of the individual's 
setpoint of the HP A axis intact. Previous studies showed that genetic factors may playa role in 
the regulation of cortisol levels. Maxwell et al (2) reported similar unstimulated plasma cortisol 
levels in a sample of female monozygotic twins. Nevertheless, this was not found in male 
monozygotic twins. Meikle et al.(3) observed evidence for a moderate genetic impact on early 
morning plasma cortisol levels. A study by Kirschbaum et al (30) investigated cortisol 
responses to three different stimulation procedures (a CRR test, a physical stimulation 
procedure and a psychological stress test), with the focus on the contribution of genetic 
factors. A decided influence of genetic factors was observed for baseline cortisol levels, as well 
as for the response to CRR, but heredity appeared to playa minor role in the adrenocortical 
response to physiological stress. One of the differences between this last study and the present 
results is, that Kirschbaum et al. demonstrated a significant intraindividual stability of baseline 
cortisol concentration in females, whereas levels in males were much less stable. In our study, 
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however, there was a highly significant individual stability of baseline cortisol concentrations in 
both sexes. Furthermore, the post 0.25 mg DEX cortisol levels were significantly correlated to 
the baseline cortisol concentrations, both in male and in female elderly individuals. 
Effect of age on pre and post DEX cortisol concentrations 
Studies concerning age related changes in basal, nonstimulated HP A function have produced 
varying results (31). Most studies have demonstrated no change or non-significant increases in 
mean baseline ACTH (6, 8, 10) and serum cortisol levels at older age (32, 33). The consistent 
lack of age and gender differences in basal cortisol levels across these various studies 
strengthens the conclusion that age does not have a major impact on basal nonstimulated 
cortisol concentrations (31). In the present study there was no relation between age or gender 
and basal total cortisol concentrations, neither in the first nor in the second examination. 
Furthennore, there was no difference between these baseline cortisol concentrations which 
were determined at an interval of approximately two and a half years. However, it has to be 
stated that our study population included elderly people only, so we were not able to compare 
baseline cortisol concentrations between young and old subjects. 
We found no correlation between post DEX cortisol concentrations and age, neither after 1 mg 
DEX nor after 0.25 mg DEX administration. Furthermore, there was no difference between 
males and females concerning their post DEX cortisol concentrations using either one doses of 
DEX. Two previous studies of healthy individuals have also demonstrated no age-related 
differences in cortisol suppression after I mg DEX (16, 17). In two other studies, however, a 
decreased suppression was reported in older subjects after the 1 mg DST (14, IS). 
The most important conclusions from our study are the observation of an individual stability of 
baseline cortisol levels, which is closely related to the feedback sensitivity of the HP A-axis in 
response to a low dose of DEX. These observations suggest a genetic influence on the set point 
of the HPA-axis. 
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LACK OF ASSOCIATION BETWEEN FIVE POLYMORPHISMS IN 
THE HUMAN GLUCOCORTICOID RECEPTOR GENE AND 
GLUCOCORTICOID RESISTANCE. 
Jan W. Koper, Ronald P. Stalk, Pieter de Lange, Nannette A.T.M. Huizenga, Gerd-Jan Molijn, 
Huibert A.P. Pols, Diederick E. Grabbee, Michael Karl, Frank H. de Jong, Albert O. 
Brinkmann, and Steven W.J. Lamberts. 
(HI/Illall Gellelics, 1997;99:663-668) 
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ABSTRACT 
Glucocorticoid resistance due to mutations in the gene for the glucocorticoid receptor has been 
suggested to be more common than is known at present, due to the relative mildness of its 
symptoms and the difficulty of its diagnosis. To investigate the prevalence of mutations in the 
glucocorticoid receptor gene responsible for relative insensitivity to glucocorticoids, we carried 
out PCR/SSC analysis of the glucocorticoid receptor gene in a group of 20, otherwise healthy, 
persons with a reduced response in a dexamethasone suppression test and in 20 controls. We 
did not find mutations or polymorphisms associated with a reduced sensitivity for 
glucocorticoids. However we identified 5 novel polymorphisms in the gene for the human 
glucocorticoid receptor, which may be useful in analysing whether loss of (part of) the 
glucocorticoid receptor gene plays a role in glucocorticoid resistant malignancies. 
Conclusion: although relative resistance to glucocorticoids seems to be rather frequent in 
otherwise healthy persons, it is not usually associated with mutations or polymorphisms in the 
glucocorticoid receptor gene. 
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INTRODUCTION 
Glucocorticoid (Ge) hormones are essential for postnatal life. GCs exert their function through 
the cellular glucocorticoid receptor (GR); absence of the GR in knock-out mice leads to death 
soon after birth (I). In humans, complete absence of functional GRs has not been observed. 
However, sever~l families have been described with hereditary "partialU or nrelative" GC 
resistance (2-5). In these four families, mutations in the part of the GR-gene coding for the 
hormone binding domain (HBD) of the protein were found to be the cause ofa reduced affinity 
of the GR for GCs (2,5)or of a reduced number of receptors per cell due to a splice site 
deletion in one allele of the gene (4). In one case, a mutation in the HBD was shown to cause 
dominant negative inhibition of the wild-type GR (5). 
The GR is a member of the intracellular- or steroid-hormone-binding superfamily of receptors. 
Other members of this family include the receptors for sex steroids, vitamins A and D and 
thyroid hormone. These intracellular (cytoplasmic andlor nuclear) receptors have a common 
structure which comprises an N-terminal transactivating domain, a central DNA-binding 
domain and a C-terminal hormone binding domain (6). 
The symptoms of partial glucocorticoid resistance are the result of the role of the GR in the 
negative feedback mechanism that governs the hypothalamic-pituitary-adrenal(HP A)-axis (7). 
Primarily, the reduced GC sensitivity results in increased cortisol production by the adrenal 
glands, which compensates for the reduced feedback inhibition of the HP A. Increased adrenal 
activity also results in increased amounts of adrenal androgens and of mineralocorticoids. It is 
this overproduction of other adrenal steroids which causes the primary symptoms 
accompanying glucocorticoid resistance such as hirsutism, menstrual irregularities and fertility 
problems in women (8), while a case of isosexual precocious puberty has been described in a 
boy (3). Increased levels of mineralocorticoids lead to hypertension and hypokalemia (9). The 
symptoms, however, are usually relatively mild and very variable in nature (8). Thus, two of 
three siblings carrying the same mutation (4,8, 10) were essentially without symptoms (8). The 
long-term effects of glucocorticoid resistance are unknown, but there are some indications that 
it may be involved in the development of hyperplasia of the pituitary corticotroph cells, and 
eventually the development of pituitary corticotroph tumors (5,11). 
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Apart from the four cases mentioned above, which have been fully elucidated at the genomic 
level, approximately 20 other patients have been described in whom glucocorticoid resistance 
has been clinically and biochemically diagnosed without further knowledge with regard to 
mutations of their GR genes (12-15). In two studies relatively large numbers of newly 
diagnosed cases of glucocorticoid resistance have been reported (8, 16). 
In the present study we have investigated the prevalence of glucocorticoid resistance in a 
population based study. Subsequently, we have searched for mutations and polymorphisms in 
the GR-gene and investigated their relationship to the observed GC insensitivity. 
METHODS 
Study populatioll 
A random sample of participants from the Rotterdam Study was invited to participate in the 
present study. The Rotterdam Study is a population-based follow-up study of the detenninants 
of chronic disabling diseases in the elderly. The study focuses on four areas of chronic disease: 
cardiovascular, neurogeriatric, locomotor, and ophthalmologic diseases; details have been 
published previously (17). The present study population included 216 persons aged 55 to 80 
years without evident psychogeriatric or endocrine disease, including treated diabetes mellitus. 
From all subjects informed consent was obtained and the study has been approved by the 
medical ethics committee of the Erasmus University Medical SchooL 
A reduced response in an overnight I mg dexamethasone suppression test (18) in 216 subjects 
(see below) was used as an indicator of relative glucocorticoid insensitivity. The 20 persons 
with the highest post-dexamethasone cortisol levels were selected. The post-dexamethasone 
cortisol concentrations in this group of persons was >50 nmaVL. From the remaining subjects 
(who all had post-dexamethasone cortisol levels <50 nmol/L) 20 age- and sex-matched 
controls were selected randomly. The GR gene of these 40 persons was analysed for the 
presence of mutations, using a polymerase chain reaction based analysis of single strand 
conformation, (PCR/SSC, 19) of the GR gene was carried out. In the case of two 
polymorphisms, their frequency was further estimated by additional peR/SSC analysis of the 
relevant part of the gene in the remaining 176 individuals. The persons with reduced 
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suppression also underwent an extensive physical examination. 
Dexamethasone sIIppressi011 test alld hormone de/ennina/iolls 
The participants were seen at the Rotterdam Study research centre after an overnight fast and 
blood was drawn between 8.00 and 9.00 am. for measurement of the concentration of 
circulating cortisol. Subsequently, all participants were subjected to an overnight I mg 
dexamethasone suppression test (18). They were asked to take their dexamethasone tablets at 
11.00 pm and fasting blood samples were again drawn the next morning between 8.00 and 
9.00 am. The concentration of cortisol was determined using kits supplied by Diagnostics 
Products Corporation (Los Angeles CAl (8). To check for compliance and possible drug-
induced abnormalities in the metabolism of dexamethasone, the dexamethasone concentration 
was also measured in a radioimmunoassay llsing antiserum obtained from IgG Corporation 
(Nashville, TN). 
peR/sse analysis and Jlue/eotide sequence determination 
DNA was isolated from peripheral blood leukocytes using standard techniques. PCR 
amplification of the GR gene was carried out employing primer sequences and amplification 
conditions previously described (4) (Table I and Fig. I). For the amplification of exons 3 
through 8 intronic primer pairs complementary to sequences in the 5'- and 3'-exon-flanking 
regions were used. Exon 2, which encodes the entire N-terminal part of the glucocorticoid 
receptor, was amplified in five overlapping segments (see also Fig. I). The non-coding exon I 
was not analyzed and of exon 9« only the 5' coding part was investigated. Exon 9p which can 
form part of the mature mRNA instead of exon 9«, after alternative splicing (20), resulting in a 
non-functional receptor protein, was not investigated. SSC analysis of the PCR products was 
carried out using 0.5 x MDE polyacrylamide gels (J.T. Baker Chemicals, Deventer, the 
Netherlands) under three conditions, as described (19), except that 5% glycerol was used 
instead of 10%. DNA-fragments displaying an abnormal migration pattern during SSC-analysis 
were subjected to direct sequencing using a modified Sanger-dideoxynucleotide chain 
termination method as previously described (4). 
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Table 1. Primers used for PCR/SSC and sequencing. 
Exon 2/1 GAT TCG GAG TTA ACT AAA AG 
ATC CCA GGT CAT TTC CCA TC 
Exon 2/2 CCA AGC AGC GAA GAC TTT TG 
TAC CTG GGG ACC CAG AAG AA 
Exon 2/3 CCA CAG AGA AGG AGT TTC CA 
TTG CCT GAC AGT AAA CTG TG 
Exon 2/4 CCA GTA ATG TAA CAC TGC CCC 
TTC GAC CAG GGA AGT TCA GA 
Exon2/5 AGT ACC TCT GGA GGA CAG AT 
GTC CAT TCT TAA GAA ACA GG 
Exon3 AGT TCA CTG TGA GCA TTC TG 
CGT GAG AAA TAA AAC CAA GT 
Exon4 GAC AGA AGG CTG TCC TTA TA 
CAT TAT GCG TAT CAA GCA TA 
Exon 5 GAA TAA ACT GTG TAG CGC AG 
TAG TCC CCA GAA CTA AGA GA 
Exon6 GAT CTT CTG AAG AGT GTT GC 
GGG AAA ATG ACA CAC ATA CA 
Exon7 GAA AGT TCT CCA AAA ITC TG 
TTG GTG TCA CIT ACT GTG CC 
Exon8 GAC ACA GTG AGA CCC TAT CT 
CAC CAA CAT CCA CAA ACT GG 
Exon 9" GGA ATT CCA GTG AGA TTG GT 
IAI AM CCA CAl GIA GIG m 
GAG AGG ATT AAT 
glu .rg 
"" 
0 0 
"" 
.J, .J, .J, .J, .J, 
GAA AAO OTT C T Inlron 4. 18 AAC 
glu Iys 
'" 
nuel. upstream 
"" 2223 363 from oxon V , ..
Inlron 3, 46 
nucl. upslream 
from axon IV 
Figure 1. Genomic organization of the glucocortiooid receptor gene and the positions of the amplified fragments 
used for peR/SSe analysis. The nature and position of the polymorphisms that were idcnlified are shonu below the 
figure. (Not drann to scale.) 
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Data allalysis 
Gender-adjusted parameters were calculated for each participant by linear regression analysis. 
The clinical characteristics of the study population were compared between controls and the 
persons with reduced suppression using Student's t-test. The Wilcoxson rank-sum test was 
used to analyze the differences in characteristics between subjects with and without mutations 
in the glucocorticoid receptor gene. P-values smatter than 0.05 were considered statisticatty 
significant. 
RESULTS 
Clillicalobservatiolls 
In the group of216 participants of The Rotterdam Study, 20 persons (prevalence: 9.3%, 95% 
C.I.: 5.4-13.2) were identified with a reduced response (cortisol> 50 nmot/L) in the I mg 
dexamethasone suppression lest. 
Table 2. Clinical characteristics of the study population'l) 
Number 
Women (%) 
Age (years) 
Body mass index (kg/m2) 
Waistlhip ratio 
Systolic blood pressure(nunHg) 
Diastolic blood pressure (mmHg) 
Hypertension(2) (%) 
Ankle/arm blood pressure index 
Polassium (mmot/L) 
Fasting cortisol (nmolJt) 
Cortisol after DST 
DEX after DST 
response in the dexamethasone 
suppression test 
posl-dex post-dex 
[cortisol] [cortisol] 
<50 nmoUL >50 nmoUL 
196 20 
53.6 50.0 
66.6 (0.4) 67.S 
26.5 (0.2) 25.6 
0.92 (0.01) 0.91 
139.3 (1.4) 137.6 
75.0 (0.7) 74.2 
29.1 40.0 
0.9S (0.02) 0.97 
4.0S (0.02) 4.0S 
509.1 (9.6) 60S.3 
22.S (0.7) 149.1 
7.39 (0.24) 6.67 
(t.4) 
(1.3) 
(0.02) 
(5.0) 
(2.3) 
(O.OS) 
(O.OS) 
(55.4) 
(39.S) 
(1l0) 
(I) Values are means with standard error in parentheses, or percentages. 
so 
p-value 
0.76 
0.40 
0.35 
0.6S 
0.70 
0.72 
0.31 
0.S6 
0.96 
0.005 
0.39 
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In Table 2 the clinical characteristics are given for all subjects. The subjects with reduced 
response in the DST also had higher fasting cortisol levels. Dexamethasone concentrations 
were not different between the two groups. Physical examination of the 20 subjects with 
reduced suppression did not reveal signs or symptoms related to hypokalemia, hirsutism or 
infertility. 
PCRlSSC- alld DNA seqllellce-mla/ysis 
PCR/SSC-analysis revealed five SSC-variants (Figures I and 2, and Table 3). Four of these 
variants were observed in three or more participants in this study, while the fifth, observed in 
one person in this study, had previously been found in another person not included in the 
present study (J.W. Koper, unpublished observations). Sequence analysis showed that all SSC-
variants were caused by point mutations. 
In the case of exon 2/1 sequence analysis revealed two point mutations separated by one base-
pair. The mutations were located at cDNA nucleotide positions (20) 198 and 200, respectively. 
The first mutation was silent, changing codon 22 from GAG to GAA, both coding for glutamic 
acid. The second mutation changed codon 23 from AGG to AAG resulting in an amino acid 
change from arginine to lysine. PCR/SSC analysis in 109 of the remaining 176 samples (i.e. in 
persons with a normal response in the DST) revealed a further 8 persons who were 
heterozygous for this polymorphism (Table 3). 
In fragment 2/5 an ATT to GTT point mutation at cDNA position 1220 resulted, 
heterozygously, in an asparagine to serine change at codon 363 in four subjects. Subsequently, 
using PCR/SSC analysis of the remaining 176 DNA samples we discovered 9 additional 
subjects who were heterozygous for tills polymorphism (Table 3). 
The polymorphisms in the amplified segments containing exons 4 and 5 were located in the 5'-
flanking intron sequences rather than in the exons themselves. In the fragment containing exon 
4 a mutation was identified as a heterozygous G to C change 46 nucleotides upstream from the 
start of exon 4, which is at cDNA position 1549 (Table 3). The polymorphism in the fragment 
containing exon 5 was more frequent and was a G to T change 16 nucleotides upstream from 
the starting point of ex on 5 which is located at cDNA position 1666. For tills polymorphism 5 
homozygous subjects were also identified (Fig. 2 and Table 3). The polymorphisms in the 
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EXON 211 EXON 
40 2 39 
,. 
.-
EXON 5 
2 3 
EXON 9 
7 8 
, . .. 
2426 
2439 
215 
40 8 21 
.. 
.... 
.-
'*""'" 
5 6 7 
9 10 11 
.. • .. 
2426 
A 
A 
A 
T 
A 
T 
2439C 
EXON 4 
37 38 
8 9 10 
.. == 
12 
39 
-
11 
... 
"'" 
I 
12 
Figure 2, sse patterns of all the polymorphisms: exon 2/1 \\1 (40) and heterozygote (2); exon 215 ,,1 (39 and 8) and 
heterozygote (40 and 21); exon 4 \,1 (37 and 38) and heterozygote (40); exon 5 ,,1 (5, 9 and 11), heterozygote (2, 3 
and 7) and homozygote variant (6, 8 and 10); eXOll 9 ,,1 (7,9, to and 11), heterozygote (12) and homozygote variant 
(8). Sequence analysis for exon 9 of the samples 7. 8 and 9. 
82 
Polymorphisms illihe Gil Kelle 
Table 3. Frequencies ofthe polymorphisms in the glucocorticoid receptor gene 
subjects \lith subjects ",ith aU subjects frequency of the 
pod~dex cortisol post-dex cortisol l'anant alleles 
<50 nmollL (%) >50 nmollL (%) (%)(95% C.I.) 
codons 22+23; wild ?,;pe GAGAGG (GluArg). variant aMMO (O/fiLys) 
GAGAGGIGAGAG 12If129 17120 13S1149 
GluArgfGluArg (93.S) (S5.0) (92.6) 
GAAAAG 
GAGAGGIGAAAAG SI129 3120 111149 11129S 
GluArgfGIIILy, (6.2) (15.0) (7.4) (3.7%) 
(0.6·6.S) 
GAAAAGIGAAAAG 0/129 0120 0/149 
GluLys/G/IiLys (0.0) (0.0) (0.0) 
codon 363: wild type ATT (AS01' variant GTT (Sa) 
ATT/ATT IS 1196 20/20 2031216 
,AsnlAsn (93.4) (100.0) (94.0) 
GTT 
ATTIGTT 131196 0/20 131216 131432 
AsnlSer (6.6) (0.0) (6.0) (3.0%) 
(0.7·5.3) 
GTTIGTT 01196 0120 0/216 
SerlSel' (0.0) (0.0) (0.0) 
intron 3, 46 nucleotide! upstream from exon 4: wild ~'pc G, variant C 
GIG 20/20 19 20 39/40 
(100.0) (95.0) (97.5) 
C 
GIC 0/20 1120 1/40 IISO 
(0.0) (5.0) (2.5) (1.3%) 
(0·4.S) 
CIC 0120 0120 0140 
(0.0) (0.0) (0.0) 
intron 4, 16 nucleotides upsteam from cxon 5: ,yild ~];e G, variant T 
GIG 9120 I 20 19140 
(45.0) (50.0) (47.5) 
T 
GIT 10120 7120 17/40 251S0 
(50.0) (35.0) (42.5) (31.3%) 
(16.6·45.9) 
TIT 1120 3120 4/40 
(5.0) (15.0) (10.0) 
codon 766: wild type AAT (As~. variant AAe (As1I) 
AAT/AAT 1620 14120 30140 
AsnlAsn (SO.O) (70.0) (75.0) 
AAC 
AAT/AAC 4120 5120 9/40 IIISO 
AsnlAslI (20.0) (25.0) (22.5) (13.7%) 
(2.9·24.6) 
AAC/AAC 0120 1120 1/40 
ASlIlAsn (0.0) (5.0) (2.5) 
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fragments containing exons 4 and 5 might be associated with sequences important in the 
splicing process, however we did not observe differences in the glucocorticoid binding capacity 
of peripheral blood leukocytes of persons with these polymorphisms (results not shown). 
Finally, the polymorphism in exon 9", which was also relatively frequent, was caused by a 
silent T to C point mutation in codon 766 (AAT to AAC, both coding for asparagine). One 
person homozygous for tills mutation was also identified (Fig 2). A single case of this 
polymorphism has been reported previously (21). 
The polymorphisms reported here were neither associated with clinical (hirsutism, 
hypokalemia, hypertension) glucocorticoid resistance, nor with a reduced response in the 
dexamethasone suppression test (for all analyses p>O.4). None of the physiological parameters 
investigated differred in a significant way between the various genotypes. Table 3 shows the 
distribution of genotypes over the two subgroups from the dexamethasone suppression test, all 
genotypes, with the exception of the codon 363 polymorphism, are evenly divided over the 
two subgroups. 
DISCUSSION 
Glucocorticoid resislance in the cases that have been described until now was found to be 
caused by mutations in the hormone-binding domain of the GR (2-4). Thus in "classical" 
glucocorticoid resistance the glucocorticoid receptor is the key-modulator of glucocorticoid 
sensitivity. Two reports show relatively high numbers of new patients with a reduced 
glucocorticoid sensitivity, based on clinical and biochenllcal observations in the endocrine out-
patients clinic (8,16). Both these reports focussed on persons with an otherwise unexplained 
reduced response in the 1 mg DST. We set out to determine whether mutations in the OR gene 
also played a role in the general differences in glucocorticoid sensitivity, such as they are 
observed in the general population. 
Our present results indicate that biochenllcal glucocorticoid resistance is more conmlOn than 
expected: 20 out of 216 subjects (9.3%, 95% C.I.: 5.4-13.2) in an elderly non-hospitalized 
popUlation were shown to have a reduced response in the 1 rug DST. However, no "classical" 
clinical and biochemical glucocorticoid resistance, accompanied by mutations in the hormone-
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binding domain of the GR, was identified in any of these subjects. 
We found five polymorphisms in the GR gene. However, none of these polymorphisms were 
associated with parameters indicative of glucocorticoid resistance. The double mutation in 
co dons 22 and 23 has also been tested in in vitro expression experiments (22). However, these 
mutations do not seem to alter the efficacy of the GR in such systems. Similarly the 
polymorphism in codon 363 did not alter the function of the GR (4, 22, 23). 
The possible effects of the intronic mutation in the 5'-flanking region to exon 5 are more 
difficult to assess. It seems unlikely that tllis mutation affects the splicing-process in some way, 
as no significant changes in the number of receptors. nor in their affinity were observed in 
persons homozygous for tllis polymorpllism. Another possibility is that this polymorphism is 
linked to another mutation in or near the GR gene that was not detected using the PCR/SSC 
approach of this study. 
Recently, a number of papers (24-26), reported that the Il-form of the human glucocorticoid 
receptor, a natural splice variant. is expressed in many tissues and might playa role in the 
response to glucocorticoids, as it was shown to have a dominant negative effect on the 
function of the uGR (24-26). In future research it will be interesting to investigate if there is a 
relation between the relative levels of expression of these two GR forms, both at the mRNA 
and at the protein levels, and the observed differences in sensitivity to glucocorticoids. 
From the present investigation we conclude that biochemical glucocorticoid resistance is quite 
common and that a number of polymorphisms exist in the gene for the GR, but that these 
polymorpllisms do not cause the observed glucocorticoid resistance. 
These polymorphisms, however, may be useful in detemlining whether loss of (part 01) one of 
the copies of the GR gene has occurred in malignancies known to be glucocorticoid resistant 
(c.f. 23,27). We are currently investigating the role of the GR in corticotroph pituitary tumors 
and we have indications that there is loss of heterozygosity for the GR in a number of these 
tumors, as observed by analysing these intragenic polymorphisms (NAT.M.H., unpublished 
observations). 
85 
Chapter 3 
List of references 
I. Cole T, Blendy J, Monaghan A ef at. 1995 Targeted disruption of the glucocorticoid receptor gene blocks 
adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev 9: 1606-1621. 
2. Hurley DM, AlX}ili D. Stralakis CA cl al. 1991 Point mutation causing a single amino acid substitution in 
the homlOne binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J Clin 
InYest 87:680·686. 
3. MalcboffDM, Bmfsk.1' A, Reardon G, McDennolt P cf al. 1993 A mutation orlbe glucocorticoid receptor 
in primary cortisol resistance. J Clin Invest 91: 1918-1925. 
4. Karl M, Lambcrfs SW, Detera-Wadleigh SD ef al. 1993 Familial glucocorticoid resistance caused by a 
splice site deletion in the human glucocortiooid receptor gene. J elin Endocrinol Mctab 76:683-689. 
5. Karl M, Lamberts SWJ, Koper JW et at. 1996 Cushing's disease preceded by generalized glucooorticoid 
resistance: clinical consequences of a novel, dominant·negative glucocorticoid rc«ptor mutation. Proc 
Assn Am Phys 108:296·307. 
6. Deato M, Herrlich P, SchUtz G. 1995 Steroid honnonc receptors: many actors in search of a plot. Cell 
83:851-857. 
7. Chrousos GP, Detera-Wadleigh SD, Kad M. 1993 Syndromes of glucooorticoid resistance. Ann Intern 
Moo 119:1113-1124. 
8. Lamberts SW, Koper JW, lliemond P et al. 1992 Cortisol receptor resistance: the variability of its clinical 
presentation and response to treatment. J Clin Endocrinol Metab 74:313-321. 
9. Vingerhoeds AC, Thijssen ill, Schwarz F. 1976 Spontaneous hypercortisolism without Cushing's 
S)lldrome. J Clin Endocrinol Metab 43: 1128-1133. 
10. Lamberts SW, Poldenllans D, Zweens M et al. 1986 Familial cortisol resistance: differential diagnostic 
and therapeutic aspects. J Clio Endocrinol Metab 63: 1328-1333. 
11. Lamberts SWJ, van der Lely AJ, de Herder WW. 1995 Transsphenoidal selective adenectomy is the 
treatment of choice in patients with Cushing's disease. Considerations concerning preoperative medical 
treatment and the long-term follow-up. J Clin Endocrinol Metab 80:3111-3113. 
12. lida S, Gomi M, Moriwaki K et at. 1985 Primary cortisol resistance accompanied by a reduction in 
glucocorticoid receptors in t\yo members of the sallle family. J Clin Endocrinol Metab 60:967-971. 
13. Dr6nnegArd M, Werner S, Gustafsson JA 1986 Primary cortisol resistance associated with a themlolabile 
glucocorticoid receptor in a patient with fatigue as the only symptom. J Clin Invest 78: 1270-1278. 
14. Gomi M, lida S, Tsugawa M el at. 1987 In vitro studies of skin fibroblasts from a patient with a ne\\' type 
of primary cortisol resistance: glucocorticoid receptor status and glucocorticoid effect on DNA S)llthesis. 
Homl Metab Res 19:328-330. 
15. Nawata H, Sekiya K. Higuchi K et at. 1987 Decreased deox)Tibonucleic acid binding of 
glucocorticoid-receptor complex in cultured skin fibroblasts from a patient with the glucocorticoid 
resistance S)lldrome. J Clin Endocrinol Metab 65:219-226. 
86 
Polymorphisms ill/he GR gelle 
16. Werner S, Thorcn M, Gustafsson JA et al. 1992 Gillcooorticoid receptor abnormalities in fibroblasts from 
patients with idiopathic resistance to dexamethasone diagnosed wben evaluated for adrenocortical 
disorders. J Clin Endocrinol Melab 75:1005-1009. 
17, Hofman A, Grobbee DE, de long PT cf al. 1991 Dctenllinants of disease and disability in the elderly: the 
Rotterdam Elderly Study. Eur J Epidemio17:403-422. 
18. Nugent C. Nichols T. Tyler F. 1965 Diagnosis of Cushing's syndrome. Single dose dexametll8sone 
suppression test Arch In! Moo 116:172-176. 
19, Orila M, Iwabana H. Kanazawa H 01 a1. 1989 Detection of polymorpbisms of human DNA by gel 
electrophoresis as single-strand confomlation polymorphisms. Proc Nail Acad Sci USA 86:2766-2770. 
20. Hollenberg SM, Weinberger C, Ong ES 01 al. 1985 Primary stmcturc and expression of a functional 
human glucocorticoid receptor eDNA. Nature 318:635·641. 
21. Soufi M, Kaiser U, Sclmeider A et al. 1995 The DNA and steroid binding domains of the glucocorticoid 
receptor are not altered in mononuclear cells of treated CLL patients. Exp Clin Endocrinol 103; 175-183. 
22. De Lange L, Koper IW, Huizenga NATM et at. 1997 Differential hOffilone-dependent transcriptional 
activation and -repression by naturally ~UITing human glucocorticoid receptor variants. Mol Endocrinol 
11:1156-1164. 
23. Gaitan 0, DeBold RC, Tumey MK el at. 1995 Glucocorticoid receptor structure and function in an 
adrenocorticotropin-secreting small cell lung canccr. Mol Endocrinol9: 1193-1201. 
24. Bambcrger eM, Bamberger AM, De Castro M et at. 1995 Glucocorticoid receptor 6, a potential 
endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 95:2435-2441. 
25. Oakley RH, Sar M, Cidlowski JA. 1996 The human glucocorticoid receptor B isofonn. J Bioi ChCDl 
271 :9550-9559. 
26. De Castro M, Elliot S, Kino T ct al. 1996 The nou-Iigand binding O-isofoffil of the human glucocorticoid 
receptor (hGRn): tissue levels, mechanism of action, and potential physiologic role. Mol Med 2:597 -607. 
27. Ray DW. 1996 Molecular mechanisms of glucocorticoid resistance. J EndocrinoI149:1-5. 
87 
88 
CHAPTER 4 
A POLYMORPHISM IN THE GLUCOCORTICOID RECEPTOR GENE 
MAY BE ASSOCIATED WITH AN INCREASED SENSITIVITY TO 
GLUCOCORTICOIDS IN VIVO. 
Nannette A.T.M. Huizenga, Jan W. Koper, Pieter de Lange, Huibert A.P. Pols, Ronald P. 
Stolk, Huibert Burger, Diederick E. Grobbee, Albert O. Brinkmann, Frank H. de Jong and 
Steven W.J. Lamberts 
(Journal o/Clinical Endocrinology and Metabolism, 1998;83:144-151) 
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ABSTRACT 
We investigated whether a polymorphism at nucleotide position 1220, resulting in an 
asparagine to serine change at codon 363 in the glucocorticoid receptor (GR) gene is 
associated with an altered sensitivity to glucocorticoids. 
In a group of 216 elderly persons, 13 heterozygotes for the N363S polymorphism were 
identified by PCRlSSCP analysis. In two DEX suppression tests (DSTs), using 1 and 0.25 mg 
DEX, the circulating cortisol and insulin concentrations were compared between N363S 
carriers and controls. In the 1 mg DST there were no differences between N363S carriers and 
controls with respect to adrenal suppression, but there was a significantly higher insulin 
response in N363S carriers. In the 0.25 mg DST, a significantly larger cortisol suppression and 
higher insulin response were seen in N363S carriers. Comparison of blood pressure, body 
mass index (BM!) and bone mineral density (BMD) between the N363S carriers and controls 
showed that N363S carriers had a higher BMI, but normal blood pressure. There was an 
obvious trend towards lower age-, BM!- and sex-adjusted BMD in the lumbar spine in N363S 
carriers. GR characteristics measured in 41 controls and 9 N363S carriers in periferal 
mononuclear leucocytes showed no differences between N363S carriers and controls with 
respect to GR number and ligand binding affinity.However, there was a trend towards greater 
sensitivity to DEX in the carriers' Iymfocytes, in a mitogen induced cell proliferation assay. In 
transfection assays the capacity of the codon 363 variant to activate MMTV promotor 
mediated transcription in COS-I cells was unaltered when compared to the wild type GR. 
We conclude that in 6.0 % of our study population, a polymorphism in codon 363 of the GR 
gene was found. Individuals carrying this polymorphism appeared healthy at clinical 
examination, but had a higher sensitivity to exogenously administered glucocorticoids, both 
with respect to cortisol suppression and insulin response. Life-long exposure to the mutated 
allele may be accompanied by an increased BM! and a lowered BMD in the lumbar spine, but 
does not affect blood pressure. 
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INTRODUCTION 
There is a considerable variability in the sensitivity to glucocorticoids (Gcs) across individuals. 
Early morning serum cortisol concentrations show a great diversity between individuals. On 
the other hand, there is a marked individual stability of baseline cortisol concentrations within 
persons which is closely related to the feedback sensitivity of the hypothalamo-pituitary-
adrenal (HPA)-axis to a low dose of dexamethasone (DEX) (Huizenga et a11997, submitted). 
Extreme examples of variability in sensitivity to GCs are the cortisol hyperreactive syndrome 
and cortisol resistance (CR). In 1990, Iida et al (I) described a patient who presented with 
signs and symptoms of Cushing's syndrome in spite of persistent hypocortisolemia. So far, this 
is the only case reported with cortisol hyperreactivity. CR is a rare condition as well. The first 
patient was described in 1976 (2) and since then, only about ten symptomatic and 
asymptomatic patients and family members have been identified (3-S). AlreadylS years ago it 
was suggested that CR might be the result of a defect in the functional characteristics of the 
glucocorticoid receptor (GR). The GR has been cloned and sequenced (6) and found to be 
organized into a series of discrete domains wich mediate the receptor functions of hormone-
binding, DNA-binding and transcriptional modulation (7). The binding of GCs to the GR 
induces a series of cellular events wich results in the activation or repression of a network of 
GC responsive genes and produces a specific cellular response (8). Thus far, the molecular 
basis ofCR has been elucidated in four kindreds (9-12). In all reported cases, mutations in the 
hormone binding domain of the GR-gene appeared to be the cause of CR The molecular basis 
of cortisol hyperreactivity (I) has not been elucidated yet. 
Variability in the sensitivity to GCs is also observed in patients treated with GCs. GCs are 
important therapeutic agents, used for the treatment of various inflammatory and autoinmmne 
diseases. Although plasma concentrations ofGCs can be ascertained, their functional effects on 
target tissues are very difficult to predict (13). In clinical observations, a considerable 
variability between subjects is seen in their sensitivity to GC therapy both with regard to 
efficacy as well as to the prevalence and severity of side effects. 
In a previous study, two dexamethasone (DEX) suppression tests (DSTs) were performed in 
216 elderly individuals in order gain insight in the sensitivity to GCs in the normal population 
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(Chapter 2). Furthennore, a general screening of the GR-gene in 40 persons was performed 
using PCR/SSCP-analysis (14). Based on indications that a previously reported polymorphism 
in the 3'-region of exon 2 which encodes for the transactivation domain of the GR of the GR 
gene (Asn363Ser, N363S, Figure IC) might be associated with an increased sensitivity to GCs 
(14), we reexamined our study population for this polymorphism and analysed whether its 
presence was associated with increased GC-sensitivity. 
SUBJECTS, METHODS AND MATERIALS. 
For the present study, a sample of participants from the Rotterdam Study was invited for an 
additional examination. The Rotterdam Study is a population-based cohort study of the 
determinants of chronic disabling diseases in the elderly. All approximately 10,000 inhibitants 
of a suburb of Rotterdam, aged 55 years and over were invited to participate as described 
elsewere (IS). The population for the present study included 216 persons aged 55 to 80 years 
(102 men and 114 women with mean ages of 67.7 ± 5.6 (SE) and 65.8 ± 6.1 years, 
respectively) who had completed the baseline visit for the Rotterdam Study not more than 6 
months earlier. Subjects with acute, psychiatric or endocrine diseases, including diabetes 
mellitus treated with medication, were not invited. Compared to other participants of the 
Rotterdam Study of the same age without diabetes mellitus, there were no differences in age 
and gender distribution and cardiovascular risk factors. From all subjects written informed 
consent was obtained and the study was approved by the Medical Ethics Committee of the 
Erasmus University Medical School. 
Two DSTs were carried out as described previously (Chapter 2). In brief, participants were 
seen at the research centre after an overnight fast. Blood was drawn by venapuncture in order 
to detennine serum cortisol and insulin concentrations. Participants were given a tablet of 1.00 
mg DEX and instructed to ingest it at 11.00 pm. Next morning, fasting blood samples were 
obtained at the same time as the previous morning. In these samples, cortisol, insulin and DEX 
concentrations were measured. Circulating cortisol DEX concentrations were determined as 
described previously (Chapter 2). Serum insulin concentrations were determined using a 
commercially available radioimmunoassay (Medgenix Diagnostics, Brussels, Belgium). Intra-
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and inter-assay variation were 8.0 and 13.7% respectively. 
Two and a half years later, all 216 participants were invited for a 0.25 mg DST.164 subjects 
agreed to participate in this second test (76 men and 88 women with mean ages of 69.1± 5.9 
and 67.6 ± 5.6 years, respectively). The same procedures were used as described for the I mg 
DST. In the fasting and post 0.25 mg DEX samples, glucose concentrations were determined 
using routine standard laboratory methods. 
Both as part of the baseline examinations of the Rotterdam Study, and at the second 
determination, body weight and height were measured in order to calculate body mass index 
(BMI, kg/m'), and sitting blood pressure was measured at the right upper arm with a random-
zero sphygmomanometer. Bone mineral density (BMD) measurements were performed by 
dual-energy X-ray absorptiometry (DXA), using a DPX-L densitometer (Lunar Radiation 
Corporation, Madison, WI, USA). Standard positioning was used with anterior-posterior scans 
of the lumbar spine and the right proximal femur. In cases of a history of hip fracture or 
prothesis implantation, the left femur was scanned. Using standard software the vertebrae L2 
to L4 and the femoral neck were analysed. Quality assurance included calibration with the 
standard of the machine, and was performed routinely every morning. The in vivo coefficient 
of variation for the BMD measurements was 0.9% in the lumbar spine and 3.2% in the femoral 
neck (16) 
PCR/SSCP analysis of the glucocorticoid receptor gene. 
DNA was isolated from periferal blood leucocytes of all subjects using standard teclmiques. 
PCR amplification and SSCP analysis of the 3'-region of exon 2 of the glucocorticoid receptor 
gene were carried out using primer sequences and amplification and electrophoresis conditions 
previously described by Koper et al (14). 
Whole cell DEX binding assay and mitogen induced proliferation assay 
From 41 randomly selected controls and nine carriers of the N363S mutation (see results), 40 
ml heparinized blood was drawn for a whole cell DEX binding assay and a mitogen induced 
proliferation assay. Glucocorticoid receptor characteristics in mononuclear leucocytes and the 
sensitivity of mononuclear leucocytes to the inhibition of phytohaemagglutinin (PHA) 
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stimulated incorporation of ['H)-thymidine by DEX were determined as described previously 
(3), 
Cell cllltllre alld tralls/ectiolls 
Monkey kidney (COS-I) cells were maintained in Dulbecco's Modified Essential Medium-
Ham's F-12 tissue culture medium (Life Technologies, Gaithersburg, MD) supplemented with 
5% dextran coated chroal treated Foetal Calf Serum (Life Technologies), For transcription 
regulation studies, cells were plated at 1.0 x 10' cells/well (10 em}, grown for 24 hr, and 
transfected overnight by calcium phosphate precipitation, as described previously (17), Cells 
were transfected with 250 ng of GR expression plasmid and 250 ng reporter plasmid per well. 
After transfection, experimental media were added, After an incubation period of 24h, cells 
were harvested for the luciferase (LUC) assay, as described previously (18), 
Statistical analysis 
Results are reported as mean ± SE unless otherwise stated, Serum cortisol, insulin and glucose 
concentrations, blood pressure, BMI, BMD and receptor characteristics were compared 
between N363S carriers and controls, using Student's t-testTo control for possible 
confounders, the analyses were adjusted for BMI if appropriate using multiple linear regression 
analysis, Values for BMD were expressed as Z-scores (number of standard deviations below or 
above the age-, BMI-, and sex-standardized average value obtained from 2446 males and 3368 
females who participated in the baseline visit for the Rotterdam study) (16), 
RESULTS 
After the I mg DST, 5 individuals were identified with a post DEX cortisol concentration 
> 140 nmolll, which is the cut-off point for a normal test result in our clinic when the DST is 
used for the screening for Cushing's Syndrome, These five subjects were further investigated 
for cortisol resistance (14), and were left out of the calculations described here, Screening for 
the codon 363 polymorphism was perfomled using PCRlSSCP-analysis, The abnomlal pattern 
in the 3'-fragment of ex on 2 was found in \3 individuals out of the whole study population of 
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216 subjects (6.0%, Figure IA). Sequence analysis of the fragment showed an A to G point-
mutation at cDNA position 1220, resulting in an asparagine to serine change at codon 363 
(Figures lB and IC) .The mutation was found to be heterozygous in all cases. 
The subjects without the mulation in codon 363 (conlrols) and Ihe 13 persons heterozygous 
for the polymorphism (N363S carriers) have been investigated further with respect to their 
HP A-axis and sensitivity to GCs. 
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Figure 1, (A) PCR/SSCP analysis of the 3'-part of ex OIl II orlbe glucocorticoid receptor gene. The analysis revealed 
a polymorphism in 13 out of 216 elderly individuals (C: control, V: variant) (B) Sequence analysis of the 
polymorphism in the 3'-part of exon 11 of the glucocorticoid receptor gene, showing a heterozygous A to G point 
mutation at eDNA position 1220. (C) Structure of the human glucocorticoid receptor gene and protein and its 
functional domains (DBD:DNA-binding domain; HBD:boffilone-binding domain), indicating the position of an 
asparagine to serine cbange al codon 363 as a result of the A to G point mutation at eDNA position 1220 of the 
glucocorticoid receptor gene. 
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In vivo results 
The group ofN363S carriers consisted of 4 men and 9 women, while in the control-group, the 
sexes were equally divided. There was one female N363S carrier who showed an additional 
mutation in the 5'-prime part of exon 2 of the glucocorticoid receptor gene. She was further 
investigated for cortisol resistance (14), and left out of all comparisons. 
At the first examination no significant difference in age between the groups was present as 
shown in Table la. The N363S carriers had a higher mean BMI compared to controls, which 
did not reach statistical significance (P~0.07). Systolic and diastolic blood pressures were not 
different between the groups (Table I a). 
At the second examination 164 of the initial 216 individuals participated, 9 of whom had the 
codon 363 polymorphism. The female N363S carrier with the additional point mutation in 
exon 2 was excluded again from the comparison, and so were two subjects who had a post 
DEX cortisol concentration >140 nmol at the first determination (Table Ib). In the control 
group the sexes were equally divided, the group ofN363S carriers now consisted of 5 women 
and 3 men. At the second examination, the N363S carriers had a significantly higher BMI as 
compared to the control group (P<0.04). In the first determination, there was no statistically 
significant difference in BMI between controls and N363S carriers in this subgroup (26.1 ± 
0.28 in controls versus 28.1 ± 1.30 in N363S carriers, P~0.09). As in the first examination, 
there were no differences between the groups with respect to systolic or diastolic blood 
pressure. 
Physical examination of the N363S carriers revealed no evident abnormalities. One male 
N363S carrier had hypertension, and two females had hyperinsulinemia (fasting insulin>25 
mUll). 
Cortisol concentrations. 
Table 2a shows the concentrations offasting serum cortisol before and after administration of 
I mg DEX, the DEX concentration and the cortisol suppression in reaction to DEX (li 
cortisol). There were no differences between the controls and the N363S carriers, neither in 
basal levels nor in response to the administration of 1 mg DEX. 
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Table la, Age, BM! and blood pressure at first examination in controls (n~198) and 
N363S carriers (n~ 12) 
Controls N363S caniers 
mean SE mean 
Age (years) 66.6 0.44 68.5 
BMI (kg 1m') 26.6 0.26 28.1 
SBP(mmHg) 139 1.35 137 
DBP(mmHg) 74.9 071 73.1 
* Test for the difference between controls and N363S carriers. 
SBP: systolic blood pressure, DBP: diastolic blood pressure 
SE 
1.64 
1.09 
7.00 
2.84 
P-value* 
0.28 
0.G7 
0.77 
0.54 
Table lb, Age, BM! and blood pressure at second examination in controls (n~153) and 
N363S carriers (n~8) 
Cont ... ls N363S caniers 
mean SE mean SE P-value* 
Age (years) 68.3 0.49 69.3 2.36 0.63 
BMI (kg 1m') 25.5 0.30 28.3 1.52 0.04 
SBP(mmHg) 143 1.50 140 10.7 0.57 
DBP(mmHg) 88.1 0.86 83.7 6.37 0.26 
* Test for the difference between controls and N363S carriers. 
SBP: systolic blood pressure, DBP: diastolic blood pressure 
Table 2b provides the same parameters before and after the administration of 0.25 mg DEX. 
Again, there were no differences in baseline cortisol, but there was a larger decrease in cortisol 
concentration (I\. cortisol) in response to 0.25 mg DEX in the N363S carriers than in controls 
(280.5 nmoVI in controls versus 373.9 nmoVI in N363S carriers, P<0.09, unadjusted data). 
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This difference in />,. cortisol was statistically significant when the data were adjusted for BMI 
(443.8 in controls versus 553.6 in N363S carriers, P<0.05). Adjusting for BMI was necessary 
because there was a statistically significant difference in BM! between controls and N363S 
carriers, and BM! is known to influence the cortisol concentration. The actual DEX 
concentrations were equal in both groups (P~0.50), so the higher response in the N363S 
carriers was not due to higher DEX concentrations. 
Table2a. Cortisol and DEX concentrations in controls (n~198) and N363S carriers 
(n~12) before and after I mg DEX 
Controls N363S carriers 
mean SE mean SE P-value* 
Fasting cortisol (nmol/l) 513.5 11.1 532.2 32.4 0.49 
Post DEX cortisol (nmol/l) 26.26 1.22 25.80 3.45 0.97 
11 cortisol (nmol/l) 488.1 10.9 506.3 33.5 0.50 
DEX (nmol/l) 7.300 0.25 8.500 1.44 0.30 
• Test for the difference between controls and N363S carriers, adjusted for BM!. 
Table2b. Cortisol and DEX concentrations in controls (n~153) and N363S carriers (n~8) 
before and after 0.25 109 DEX 
Controls N363S carriers 
mean SE mean SE P-value* 
Fasting cortisol (nmolll) 541.7 12.0 566.5 44.9 0.53 
Post DEX cortisol (nmol/l) 261.2 11.4 192.6 38.1 0.13 
/>,. cortisol (nmol/l) 280.5 12.6 373.9 37.2 <0.05 
DEX (nmol/l) 2.820 0.13 3.300 0.55 0.48 
• Test for the difference between controls and N363S carriers, adjusted for BM!. 
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Insulin and glucose cOllcentrations 
Tables 3a and 3b show the fasting insulin concentrations before and after the administration of 
I and 0.25 mg DEX, respectively, and the increase in insulin levels in response to DEX 
administration. In order to be certain that only the data from subjects with a normal 
carbohydrate tolerance were analysed, subjects with hyperinsulinaemia or diabetes mellitus 
(fasting insulin or glucose concentrations above values of25 mUll or 7.8 mmolll, respectively), 
were excluded from this analysis (20 controls excluded, n~ 178 and 2 N363S carriers excluded, 
n= I 0). There was a significant increase in insulin concentrations in response to the 
administration of I mg DEX among the remaining 188 subjects (12.9 ± 0.53 mUlL before, and 
19.1± 0.80 mUlL after DEX administration, respectively, P<O.OOI). There were no significant 
differences between the groups in fasting or post DEX insulin concentrations, but there was a 
significantly larger increase in insulin levels in the N363S carriers in response to I mg DEX 
(p<O.OI) compared to controls. As mentioned before, these differences in insulin response 
were not due to differences in DEX concentrations between the two groups (Table 2a). 
Table 3a. Insulin concentrations in controls (n~ 178) and N363S carriers (n~ I 0) before 
and after I mg of DE X 
Controls N363S carriers 
mean SE mean SE P-value* 
Fasting insulin (mUll) 11.8 0.39 11.2 1.69 0.34 
Post DEX insulin (mUll) 17.6 0.67 23.5 5.19 0.08 
!J. insulin (mUll) 5.84 0.57 12.3 4.09 <0.01 
• Test for the difference between controls and N363S carriers, adjusted for BM!. 
Subjects with fasting insulin>25 mUll were left out of the calculation; 2 N363S carriers 
and 20 controls were excluded. 
After the administration of 0.25 mg DEX, there was a drop in insulin concentrations in the 
controls. In the N363S carriers there was a slight increase in insulin concentrations. After 
comparison of the insulin responses to 0.25 mg DEX between the two groups, again a 
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significantly larger response in the N363S carriers became apparent (p< 0.03). Glucose levels 
did not increase in response to DEX administration. nor were there differences in glucose 
concentrations between the two groups. 
Table 3b. Insulin concentrations in controls (n~127) and N363S carriers (n~7) before 
and after 0.25 mg of DE X 
Controls N363S carriers 
mean SE mean SE P-value"'" 
Fasting insulin (mUll) 14.8 0.46 13.7 2.29 0.16 
Post DEX insulin (m UIl) 13.7 0.51 15.5 2.83 0.69 
A insulin (mUll) -1.10 0.36 1.80 1.98 0.03 
Fasting glucose (mmol/1) 5.60 0.06 5.40 0.29 0.26 
Post DEX glucose (010101/1) 5.48 0.05 5.50 0.25 0.75 
A glucose (mmol/1) - 0.12 0.04 0.07 0.09 0.19 
• Test for the difference between controls and N363S carriers. adjusted for BM!. 
Subjects with fasting insulin>25 mUll or fasting glucose >7.8 nmolll were left out of the 
calculation; I N363S carrier and 26 controls were excluded. 
Bone mineral density 
In Figure 2, the mean values and standard deviation for BMD in the lumbar spine and the 
femoral neck in controls and N363S carriers expressed as ZMscores are shown. The figure 
shows that in the lumbar spine there was a trend towards lower BMD in the N363S carriers 
compared to controls (z-scores -0.48 versus 0.02 respectively, P~0.08). In the femoral neck, 
there were no differences in BMD between the two groups (P~0.67). 
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Figure 2. Mean values and SD for bone mineral density in the lumbar spine and the femoral neck in controls and 
N363S carriers, expressed as Z·scorcs. There is a Irend lowards lower Bl\1D in the lumbar spine in N363S carriers 
compared to controls (Z-scores -0.48 in N363S carriers versus 0.02 ill controls, P=O.08). There are 110 differences in 
feroral neck BMD between both gro11lls (P~l.67). 
In vitro results 
Whole cell Dk:r binding assay and mitogen induced pro!!feralio/1 assay 
Figure 3 shows the results from 50 whole cell DEX binding assays and mitogen induced 
proliferation assays (41 randomly selected controls and nine N363S carriers). The number of 
receptors (n,Figure 3A) and the dissociation constant (K, figure 3B) were not different in 
both groups (n~7056 ± 200 in cOlltrols, IF7242 ± 645 ill N363S carriers; Kd~10.6 ± 0.63 in 
controls, Kd~8.5 ± 1.14 in N363S carriers respectively). Also, no statistically significant 
difference in ICso values between the N363S carriers and controls was found; as shown in 
fIgure 3C, there was a trend towards a lower IC" ill the N363S carriers (1<;'. ~47.7± 9.6 in 
controls, IC,,~21.8 ± 6.4 in N363S carriers, respectively) . 
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Figure 3. Glucocorticoid receptor characteristics in peripheral blood mononuclear leucoc}1es in 41 randomly 
selected controls and 9 N363S carriers. (A) Number of receptors in controls and N363S carriers obtained from 
whole cell DEX binding assays. There is no difference between controls and N363S carriers in number of receptors 
per cell. (B) Ligand affInity of the receptors (KJ) in controls and N363S carriers obtained from whole cell DEX 
binding assays. There is no differcnce in K,J between controls and N363S carriers. (C) Concentrations of DEX 
necessary to achieve 50 % of the maximal inhibition (IC5¢) in mitogen induced proliferation assays in controls and 
N363S carriers. There are no differences ill IC5¢ values between controls and N363S carriers. 
103 
Chapter .f 
Transcriptional activatioll studies 
To investigate whether the observed codon change at position 363 resulted in an altered 
capacity of the GR protein to activate transcription, we co-transfected a plasmid containing 
this variant receptor and a Mouse Mammary Tumor Virus (MMTV)-driven luciferase (LUC) 
reporter plasmid in COS-! cells. Cells were incubated with increasing concentrations of DEX. 
At DEX concentrations between zero and 100 nmolll, the capacity of the N363S variant to 
activate transcription from the MMTV promotor of the N363S variant was unaltered 
compared to the wild type GR (Figure 4). 
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FJgurc 4. Transcriptional activation of an MMTV-LUC reporter gene by the wiJd-type receptor (closed circles) and 
the codon 363 mutant (open circles), Data are the average of three separate transfection assays, each performed in 
duplicate. At concentrations of DE X between zero and 100 nmoVL, the capacity of the N363S variant to actlvate the 
tCans(:ciption from the MMTV promotor was unaltered compared to the wild type GR. 
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DISCUSSION 
In this study, we examined differences in the sensitivity to GCs within a normal elderly 
population, using DSTs with two different doses of DE X. In a previous study (14), looking for 
mutations in the GR gene which cause the clinical syndrome of CR (9-12), we found a 
polymorphism which appeared to be associated with increased sensitivity to GCs. TIlls 
polymorphism located at nucleotide position 1220 (AAT to AGT), results in a asparagine to 
serine change in codon 363 of the GR protein. This polymorphism was heterozygously present 
in 13 out <if the 216 subjects. One of these subjects had hypertension and two had elevated 
insulin concentrations. The other N363S carriers were healthy elderly individuals, and showed 
no signs or symptoms of CR. 
A I mg DST carried out to asses differences in GC sensitivity showed no differences in early 
morning post-DEX cortisol concentrations. Because I mg may be a relatively high dose (93% 
of the subjects suppressed to a level < 50 nmol/l) we also carried out a 0.25 mg DST. In this 
experiment, post DEX cortisol concentrations showed a much broader range than after I mg 
DEX(Chapter 2).The decease in early morning cortisol levels (~ cortisol) was significantly 
greater in N363S carriers than in controls. The absolute post-DEX cortisol levels were also 
lower in N363S carriers, but tills difference was not statistically significant. 
Another parameter for the sensitivity to exogenously administered GCs is the fasting insulin 
concentration before and after DEX administration. It has been recognized for a long time that 
GCs impair insulin mediated glucose metabolism and induce insulin resistance (19). In this 
study, fasting insulin levels before DEX were sinlilar in the two groups, but in response to the 
adnlinistration of I mg DEX there was a significantly larger increase in the serum insulin levels 
in N363S carriers than in controls. After the adnlinistration of 0.25 109 DEX, there was a slight 
drop in insulin concentrations in the control group, whereas in the N363S carriers, mean 
insulin concentrations rose. It appears that in controls 0.25 mg DEX is not sufficient to induce 
insulin resistance, while in the N363S carriers this low dose of DEX forces the insulin 
concentrations to increase in order to maintain a normal plasma glucose concentration. These 
data support the assumption that N363S carriers have an increased sensitivity to GCs. 
With respect to the potential long term effects of the codon 363 mutation, three parameters 
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were investigated: BM!, blood pressure and BMD. GCs are involved in the syndrome of 
abdominal obesity due to stimulatory effects on lipid accumulation in adipose tissue (20). 
Patients with Cushing's syndrome have a centripetal fat distribution, resulting in a higher BM!. 
This seems to be due to an increased lipoprotein lipase activity in combination with a lowered 
capacity for fat mobilization in the central regions (21). The net effect of hyper corti solemi a is 
an increase at triglyceride storage in visceral adipocytes (22). At the second examination, the 
N363S carriers had a significantly higher BM! than controls, while at the first examination 
there was a trend towards a higher BM! in the N363S carriers. The higher BM! observed in in 
these persons supports the view that they are more sensitive to effects of CGs. There were, 
however, no differences in blood pressure between the two groups, neither at the first, nor at 
the second examination. 
It is well known that patients under treatment with GCs show a reduced bone mass and an 
increased fracture risk. GCs have been found to influence bone and calcium metabolism at 
several levels (23, 24). The effects of GCs on BMD are more profound on trabecular bone 
than on cortical bone (24). The data from the present investigation indeed demonstrate a lower 
BMD in the lumbar spine of the N363S carriers compared to control subjects. However, this 
difference in BMD did not reach statistical significance. In the femoral neck, there were no 
differences in BMD between the groups. 
Other investigations have previously found the N363S polymorphism in a CR-patient, who 
also showed a splice-site deletion (10) and in the small cell long cancer (SCLC) cell lines 
DMS-79 (25) and COR L24 (26). These authors found no significant difference in the capacity 
of this variant GR relative to the wild type to activate transcription of the CAT gene in an 
MMTV driven reporter construct, after transfection into COS-I cells. Our own results using 
the more sensitive MMTV-LUC system also do not indicate a difference between N363S and 
wild type GR in this respect. Apart from transcriptional activation, GR is also involved in 
transcriptional repression of target genes. It does so either by binding directly to so-called 
negative glucocorticoid responsive elements (nGREs) (27, 28), or via interactions with factors 
such as activating protein-I (AP-I) (29, 30) or nuclear factor (NF)-xB (21-23), thereby 
preventing these factors from activating their target genes. Co~transfection experiments have 
shown that the codon 363 variant has an unaltered capacity to repress target genes via nGREs 
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or via the above mentioned transcription factors (31). 
Our results of the whole cell DEX binding assays demonstrate no ditTerences between the 
variant- and the wild type GR in tlus respect, but as the mutation is located in the N-terminal 
part of the GR, no aIterations in the number of receptors or the ligand binding capacity in 
peripheral mononuclear leucocytes from N363S carriers were expected. The mitogen induced 
proliferation assay on the other hand, reflects the cellular response to GCs (32). One would 
expect to find aIterations in the suppressibility of mitogen-stimulated thymidine incorporation 
in cultured Jeucocytes from N363S carriers. Indeed, a trend towards lower ICso values in the 
N363S carriers compared to controls was observed, but these ditTerences did not reach 
statistical significance, probably as a resuIt of the wide range of values obtained in controls. 
In summary, we have showed significant effects of the N363S mutation on changes in insulin 
and cortisol levels after the adnunistration of DEX, indicating increased sensitivity to acutely 
increased GC levels. Long term effects of increased sensitivity to endogenous Gcs - which 
nught be partly compensated by counterregulatory mechanisms - could be reflected in the 
trends to increased BMI and decreased BMD in trabecular bone. In this connection, it is of 
interest that about 5% of the patients treated with Gcs develop severe side etTects soon after 
starting the therapy; N363S carriers nught be included in this subpopulation. The apparent 
discrepancy between these ill vivo etTects and our inability to confiml this increased sensitivity 
to Gcs ill vilro is likely to be due to the earlier mentioned broad spectrum of regnlatory 
mechanisms in which Gcs and their receptors are involved. We showed earlier that GR 
mutations can etTect transcriptional activation and -repression ditTerently (31). It could well be 
that COS-I cells lack the transcription factors detemuning the etTect of the N363S mutation ill 
vivo and that the presence of endogenous GR in these cells is an impediment for the study of 
subtle etTects of this mutation ill vitro. 
Finally, our resuIts may indicate that this polymorplusm is linked to an additional genetic 
aIteration in a gene of which the product is involved in the observed phenotypic ditTerences. 
This yet unknown factor might interact with the GR protein to exert its effect. However, for 
diagnostic purposes, the recognition of a point mutation in the GR gene linked to a phenotypic 
ditTerence may prove very useful, whether or not this may solely, in part or not at all be a 
consequence of aItered GR function. A next step will be to investigate whether the codon 363 
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polymorphism might predict an increased sensitivity to the development of early andlor serious 
side effects during therapy with GCs. 
In conclusion, our findings show that ill vivo the codon 363 variant of the GR is associated 
with an increased sensitivity to GCs in the direct response to exogenously administered DEX. 
BMI and BMD might also be effected by this variant GR. The molecular basis for this 
increased sensitivity remains to be elucidated. 
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ABSTRACT 
Cortisol resistance (CR) is a rare disease characterized by a generalized reduced sensitivity of 
end-organs to the actions of glucocorticoids (GCs). GC effects are mediated by the 
glucocorticoid receptor (GR). The molecular alterations in CR described thus far were located 
in the hormone binding domain of the GR gene. Recent reports of a considerable prevalence of 
abnormalities in the GR in patients attending the endocrine clinic prompted us to carry out 
further investigations with respect to GR protein and GR gene in patients attending the 
endocrine clinic for a broad spectrum of complaints and biochemical evidence suggesting a CR. 
In the present study, we describe 5 patients with biochemical and clinical CR. All patients 
showed a diurnal rhythm of serum cortisol concentrations, albeit at a high level, an insufficient 
suppression of serum cortisol concentration in reaction to I mg of dexamethasone (DEX), 
variable degrees of androgen overproduction, in the absence of clinical signs and symptoms of 
Cushing's syndrome. Three of the four female patients presented with complaints of androgen 
overproduction, two of them in combination with fatigue. The other female patient had severe 
steroid resistant asthma. The only male patient and his son were asymptomatic. 
In 4 patients, we investigated receptor protein characteristics on mononuclear leukocytes in a 
whole cell DEX binding assay, and studied the ability of DEX to inhibit mitogen induced cell 
proliferation in mononuclear leukocytes ill vitro. In all patients investigated, we found 
alterations in receptor number or ligand affinity andlor the ability of DEX to inhibit mitogen 
induced cell proliferation. 
In order to investigate the molecular defects leading to the clinical and biochemical pictures in 
these patients, we screened the GR gene using PCRlSSCP/sequence analysis. No GR gene 
alterations were found in these patients. 
In conclusion, the five patients described had clinical and biochemical evidence of CR but no 
abnonnalities were demonstrated in the GR gene. 
Probably, as yet undefined alterations somewhere in the cascade of events starting with ligand 
binding to the GR protein, and finally resulting in the regulation of the expression of GC 
responsive genes, or post-receptor defects or interactions with other nuclear factors form the 
pathophysiologic basis of CR in these patients. 
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INTRODUCTION 
Cortisol resistance (CR) is a rare condition characterized by a generalized reduced sensitivity 
of end-organs to glucocorticoids (GCs). The disease is typified by increased serum cortisol 
levels, a normal circadian rhythm of cortisol concentrations albeit at an elevated level, relative 
resistance of adrenal cortisol suppression to dexamethasone (DEX) and the absence of the 
clinical stigmata of Cushing's syndrome (I). After the original description of a father and son 
with CR by Vingerhoeds (2), about 30 symptomatic patients and (a)symptomatic family 
members have been identified (1-13). In generalized CR, the decreased sensitivity to cortisol 
results in activation of the HP A-axis with increased ACTH and cortisol secretion. In most 
cases, the elevated cortisol levels sufficiently compensate to overcome peripheral cortisol 
resistance. The elevated cortisol concentrations are beneficial in these patients and no signs or 
symptoms of Cushing's syndrome are present. The clinical presentation of CR is in most 
instances related to the secondary ACTII-driven overproduction of adrenal androgens and 
mineralocorticoids. Hypertension and hypokalemic acidosis may develop secondary to 
overproduction of mineralocorticoids (I, 2). In females, the secondary overproduction of 
adrenal androgens may result in acne, hirsutism, menstrual irregularity and infertility (I, 6). The 
overproduction of adrenal androgens gives rise to signs of hyperandrogenism in females only, 
because of the much higher gonadal androgen production in males compared to females. In 
some patients with CR chronic fatigue is the only symptom (5), probably due to an insufficient 
overproduction of cortisol. Finally, several patients with steroid resistant asthma have been 
described, which in two cases appeared to be caused by generalized CR (13). 
The biological effects of cortisol are mediated by the GC receptor (GR), a member of the 
family of intracellular hormone receptors (14), to which the vitamin D and retinoic acid 
receptors belong as well. These receptors are characterized by a three-domain structure: a 
carboxy terminal ligand-binding domain, a central DNA-binding domain and an N-terminal 
domain responsible for the interactions with other transcription factors (14). Hormone-bound 
GRs translocate to the nucleus and regulate the expression of GC responsive genes. 
It has become clear from previous studies that the molecular basis of CR may be located in the 
GR gene. Up to the present, this has been elucidated in four different kind reds (15-18), in 
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which mutations in the hormone binding domain of the GR-gene appeared to be the cause of 
CR. 
Because of the large variation in clinical manifestation of CR, the disease might be less rare 
than previously thought. In six patients described by Lamberts et al (I), at least 3 different 
clinical forms ofCR could be identified. 
In the present study, we report five additional patients with very diverse clinical presentations. 
Eventually, in all patients clinical andlor biochemical cortisol resistance was diagnosed. Using 
PCRlSSCP and sequence analysis, we screened the GR gene in these patients for alterations, in 
order to characterize the cortisol resistance on the molecular level as well. No evidence for 
mutations in the GR gene was found in any of the patients, however. Suggestions for other 
possible mechanisms of CR in these individuals are made. 
MATERIALS AND METHODS 
Biochemical determinatiolls 
The diagnostic procedures used in measuring the activity and responsiveness of the HP A axis 
in the patients tested in our own clinic have been described previously (19, 20) Circulating 
cortisol, ACTH, desoxycortisol, androstenedione, dehydroepiandrosterone (DHEA), DHEA 
sulfate (DHEAS) and testosterone levels were determined by RIA kits. The inter- and intra-
assay variations of these determinations have been reported previously (I). Urinary cortisol 
was measured with the same RIA kit as that used for circulating cortisol. Patient 3 (see results) 
was tested in Antwerp (Belgium). Differences in normal values compared to the normal values 
in our clinic are indicated in the results section. 
Peripheral blood mOl/ol/lle/ear cells 
40 ml of blood was drawn into heparinized tubes between 8.00h and 9.00h by vena puncture. 
Peripheral blood mononuclear leukocytes (PBMLs) were isolated as described previously (21). 
The blood was diluted twofold with saline and layered over Ficoll-Hypaque (Pharmacia, 
Uppsala, Sweden). The PBML enriched interphase was isolated and washed twice with saline. 
The final cell pellet was resuspended in 15 ml RPMI-1640 medium (Gibco Europe, Breda, the 
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Netherlands), containing 15 mM Hepes, 10% charcoal adsorbed fetal calf serum 
(AmstelstadlFlow, Zwanenburg, the Netherlands), 2 mM glutamine, 100 V/ml penicillin, 100 
mgtml streptomycin and 1.5 mgtml filllgizone. The cells were incubated for 30 minutes at 37'C 
in a shaking waterbath in order to remove endogenous cortisol. The cell suspension was 
centrifuged and resuspended in IS m1 medium. This procedure was repeated twice more. 
Finally, the cells were resuspended at a density of2.5-10 x 10' cells per ml in the medium. 
Whole cell dexamethasone binding assay 
The whole cell dexamethasone binding assay was performed as described previously (21). 
Briefly: incubation was started in a volume of 240 1'1 (0.5-2 xIO' cells) containing H-
dexamethasone at concentrations of 1.3 to 40 nM without (total binding) and with (non-
specific binding) a 400-fold excess of unlabelled dexamethasone. Two tubes without labelled 
dexamethasone were incubated under the same conditions for determination of cell number and 
viability at the end of the procedure. The tubes were incubated during I hour at 30°C in a 
shaking water bath. The incubation was stopped by the addition of 2 m1 cold saline, followed 
by centrifugation and two washing steps. Finally, the cells were resuspended in 250 1'1 medium. 
Radioactivity in 200 1'1 of this suspension was counted in a liquid scintillation counter. Specific 
binding was calculated by subtracting non-specific binding from total binding. Receptor 
number and ligand affinity (11K,) were calculated from the data using the method of Scat chard 
(22). Normal values for the number of receptors per cell (6352 ± 310 per cell) and K, (7.7 ± 
0.4 nmollI) were described previously (I, 23) 
Inhibition of mitogen-stimulated incorporation of ['H)-thymidine by DEX 
The sensitivity of mononuclear leukocytes to the inhibition of phytohaemagglutinin (PHA) 
stimulated incorporation of ['H)-thymidine by DEX was determined as described previously 
(I). After isolation, mononuclear leukocytes were seeded, PHA (5 I'gtmL) and DEX in 9 
concentrations between 0 and 1000 nmollL were added. The cells were incubated at 37'C 
during 96 hour. The last four hours of incubation was in the presence of 0.5 I'Ci of ['H)-
thymidine. At the end of the incubation the cells were harvested, washed and incorporated 
['H)-thymidine was measured by liquid scintillation counting. The concentration of DEX 
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necessary to achieve 50% of the maximal inhibition (IC,,) was calculated. Normal values for 
IC" «15 nmoVI) were described previously (I, 23) 
PCR/SSCP analysis of the glucocorticoid receptor gene. 
DNA was isolated from peripheral blood leukocytes using standard techniques. PCR 
amplification of the glucocorticoid receptor gene was carried out using primer sequences and 
amplification conditions previously described by Karl et al (16). SSCP analysis of the PCR-
products was carried out using 0.5 x MDE polyacrylamide gels (from J.T. Baker Chemicals, 
Deventer, the Netherlands) at 4 "C in the presence and absence of 5% glycerol, generally as 
described by Orita et al (24). DNA-fragments displaying an abnormal migration pattern during 
SSCP-analysis were subject to direct sequencing using a modified Sanger-dideoxynucleotide 
chain termination method (16, 25). In all patients, a second PCR amplification of the exons 2 
and 4 to 9 of the GR gene was carried out using other primer sequences (data not shown, 
sequences available on request), in order to obtain PCR fragments with a length of about 200 
nucleotides. SSCP analysis of the PCR fragments was carried out as described above. Finally, 
PCR fragments of exons 4 to 9 (coding for the hormone binding domain of the GR) in all 
patients and of the whole coding part of the GR gene in patients I and 2, were subjected to 
direct sequencing as described by Karl et al (16). 
RESULTS 
Patient 1 was first investigated at the age of 18 years because of hirsutism, menstrual 
irregularities and weight gain of IS kg over the past two years. Physical examination revealed 
an obese young woman (length 1.60 m, weight 85 kg), with a normal fat distribution. Blood 
pressure was 160/85 mm Hg. She had profound hirsutism on arms, legs, chest and especially 
face. She had a round face and acne. There was no skin atrophy. 
Endocrine testing showed a diurnal rhythm of plasma cortisol concentrations at an elevated 
level (Table I). 24 hour urinary cortisol secretion was elevated (Table I). ACTH secretion was 
in the higher normal range. A I mg overnight dexamethasone suppression test (DST) showed 
insufficient cortisol suppression (323 nmoV!, Table I), but intravenous administration of a 
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high-dose DEX adequately suppressed cortisol secretion. Further studies (Table 2) showed 
increased androstenedione and testosterone levels and a slightly increased desoxycortisol 
concentration. At that time, the diagnosis of pituitary dependent Cushing's syndrome was made 
and a left sided adrenalectomy was performed followed by external pituitary radiation. 
A year and a half later, the patient was admitted with a fever, vomiting and diarrhoea. 
Although the cortisol concentration at the time of admission was normal (528 nmolll), there 
was a dramatic improvement of the clinical condition following intravenous administration of 
hydrocortisone. In retrospect, relative adrenocortical insufficiency during this intercurrent 
disease was suspected. 
One year later, the patient presented with increasing fatigue, further weight gain, dizziness and 
increasing hirsutism. Physical examination showed an obese woman with a normal fat 
distribution. She had a round face and profound hirsutism on the chest. Endocrine screening 
revealed an insufficient cortisol suppression in the I mg overnight DST. Because of the 
pituitary radiation, no further endocrine testing of the HPA-axis was possible. She was treated 
with oral contraceptives containing cyproterone acetate. 
Twelve years after the first admission, the patient was screened with respect to cortisol 
receptor characteristics. It appeared that she had a normal number of receptors per cell in 
mononuclear leukocytes, and also the ligand binding affinity of the receptors was normal 
(Table 4). From the mitogen induced proliferation assay, however, it became clear that the 
PBMLs were extremely insensitive to DEX (Table 4, Figure I). PCRlSSCP analysis of the GR 
gene showed an abnormal pattern in the N-terminal part of exon 2. Sequence analysis of the 
fragment revealed the presence of a polymorphism, leading to a GAG to GAA (both Glu) in 
codon 22 and a AGG to AAG (Arg to Lys) change in codon 23 as described previously by 
Koper et al (25). Further sequence analysis of the whole coding part of the GR gene revealed 
no additional alterations. 
Based on clinical and biochentical findings, the diagnosis of generalized cortisol resistance was 
made, and a treatment with low doses DEX at night was started. Cortisol-, androstenedione-
and testosterone levels were significantly suppressed during DEX treatment (Table 2), and 
there was a slight improvement of the hirsutism. 
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Table 1. Patient data concerning the HP A-axis in 4 patients with partial cortisol 
resistance. 
Diurnal rhythm of cortisol 
(nmolll) 
Pt sex age 8.00 hr 17.00 hr 22.00 hr 1 mg DST ACTH UCS 
(~r) (nmoll!) ( nllL!) (I,ld 
F 18 653 508 403 323 46 I 
3 M 65 524 364 107 471 25 
4 F 33 1355 1040 870 857 28 
5 F 33 321 252 89 503 17 
Diurnal rhythm of cortisol: Normal values: 8.00 hr: 200-800 nmolll; 
I mgDST 
UCS: 
ACTH: 
17.00 hr:< 75% of8.00 hr value; 
22.00 hr:< 75% of8.00 hr value. 
I mg dexamethasone suppression test, 
cortisol at 8.00 hr, normal value <140 nmolll 
As the methodology used differed between patients, only an 
indication ofthe result in comparison with normal levels is given. 
Normal value <60 pmolll 
Patient 2, a girl born in 1976, presented at the age of 7 years with very severe asthma. Because 
of the severity of the astlmla, she spent several times in a center for asthmatic diseases in the 
Swiss Alps. Initially, she was treated with inhalation corticosteroids, p-sympaticomimetics and 
anti cholinergic drugs in combination with short periods of high doses of orally administered 
corticosteroids (prednisone). When she was referred to our clinic at the age of 17 years, she 
had been treated with prednisone 25 mg daily continuously for two years, which regularly had 
to be elevated to a dose of 60 mg per day over a period of 10-12 days. Despite this therapeutic 
regimen, she still had severe complaints of astlulla, not allowing her to live a normal life. 
Because this very poor clinical response to therapy in combination with the fact that she had no 
signs or symptoms of Cushing's syndrome, she was referred to our clinic for investigation 
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whether this steroid resistant asthma was based on a defect in the GR gene. 
Physical examination revealed a tall, slender young woman, without signs or symptoms of 
Cushing's syndrome. She had a normal blood pressure. There were no signs of skin atrophy, 
hirsutism, hematomas or muscle weakness. Using oral contraceptives, she had regular menses, 
Despite the continuous high dose prednisone therapy during puberty, her final height was over 
10 em above the parents' height (1.70 m). Because of the high dose of prednisone the patient 
was taking, we were not able to perform regular testing of the HPA-axis. Furthermore, as 
became clear from a previous study (21), prednisone is an agent that interferes with the whole 
cell DEX binding assay and the mitogen induced thymidine incorporation assay, making it 
impossible to obtain meaningful results from these tests. 
Using PCRlSSCP analysis, we found the same polymorphism as described for patient I in 
exon 2 of the GR gene. No other mutations were found despite sequencing of the whole 
coding part of the GR gene. 
The patient,s grandparents, parents and her two younger brothers were tested with respect to 
CR as well. They were all healthy without clinical signs of GR. They all showed a normal 
cortisol suppression in the I mg overnight DST. Nevertheless, it appeared that the 
grandmother (from mothers side), the mother and the oldest brother showed the same 
polymorphism in exon 2 of the GR gene. 
Patient 3 is a 65 years old Belgian man. Hypertension was diagnosed at the age of 50. Fifteen 
years before presentation, a CT scan revealed a tumor in the right kidney and a tumorous 
enlarged right adrenal gland. He underwent a partial right sided nefrectomy in combination 
with an adrenalectomy. Histopathological evaluation revealed an infiltrating clear-cell 
adenocarcinoma ofthe kidney and nodular adrenal hyperplasia. 
Two years later, he presented with obesity and insulin resistance. He was treated with a diet 
and biguanides. Serum cortisol concentrations and 24 hr urinary cortisol excretion were tested 
because of the adrenal hyperplasia that was previously found. Basal cortisol concentration at 
that time was 432 nmoVI at 8.00 am, which is within the normal range. Nevertheless, 24 hr 
urinary cortisol excretion was increased considerably to twofold over the normal range. 
Five years later, a CT scan revealed a nodule of 2 em in a nodular enlarged left adrenal gland. 
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There were no clinical symptoms of Cushing's syndrome. 
Endocrine testing at that time (Table I) showed a normal diurnal rhythm of cortisol 
concentrations with high-normal ACTH concentrations. There was an insufficient suppression 
of cortisol in the overnight 1 mg DST (471 nmoVI). In response to the iv administration of 0.1 
U/kg insulin, he developed hypoglycemia followed by a just subnormal increase in cortisol 
levels (Table 3). 
Three yaers later, a CT scan confirmed the macronodular hyperplasia of the left adrenal gland. 
A CT scan of the pituitary revealed no abnormalities. At present, he is still asymptomatic 
without signs or symptoms of Cushing's syndrome. 
In the whole cell DEX binding assay, a normal number of GC receptors per cell in PBMLs 
became apparent (Table 4). On the other hand, the receptors showed a diminished affinity for 
DEX, with a K, of 22.3 nmolll (Figure 2). In the mitogen induced proliferation assay, a 
maximal inhibition of 77% could be achieved with an IC" of33.1 mnoVI, which is in the higher 
normal range. 
Using PCRfSSCP analysis of the whole coding part of the GR gene in combination with 
sequence analysis of the whole hormone binding domain (exons 4-9), no alterations in the GR 
gene could be identified. 
The patient's three sons and only daughter were tested with respect to CR as well. One ofthe 
sons had an increased 24 hr urinary cortisol excretion. He was a healthy young man, and had 
no hypertension. In a I mg overnight DST, he showed an insufficient cortisol suppression 
(cortisol after I mg of DEX was 364 nmolll). Also in the son, no alterations in the GR gene 
could be identified. 
As the increased 24 hr urinary cortisol excretion and the diminished cortisol suppression in the 
overnight I mg DST were found by coincidence, and the patient was, apart trom the increased 
blood pressure, asymptomatic, he was not treated with DEX. 
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(exons 4 to 9) revealed no alterations in this part of the gene. 
Her parents and only sister were healthy and showed a normal cortisol suppression in an 
overnight I mg DST. 
Based on the clinical and biochemical data, the diagnosis of generalized cortisol resistance was 
made. The patient has been treated with low doses of DEX for the past three months. Within a 
couple of weeks a dramatic improvement of the clinical course was observed: Fatigue and 
mental instability greatly improved. The patient started working again and jogs 10 km every 
other day. Nevertheless, Table 3 shows that the HP A axis was not sufficiently suppressed by 
0.5 mg of DEX administration. Cortisol and desoxycortisol concentrations were still elevated 
while adrenal androgen production was not suppressed. Probably, this low dose of DE X was a 
sufficient dose to induce the clinical improvement in the patient, but was not high enough to 
adequately suppress the HP A axis. 
Patient 5 is a 33 year old woman who was admitted for analysis of severe tiredness, hirsutism 
and oligomenorrhea. Furthermore, there were complaints of diminished concentration and 
muscle weakness. She was not able to perform her job as a schoolteacher anymore. In the past, 
she had been analysed several times for fatigue and pain in the throat which was interpreted as 
a viral infection. Furthermore, she had hirsutism and irregular menstruations. 
Endocrine testing showed a normal circadian rhythm of cortisol, ACTH and a normal urinary 
cortisol excretion (Table I). There was an insufficient cortisol suppression in reaction to the 
administration of I mg of DEX (Table I). A normal GH response in reaction to an insulin 
induced hypoglycemia was observed, but cortisol concentrations did not increase sufficiently 
(Table 3). Table 2 shows that the desoxycortisol concentration was slightly elevated and the 
androgen concentrations were increased considerably. The patient had no brothers or sisters, 
her parents were both healthy and showed normal cortisol concentrations and a normal adrenal 
cortisol suppression in an overnight 1 mg DST. 
Analysis of cortisol receptor characteristics in mononuclear leukocytes showed a normal Kd, in 
combination with a significantly lowered number of receptors per cell (Figure 3). The bioassay 
showed a normal capactty to inhibit mitogen induced proliferation (Table 4). PCRlSSCP 
analysis of the whole coding part of the GR gene showed no abnormal nligration patterns. 
124 
Five patiellts with CR 
Furthermore, sequence analysis of the hormone binding domain of the GR gene (exons 4-9) 
revealed no alterations in this part of the gene. 
Based on the clinical and biochemical determinations, the diagnosis of partial cortisol 
resistance was made. The patient has been treated with low doses of DEX for the past 6 
months. Table 3 shows that the androgen concentrations are still slightly elevated, but 
suppressed as compared to pre-treatment values. Hirsutism has improved and the menstmal 
pattern has normalized. Furthermore, the tiredness has dramatically improved, the patient feels 
extremely well for the first time in years, and started to work again on a regular basis. 
Table 4. 
Patient 
3 
4 
5 
Cortisol receptor characteristics and inhibition of PHA-stimulated ['H]-
thymidine incorporation in mononuclear leukocytes by dexamethasone. 
mononuclear leukocyte 
cortisol receptor characteristics 
no. of receptors I K, 
cell (nmolll) 
7429 8.6 
6659 22.3 
5938 17.4 
3500 8.1 
inhibition of PHA-stimulated ['H]-
thymidine incorporation by DEX 
maximal inhibition Ie" 
(%) (runolll) 
0 00 
77 33.1 
35 00 
95 27.7 
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Figure 1. Mitogen induced proliferation assay in patient I (circles), patient 4 (triangles) and a healthy control 
(squares). In both patients DEX showed a dramatically reduced capacity to inhibit mitogen induced cell proliferation 
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Figure 2. (right) Whole cell DEX binding assay in patients 3 (triangles) and 4 (squares) and a healthy ('''Ootrol 
(circles), Doth patients showed a decreased amnit)' of the OR to DEX. 
Figure 3. (left) Whole cell DEX binding assay in patient 5 (squares) and a healthy control (circles), The patients 
showed only half oflhe normal receptor number per cell. 
126 
Five patients with CR 
DISCUSSION 
Ever since the first description 1976 by Vingerhoeds et al (2), only about 30 patients and 
(asymptomatic) family members with CR have been described. Up till now, the molecular basis 
for CR has been described in four patients and affected (asymptomatic) family members (15-
18). In all four cases, mutations in the hormone binding domain of the GR gene were 
responsible for the clinical manifestation of cortisol resistance. Recent reports of a considerable 
prevalence of possible abnormalities in the GR in patients attending the endocrine clinic for 
hypokalemia, hypertension, acne, hirsutism and menstrual disorders (I, 11), prompted us to 
carry out a thorough investigation with respect to the GR protein and the GR gene in patients 
attending the endocrine clinic for a broad spectrum of complaints suggesting a possible CR. In 
the present study, we describe 5 patients with variable clinical presentation which all seem 
clarified by the syndrome of generalized CR. 
In patient 1, extreme hirsutism was the most profound complaint after she was treated for 
Cushing's disease (at that time the treatment of choice was adrenalectomy followed by 
pituitary radiation). Two years later she was readmitted with clinical signs and symptoms 
which were probably related to relative adrenocortical insufficiency. About 20 years later at 
retesting, it appeared that her PBMLs were extremely insensitive to the inhibitory effect of 
DEX on mitogen induced proliferation. Treatment with low doses of DEX decreased the 
serum androgen concentrations, and there was a slight improvement of the hirsutism after 
several months of treatment. Patient 4 had complaints ofhyperandrogenism, mood unstability, 
increasing fatigue and hypertension. Endocrine testing elsewhere pointed towards Cushing's 
disease. She underwent transsphenoidal pituitary surgery, during which normal pituitary tissue 
was removed. Further investigations showed that the GR ligand affinity on PBMLs was 
markedly diminished. From the clinical history of these two patients, it can be concluded that it 
is important to distinguish Cushing's syndrome from CR in cases of hypercortisolemia. The 
patients showed an increased (patient 4) or high normal (patient I) early morning cortisol 
concentration, but, in both patients, there still was a virtually normal diurnal rhythm of 
cortisol, albeit at an elevated level. In Cushing's syndrome, the diurnal rhythm of cortisol is 
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absent. Another important observation in patient 4 was that she had a completely normal bone 
mineral density despite the elevated cortisol concentrations, wlule also both cortisol and GH 
levels adequately increased in response to an insulin induced hypoglycemia. Both observations 
would not have been observed in an individual with Cushing's syndrome. On the other hand, it 
cannot be excluded that patient 4, who showed very high serum cortisol concentrations will 
eventually develop Cushing's syndrome. Karl et al (18) described a patient who developed 
pituitary Cushing's syndrome preceded by generalized CR. A previous study by our group, 
however, indicated that in patients with Cushing's disease due to ACTH secreting pituitary 
adenomas, no GR gene alterations in DNA extracted from PBMLs could be identified (26). In 
patient 4, we observed clinical improvement during treatment with low doses of DEX. 
Nevertheless, cortisol and desoxycortisol concentrations remained elevated, while adrenal 
androgen production was not suppressed. Probably, this low dose of DEX was sufficient to 
induce the clinical improvement in the patient, but was not high enough to adequately suppress 
the HP A axis. 
In patients 4 and 5, fatigue was, besides signs of hyper androgen ism, an additional complaint. In 
a previous report by Bronnegard (5), a family with CR was described, in whom chronic fatigue 
was the only symptom. It was hypothesized that there was an insufficient compensation by 
increased GC secretion in certain target tissues, like for example the central nervous system. In 
patient 5, a nonnal diurnal rhythm of cortisol concentrations was seen, but she showed 
insufficient adrenal cortisol suppression in an overnight 1 mg DST. Furthermore, an insufficient 
cortisol response in reaction to an insulin induced hypoglycemia was seen. After treatment with 
low doses of DEX, the patient felt much better and the fatigue disappeared. In tlus patient, an 
insufficient increment of GC secretion to overcome the CR might be an explanation for the 
clinical picture. 
Patient 2 was a young girl with severe asthma, who was using prednisone therapy for several 
years, without beneficial effects with respect to her asthma, but also without adverse effects 
with respect to signs and symptoms of Cushing's syndrome. It was striking that there was no 
growth impairment during puberty, and her final length was well above her parents' length. 
Because of the GC therapy, we could not perform endocrinological testing, nor deterollne 
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receptor protein characteristics. Nevertheless, the diagnosis CR was based on the complete 
absence of signs and symptoms of Cushing's syndrome. The results ofa number of studies (27, 
28) suggest that in cases of rheumatoid arthritis, astluna and sepsis, high local concentrations 
of cytokines induce a localized CR at the site of inflammation, which can insufficiently be 
overcome by excess exogenous GCs. Tlus reversible cytokine-induced form of CR should be 
differentiated from the situation in our patient in whom steroid resistant asthma was probably 
due to an irreversible (generalized) CR, which was previously described in two patients by 
Sher et al (13). Tlus differentiation can be made on base of the appearance of side effects: In 
patients with cytokine-induced CR, OCs do have deleterious systenuc effects, while in patients 
with generalized CR, no side effects of treatment with lugh doses of OCs are seen. 
Patient 3 was an asymptomatic man, in whom a greatly increased urinary cortisol excretion 
was identified as he was endocrinologically tested because of an incidentally discovered adrenal 
enlargement. It appeared that there was an insufficient adrenal suppression in the overnight I 
mg DST, a normal diurnal rhythm of semm cortisol concentrations with ACTH concentrations 
around the upper limit of the normal values. Also Ius asymptomatic son showed an increased 
udnary cortisoJ excretion and insufficient cortisol suppression in the I mg DST. It appeared 
that the GR in PBMLs from the patient showed diminished affinity for DEX. 
To search for possible alterations in the OR gene explaining the clinical pictures in the patients 
described in this study, PCRlSSCP analysis of the whole coding part of the OR gene was 
performed. Furthermore, the hormone binding domain of the GR gene (exons 4-9) was 
screened using sequence analysis. Two of the patients described carried a polymorphism 
characterized by a double point mutation at codon 22 and 23. Tlus polymorphism has 
previously been described in a general population screening by Koper et al (25). In that study, 
a I mg overnight DST was performed in 2 I 6 healthy elderly individuals. The same 
polymorphism was found in this population study in eleven individuals, including a person with 
the highest post DEX cortisol concentration (256 nmolll). Moreover, two other subjects with 
diminished cortisol suppression (post DEX cortisol concentration were 110 and 241 nmolll, 
respectively) were found to carry the same mutation. However, eight other subjects out of this 
group of 216 volunteers, showed this polymorphism in combination with a normal cortisol 
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suppression in reaction to I mg of DEX. From patient 2, we screened her family with respect 
to this polymorphism as well. It appeared that her healthy grandmother, mother and brother 
carried the mutation. They all showed a normal cortisol suppression in the I mg DST. In ill 
vitro expression experiments, this polymorphism showed no alterations in the efficacy of the 
GR to activate transcription in such systems compared to the wild-type receptor (29). Possibly, 
in the patients with CR carrying this polymorphism, the mutation is linked to another mutation 
I polymorphism in or near the GR gene that was not detected in our study using the 
PCRlSSCP/sequence approach. 
In patients 3-5, who all showed clear clinical and biochemical pictures of CR, no GR gene 
alterations were found however. It is clear that there is a discrepancy between the clinical and 
biochemical picture in these patients on the one side, and the molecular characterization on the 
other side. This is especially true for the patients who showed a lowered Kd . In these patients 
one would expect to find alterations in the hormone binding domain of the GR gene. Patient 5 
showed only half of the normal numbers of GR per cell in PBMLs. In a family with only half of 
the number of receptors previously described by Karl et al (16), it appeared that tlus was due 
to a splice site mutation in one of the alleles of the GR gene, resulting in an unstable mRNA. 
Another possibility might be that there is a mutation/deletion in one of the alleles which alters 
the structure of the hormone binding domain in such a way, that no ligand can be bound. On 
the other hand, one would expect to find such alterations using PCRlSSCP/sequence analysis. 
Not only GR expression level and ligand binding affinity, but also ligand induced GR 
conformation changes, dissociation from heat shock proteins, phosphorylation and nuclear 
transformation are important determinants of GC sensitivity (30). Another possibility could be 
that post-receptor defects or interactions with other nuclear factors form the pathophysiologic 
basis of CR in these patients. In order to investigate the GR gene more extensively, a next step 
will be to look at the transcriptional level by studying mRNA expression. 
It can be concluded that in all five patients described, there was clinical andlor biochenucal 
evidence for generalized CR. On the other hand, we could not identity GR gene alterations 
which give a molecular explanation for the clinical and biochemical CR. 
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ABSTRACT 
Generalized glucocorticoid resistance is associated with chronic hyperactivation of the 
hypothalamic-pituitary-adrenal-axis, compensating for impaired glucocorticoid receptor 
function. We report a unique patient with sporadic generalized glucocorticoid resistance who, 
at age 33, presented with infertility and hypertension and, at 38, developed pituitary Cushing's 
disease. Leukocyte-binding studies revealed normal affinity of the glucocorticoid receptor but a 
reduction of binding sites by 50%. ['H)-thymidine incorporation by this patient's lymphocytes 
was not suppressible by dexamethasone. He bad a novel heterozygous missense mutation in 
the glucocorticoid receptor gene (isoleucine 559 to asparagine 559). The mutant receptor 
exhibited a strong dominant-negative effect on the ability of the wild-type receptor to induce 
gene transcription in vitro. The mutation was present in all of the patient's cultured 
lymphoblasts and fibroblasts as well as in 50% of his sperm, as demonstrated by single-cell 
polymerase chain reaction; it was not present in his parents and seven siblings. TillS novel 
mutation was thus both de novo and present in the germ line. Immunohistochemical staining of 
this patient's pituitary corticotropinoma revealed accumulation of p53 protein, indicating the 
presence of a putative somatic oncogenic mutation in the p53 gene in the tumor cells. 
Investigation ofthe lymphoblast and skin fibroblast cultures for p53 abnormalities did not show 
any aberration. Thus, a novel de novo germ line mutation of the glucocorticoid receptor with 
strong dominant-negative activity caused severe sporadic generalized glucocorticoid 
resistance, which preceded corticotroph adenoma formation. The latter probably was due to 
the combined effects of chronic corticotroph hyperstimulation, decreased glucocorticoid 
negative feedback, and at least one subsequent somatic defect in the control of the cell cycle. 
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INTRODUCTION 
Increased secretion of cortisol is present in both generalized glucocorticoid resistance (GGR) 
(1,2) and Cushing's disease (3). Yet in the former, circadian and stress induced secretion of 
cortisol remain intact, whereas in the latter, they are disnopted. Patients with GGR develop 
neither Cushing's syndrome stigmata nor glucocorticoid deficiency. Their excess 
adrenocorticotropic hormone (ACTH) secretion, however, results in increased production of 
adrenal steroids with salt-retaining or androgenic activity. Salt retaining steroids cause 
hypertension or hypokalemic alkalosis, whereas androgenic adrenal steroids lead to symptoms 
and signs of androgen excess, such as acne, hirsutism, and disturbances of reproductive 
functions in women and virilization in children. GGR has been associated with quantitative or 
qualitative defects the glucocorticoid receptor (GR) (2). To date, the molecular basis of GGR 
has been elucidated in three families (4-6). In Cushing's disease one sees the deleterious effects 
of chronic hypercortisolism in humans (3). This condition usually is caused by ACTH 
hypersecretion from an ACTH-secreting pituitary adenoma. The hypercortisolism produces the 
characteristic features of Cushing's syndrome. including central obesity, moon facies, muscle 
wasting, easy bnoisability, depression, glucose intolerance or diabetes, and osteoporosis. In 
Cushing's disease, the negative-feedback loop of the hypothalamic-pituitary-adrenal (HPA) axis 
is disnopted at the level of the ACTH-secreting adenoma, and the elevated ACTH levels 
usually are accompanied by bilateral adrenal hyperplasia or unilateral or bilateral adrenocortical 
macronodules (7,8). The chronic exposure ofcorticotrophs to elevated levels of hypothalamic 
releasing factors has been suggested as a possible mechanism leading to pituitary tumorigenesis 
(8). However, recent reports of putative somatic mutations of tumor suppressor genes, such 
as pS3 (9), or oncogenes, such as Gs (10), in corticotropinomas suggested that inherent 
adenomatous cell-specific changes might play a primary role in the pathogenesis of these 
neoplasms. 
In tllis study, we present the unique case of a Dutch man with GGR who developed aggressive 
Cushing's disease at the age of 38 years. We examined the molecular pathophysiology of GGR 
of this patient, with findings that provided new insights on both the mechanisms of 
glucocorticoid resistance and the pathogenesis of Cushing's disease. 
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METHODS 
Subjects alldfamily history 
A moderately obese man was evaluated for infertility at the age of33 years. He first was found 
to be oligospermic and mildly (stage I) hypertensive (145/90 mm Hg). He was followed 
regularly and when his arterial blood pressure increased to 1501100 mm Hg (stage 2) at the age 
of 36 years, he was started on standard doses of hydrochlorothiazide. On tllis regimen over 
several weeks, he developed severe life-threatening, symptomatic hypokalemia (plasma K 1.0 
mmol/l). Reevaluation at this time revealed hypercortisolism, without any clinical evidence of 
Cushing's syndrome (11). His bone density was normal. He was started on dexamethasone, 3 
mglday PO and felt well over the next 2 years. His blood pressure normalized. His morning 
serum cortisol levels and ACTH levels,. however, remained elevated at 3000 muol/l (normal, 
200-580 muoVI) and 25.2 pmol/l (normal 4.4-14.3 pmol/l), respectively, as was his urinary free 
cortisol excretion at 87,500 muoVday (normal, < 450 nmoVday). Two years later, he became 
floridly cushingoid over a period of 6 weeks. His blood pressure was elevated (1651105 mm 
Hg), his serum cortisol levels increased to 10700 nmol/l, and his urinary free cortisol excretion 
nearly doubled to 160000 nmoVd. Despite discontinuation of the dexamethasone substitution, 
the patient continued to gain centripedal weight, his hypertension worsened and he complained 
of severe back pain. Bone densitometry performed at that time was within the normal range 
but significantly increased in the lumbar spine, hips, and lower arm compared with the mean of 
age- and sex-matched controls. Serum cortisol concentrations increased further to levels 
between 20000 and 24000 nmol/l, without diurnal variation. The diagnosis of pituitary 
Cushing's disease was made, but pituitary magnetic resonance imaging was negative. The 
patient elected to have bilateral adrenalectomy. Aller an uneventful surgery, the patient was 
placed on 1.5 mg dexamethasone and 50 ~g f1udrocortisone by mouth daily, and his condition 
improved. Blood pressure normalized, and he needed no further antihypertensive medication. 
However, his morning plasma ACTH levels increased in the subsequent months to a maximum 
of 130 pmol/l. Repeat magnetic resonance imaging 8 months after adrenalectomy revealed a 
pituitary tumor with a diameter of 9 mm, which was removed by transsphenoidal 
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adenomectomy. Histological examination of the pituitary tissue confirmed the diagnosis of a 
corticotropinoma and excluded corticotroph hyperplasia. After the transsphenoidal surgery 
(TSS), the patient has remained on 1.5 mg dexamethasone and 50 ~g f1udrocortisone daily by 
mouth, without any stigmata of Cushing's syndrome. [3H]dexamethasone binding and 
[3H]thymidine incorporation studies were performed with the patient's leukocytes after the 
TSS. Three years later, circulating ACTH levels vary between 33 and 40 pmoVI. The patient 
has been symptom free and nornwtensive. The patient's parents, five brothers, and two sisters 
had no clinical or biochemical evidence ofGGR (Figure I). 
Whole cell dexamethasolle billdillg assay 
GR concentrations and affinity for [3H]dexamethasone were determined in Ficoll-Isopaque 
extracted mononuclear leukocytes as previously described (II) Ligand incubation was carried 
out for I hr at 30' C. 
Illhibitioll of mitogen-stimulated illcOIporatioll of !'Hjthymidille by dexamethasolle 
Mitogen-stimulated incorporation of [3H]thymidine was inhibited by dexamethasone as 
previously described (II). Mononuclear leukocytes isolated with the Ficoll-Isopaque method 
were seeded at 10' cellslwell, and 5 ~g, phytohemagglutinin (PHA) was added to each well. 
Subsequently cells were exposed to dexamethasone at six different concentrations ranging 
from 3-1000 nM for 72 he. [3H]thYlnidine was added to each well, and incubation was allowed 
for 4 he. After centrifugation, precipitation, and washing of the cell pellet, radioactivity was 
determined by liquid scintillation counting. The concentration of dexamethasone necessary to 
achieve 50% of the maximal inhibition of thymidine incorporation (IC,,) then was estimated 
graphically by graph fitting. 
Establishmellt of a permallelltlymphoblast celllille 
Epstein-Barr virus transformed (EBV-transformed) lymphoblast lines were established from 
the patient peripheral blood lymphocytes, as previously described (12). The cell lines were 
grown in RPMI- 640 medium supplemented with 10% fetal bovine serum (FBS), and 2 mmoVI 
138 
Cushing's disease preceded by cortisol resistance 
glutamine in the presence of 100 unitslml penicillin and 100 ~glml streptomycin (Gibco-BRL, 
Gaithersburg, MD) in a 5% carbon dioxide atmosphere. 
Establishment of afibroblastline 
Fibroblast cultures were derived from skin and prepared as previously described (13). Cells 
were maintained in culture as described earlier. 
COS-7 eel/lines 
COS-7 cells were obtained from the American Type Culture Collection (Rockville, MD) and 
cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% charcoal-
treated FBS (HyClone, Logan, UT), 2 mmol/l glutamine in the presence of 100 unitslml 
penicillin and 100 ~glml streptomycin (Gibco-BRL) in a 5% carbon dioxide atmosphere. 
Extraction of DNA 
DNA was extracted either directly from isolated peripheral white blood cells of the patient, his 
relatives, and control subjects or from the EBV-transformed lymphoblast cell lines and cultured 
skin fibroblasts using the QIAamp Blood Kit (Qiagen Inc., Chatsworth, CAl. 
Extraction of RNA 
Total RNA was isolated from the EBV cell line and skin fibroblasts using a monophase 
solution of phenol-guanidinium thiocyanate (RNA STAT-60) in a single-step method 
according to the manufacturer's instructions (TEL-TEST "B", Inc., Friendswood, TX). 
Amplification of genomic DNA by Polymerase Chain Reaction (PCR) 
PCR was performed as previously described, with minor modifications (5). Briefly, 
amplifications were carried out in a total volume of 50 ~g containing 50-100 ng of genomic 
DNA, 15 pmol of each nucleotide primer, 0.2 mM dNTP, 50 mM KCI, 10 mM Tris (pH 8.3), 
1.5-3 mM MgCI2 and 2.5 units ofTaq-DNA-Polymerase (Boehringer Mannheim, Indianapolis, 
IN) or Ampli-Taq (perkin-Elmer, Emeryville, CAl. PCR was performed for 30 cycles each 
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cycle consisting of incubations for 30 sec at 94°C for denaturation, for 30 sec at 55°C or 60°C 
for annealing, and for 45 sec at noc for primer extension in a GeneAmp PCR System 9600 
(Perkin-Elmer, Emeryville, CAl. In the first cycle, the denaturation period was lengthened to 4 
min, and temperature was increased to 95°C; at the end of the last cycle, extension was 
lengthened to 4 min. Primer pairs were complementary to sequences in the 51. or 3'-exon-
flanking regions of the GR -gene and ofexons 5-8 of the p53 gene, respectively (5). 
PCR of sillgle cell exlracts 
Extracts of single cells from the lymphoblast or fibroblast cultures and sperm were amplified 
using a specific primer pair located in the 5'- and 3'-intron-flanking region of exon 5 using the 
same conditions as described previously. An aliquot (2 ~I) of the first PCR amplification was 
reamplified using nested primer pairs. 
Synthesis of eDNA 
Total RNA was reverse transcribed using a first-strand cDNA synthesis kit (Boehringer 
Mannheim). Briefly, RNA (I ~g) was denatured at 65°C for 15 min and chilled on ice for 5 
min. Reverse transcription was carried out in a total volume of 20 ~tI containing 10 mM Tris, 
50 mM KCI (PH 8.3), 5 mM MgCI,,1 mM each of dATP, dCTP, dTTP, and dGTP, SO units of 
RNase inhibitor, 20 units of avian myeloblastosis virus (AMV) reverse transcriptase and SO 
pmol of a specific antisense primer of the GR cDNA. The reaction mixture was incubated first 
at room temperature for 10 min and then at 42°C for I hr. Thereafier, the AMY reverse 
transcriptase was denatured by incubating the reaction at 99°C for 5 min and cooling on ice for 
5 min. PCR amplification was performed in a total volume of 100 ",I containing an aliquot of 
the first-strand cDNA reaction (5-10 ",I) in the presence of 10 mM Tris, SO mM KCI (pH 8.3), 
2.5 mM MgCI" 0.2 mM each ofdATP, dCTP, dTTP, and dGTP, SO pmol of each, a specific 
sense and antisense cDNA primer, and 2.5 units of Taq DNA Polymerase (Boehringer 
Mannheim) or Ampli-Taq (Perkin-Elmer). PCR was carried out for 40 cycles in a GeneAmp 
PCR System 9600 (perkin-Elmer) using the cycling conditions previously described. 
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Direct sequellcillg of asymmetric PCR-amplified products 
Single-stranded DNA was synth~sized using as template the product of the symmetrical PCR. 
For the amplification of one DNA strand selectively, only a sense or an antisense primer (50 
pmol) was added, and the asymmetric PCR was carried out for 20 cycles. Single-stranded PCR 
products then were purified using a QIAquick-spin PCR purification kit (Qiagen Inc., 
Chatsworth, CAl, according to the manufacturers instructions. Direct sequencing of the 
purified asymmetric PCR products was performed by the Sanger-dideoxynucleotide chain 
termination method, using modified T7-DNA polymerase in the presence of Redivue [a-"Sj 
dATP (Amersham Life Science Inc, Arlington Heights, IL), as previously described (5). 
Sau-3A Digestioll of the ExOIl 5-Amplicoll of the GR 
The amplicon of exon 5, including intron-flanking regions (470 or 421 bp, respectively) 
harbored a single recognition site for the restriction enzyme Sau-3A (GATC). Digestion of the 
wild-type exon 5 amplicon with Sau-3A, under standard conditions, resulted in two fragments 
of273 and 197 bp or 254 and 167 bp, respectively. A mutation within this region abolished the 
ability of Sau-3A to digest the fragment. Digested or undigested fragments were visualized by 
agarose gel electrophoresis. 
COllstructioll of Plasmid pRShGR-AsIl559 
An expression vector for the mutant GR asparagine 559 (Asn559) was constructed by 
replacing a ClaIfSauI fragment, including human glucocorticoid receptor (hGR) nue1cotides 
1524-2159 of plasmid pRSh-GRa (kindly provided by Dr. R.M. Evans, Salk Institutc), with 
the corresponding cassette harboring the mutant adenosine (A) substitution. Site-directed mu-
tagenesis by overlap extension PCR was employed to replace the wild-type thymine (T) at 
nucleotide position 1808, with the mutant A using the expression vector pRShGRa as a 
template. Each of two pairs of oligonucleotides were used in separate PCR reactions to 
amplify overlapping hGR cDNA fragments that incorporated the base substitution. An aliquot 
of each of the two initial reactions then was added to a third PCR reaction in order to amplify 
the cDNA region including nucleotides 1524-2159. The product ofthe third PCR was digested 
with ClaI and Saul. The ClaI-XhoI fragment of the pRShGRa (including nucleotides 1524-
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2463) was inserted into the multiple cloning site of the cloning vector pBluescript II phagemid 
(Stratagene, La Jolla, CAl. After digestion of the recombinant plasmid with ClaI and Saul, the 
digested PCR fragment was ligated into the plasmid to replace the wild-type sequence. 
Subsequently, the recombinant ClaI-XhoI fragment of the hGR« cDNA was ligated back into 
pRShGR«. The entire ClaIlSauI cDNA insert then was sequenced to confirm the Al808 
substitution without any other base changes. The recombinant plasmid was designated 
pRShGR-Asn559. 
Tralls/eClion Sludies 
COS-7 cells (ATCC) cultured in DMEM supplemented with 10% charcoal-treated FBS, 1% 
glutamine and penicillin-streptomycin were tranfected using lipofectine or lipofectamine 
(Gibco-BRL) as previously described with minor modifications (5,14). Briefly, 12 to 14 he 
prior to transfection, COS-7 cells were harvested and seeded in six well plates (Costar, Cam-
bridge, MA) at a density of 4.2 x 10' cells/35-mm well. At 70-80% confluency, cells were 
incubated for 5 h in 1 ml ofOpti-MEM (Gibco-BRL) containing 6/l1 oflipofectamine or 10 /ll 
of lipofectine and the plasmids to be transfected. For reporter gene expression, 0.4 /lg of 
pRShGR« or pRShGR-Asn559 was incubated with 1.6 /lg of the reporter plasmid pLTR-Luc 
(gift of Dr. G. Hager, National Cancer Institute, NIH. Bethesda, MO). Twenty hours after 
transfection, cells were incubated with graded concentrations of dexamethasone (10·"-10·' M). 
For co expression of wild type and mutant GR, increasing quantities ofpRShGR-Asn559 (0.02, 
0.04, 0.06, and 0.10 /lg) were added to constant amounts of pRShGR« (0.02/lg) and pLTR-
Luc (1.0 /lg). The plasmid pSV-p-gal served as a control for transfection efficiency in these 
experiments (0. 1 /lg). The total amount of DNA transfected remained constant by the addition 
of appropriate amounts of plasmid pRSv-erbA. Cells were stimulated with medium containing 
10 -7 M dexamethasone. For Western blot and hormone-binding analyses, cells were 
transfected with O.4/lg ofpRShGR-Asn559 or pRShGR« with or without reporter genes. 
LI/cijerase Assay 
COS-7 cells cotransfected with the wild-type GR expression vector pRShGR«, the mutant GR 
expression vector pRShGR-Asn559, or a combination of pRShGR« and pRShGR-Asn559 
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together with the reporter plasmid pLTR-Luc were harvested 48 hr after transfection. Briefly, 
media were removed from the cell culture plates, and the cells were rinsed twice with 
phosphate buffered saline without Ca2• or Mg'. Cells were covered with 350/11 of cell lysis 
buffer (0.1 M potassium phosphate buffer, pH 7.8, 1% Triton X-100, I mM DTT, and 2 mM 
EDTA) and incubated at 4°C for 20 min. Cells were collected by scraping, transferred to an 
Eppendorf-centrifuge tube and spun for 10 sec to remove cellular debris. For the luciferase as-
say 100 /11 of assay buffer solution consisting of 30 mM Tricine, 3 mM A TP, 15 mM MgSO" 
and 10 mM DTT (pH 7.8) were added to 5 /11 of cell extract. Luciferase activity was measured 
on a Monolight 2010 Luminometer after the injection of 100 /11 of I mM D-Luciferin (pH 6.1-
6.5) (Analytical Luminescence Laboratory, San Diego, CAl. Protein concentrations of the 
extracts were determined using a Coomasie Protein Assay Reagent (Pierce Chemical Co., 
Rockford, IL) to normalize for cell lysate. In the coexpression studies ofwt-hGRa and mutant 
GRAsn559, galactosidase activity was detennined in the samples using, a galactosidase assay 
system (promega, Madison, WI). 
Proteill-Electrophoresis alld Western Blot Allalysis 
Cells transfected with 0.4 /1g of pRShGR-Asn559 or pRShGRa, with or without 1.6 /1g of 
pLTRLuc, were harvested by trypsinization with 250 /11 TrysinVersene (0.05% Trysin and 
0.02% Versene in EBSS without calcium and magnesium, Biofluids, Inc., Rockville, MD) for 
3-5 min, collected in microcentrifuge tubes, and washed three times with phosphate suffered 
saline. Cell pellets were stored at _70°C. Samples were resuspended in TAPS-Buffer (pH 8.8). 
Protein, 10 /1g/1ane, was applied to 8% precast polyacrylamide gels, mn according to Laemmli, 
and transferred onto nitrocellulose by electroelution. The blot was preincubated in milk block 
buffer. A polyclonal rabbit anti-human GR antibody (Clone 57, Affinity Bioreagents, Neshanic 
Station, NJ) was applied overnight at 4°C (1:5000 dilution).The blot was washed and 
incubated with peroxidase-conjugated antirabbit i1mnunoglobulin antibody (I :2000, Dako, 
Copenhagen, Denmark) at 22°C for I hr. Bands were detected by chemiluminescence (15). 
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Receptor binding assays in vitro and determination oj relalive binding ajfinities 
COS-7 cells were transfected with 0.4 Jig of plasmids pRShGR«, pRShGRp or pRShGR-
Asn559 as described earlier. Thirty-six hours after transfection, cells were washed three times 
with Opti-MEM (Gibco BRL) and incubated with 10 nM of [I, 2, 4-3H]-labeled 
dexamethasone (Amersham Life Science Inc., Arlington Heights, IL) in the absence or 
presence of increasing concentrations of radioinert competitor (10"12 -10" M) dexamethasone 
(Sigma Chemical Company, St. Louis, MO). After a Ihr incubation at 37°C, cells were 
washed three times with ice-cold phosphate-buffered saline, trypsinized by addition of 600 Jil 
ofTrysin-Versene (0.05% Trysin and 0.02% Versene in EBSS without calcium or magnesium, 
Biofluids) at 37"C for 3-5 minutes, and collected in microcentrifuge tubes. Aliquots of300 ml 
of the suspension were transferred into scintillation vials containing 15 ml of scintillation fluid 
(Aquassure, Dupont NEN, Boston, MA). Radioactivity was determined by scintillation 
counting (Beckmann 6000IC counter) of duplicate samples for each concentration. Relative 
binding was expressed as a percentage of the control incubates in the absence of radioinert 
competitor. 
ImmulJohistochemical Procedures 
Tissue removed at surgery was fixed in 10% neutral buffered formalin and processed for 
paraffin embedding in standard fashion. Sections were cut at 5 Jim and stained with 
hematoxylin and eosin, Wilder's reticulin, and periodic acid Schiff. Sections for immuno-
histochemistry of the pituitary gland were stained using an avidin-biotin complex method with 
XantiACTH (polyclonal, I :4000, kindly provided by the National Hormone and Pituitary 
Agency, NIDDK), and with anti-p53-antibodies (Polycional,I:50, Dako), on a Ventana 320 ES 
automated stainer (16). 
RESULTS 
III Vitro ['Hjdexamethasone Binding and ['Hjthymidine IncO/poration Studies 
Binding studies were performed on mononuclear leukocytes isolated from peripheral blood of 
the patient after he had had the adrenalectomy and TSS and while he was receiving 
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dexamethasone, These studies demonstrated a normal GR affinity (Kd ~ 7,5 nM, controls ~ 7,7 
± 0,2; n ~ 18) and a markedly reduced GR number (2929 sites/cell, controls 7191 ± 216; n ~ 
18) (Figure 2), These results were consistent either with expression of only one of the two GR 
alleles, as previously reported in another family with GGR (5), or with the expression of one 
normal allele coding for a ligand-binding receptor and one mutated allele coding for a protein 
unable to bind ligand, Interestingly, this patient's cells showed no suppression of [3H]thymidine 
incorporation by concentrations of dexamethasone as high as 10 .. M, suggesting marked 
impairment of the function of the expressed ligand binding GR (Figure 2), 
Allalysis of the GR gelle alld eDNA 
The exons of the entire coding region of the GR-gene (2- 8 and 5'-region of 9«) including the 
intronic flanking regions, were amplified by PCR and analyzed by direct sequencing (17), A 
single missense mutation was disclosed in exon 5, in the coding region of the GR gene of the 
patient (Figure 3, top), In one of the two alleles, the nucleotide thYlnine (T) of the wild-type 
sequence was substituted by adenine (A) at cDNA position 1808 (I8) (Figure 3, middle, left), 
Sense and antisense strands of the independently amplified amplicons of exon 5 were 
sequenced several times to verilY the base change, thereby excluding a PCR-introduced 
artefact. 
I 
FJgure 1. Family pedigree. The propositus, the second youngest of a nonconsanguineous marriage. is indicated by 
the arrow. He had severe generalized glucocorticoid resistance and developed a pituitary corticotropinoma at age 38. 
Neither of his parents and none of his siblings had the clinical or biochemical signs of giucocorlicoid resistance or 
Cushing's disease. (Males are represented by squares, females by circles). 
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The expression of both mutant and wild-type alleles in the patient was confirmed by 
sequencing cDNA transcripts derived from reverse transcriptase PCR-amplified RNA extracted 
from the lymphoblast and fibroblast culture (Figure 3, middle, right). The location of the 
heterozygous mutation corresponded to the second base of codon 559 (ATC to AAC) in the 
GR (Figure 3, bottom). The nucleotide substitution was responsible for an amino acid change 
from the neutral and hydrophobic isoleucine (lie) to the neutral but polar asparagine (Asn). 
Investigation of the corresponding amplicon in the patient's relatives, in contrast, excluded the 
presence of the mutation in both of his parents and in each of his siblings (see Figure 1). 
Therefore, the alteration identified in the patient originated either as a de novo germ-line 
mutation or as a somatic mutation that occurred postzygotically during early embryogenesis. 
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Figure 2. Whole-cell [lHJdex80lcthasone binding assay and dexamethasone-inhibition of PHA-stimulated 
[lH]thymidine incorporation. (a) Scatcbard analysis ofwhole-ccU ligand-binding assays of mononuclear leukocytes 
with [lIDdexamethasone. Open circles represent the results from 18 control subjectS, closed circles the results from 
the patient. Glucocorticoid binding sites were reduced by 50% in the patient (2929 sites/cell, controls 7191 ± 216), 
while the K,J remained ill the normal range (7.5 nM; controls 7.7 ± 0,2). (b) Inhibition by dexamethasone of 
mitogen-stimulated incorporation of [lH]thymidine in mononuclear leukocytes. The open symbols represent 
dexamethasone-induced iullibition of [lI-I]thymidine incorporation in nine control subjects. The closed circles 
represent the result of the measurement in the patient. Maximal inhibition was defmed as the inhibition observed 
with I J1M dexamethasone. The concentration of dexamethasone needed to achieve 50% of the maximal inhibition 
(IC~o) was estimated by curve fitting, The maximal inhibition in nine wlllrol subjects was 85 ± 4%, theJC was 
10.1 ± L 1 nM". No significant inhibition of [lH]thymidine incorporation by dexamethasone was observed in the 
propositus. 
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We employed the technique of single-cell PCR amplification to search for the presence and 
prevalence of the alteration in cells of different tissues. Single cells of the fibroblast and 
lymphoblast cell cuitures, as well as single sperm, were separated by a micromanipulation 
process and lysed. The genomic DNA obtained from a single cell then was subjected to two 
PCR reactions consisting of30 cycles each. An aliquot of the first specifically primed PCR was 
reamplified in a second reaction, using a pair of nested primers. The amplification yielded a 
single fragment of421 bp. The wild-type sequence of the amplicon harbored a single GATC 
recognition site for the restriction enzyme Sau-3A This restriction enzyme recognition site 
was eliminated by the mutation at cDNA position 1808 (GAAC). Digestion of the wild-type 
amplicon by Sau-3A yielded two fragments of 167 and 254 bp, respectively, whereas the 
mutant fragment remained uncut. Screening of the products of the single-cell PCR by Sau-3A 
digestion demonstrated the presence of both the mutant and wild-type alleles in each of the 
fibroblasts and Iymphoblasts investigated. In addition, the mutation was detected in 50% of the 
haploid sperm. 
Following a similar strategy, we screened for the presence of the mutation in normal subjects. 
DNA extracted from peripheral white blood cells of more than 30 unrelated controls were 
specifically amplified by PCR and digested by Sau-3A. The mutation was not detected in any 
of these subjects, excluding the base change as a common polymorphism. In addition, in more 
than 100 normal Dutch subjects, no such polymorphism was detected in the ligand-binding 
domain of the receptor by single-strand conformational polymorphism analysis. 
AI/alysis oj Ihe GR mulaliol/ 
The impact of the amino acid substitution Asn559 on the function of the GR was studied by 
cloning the T-to-A nucleotide substitution into a wild-type GR expression vector and 
transfecting COS-7 cells with the mutant vector. In transfected COS-7 cells, expression of 
mutant hGR-Asn559 and wild-type hGRa were demonstrated by Western blot analysis, with 
both species migrating at the expected molecular size (Figure 4a). The mutant hGR-Asn559 
receptor showed a basal binding capacity and relative binding affinity shnilar to that observed 
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Figure 3. Analysi'i of the glucocorticoid receptor gene and its expression. (Top) Exons are represented by open 
boxes; lines between indicate intervening sequences (nol to scale). The amino-ternimal oflbe receptor is encoded by 
cxon 2; the h\'o zinc-fingers of the DNA binding domain are encoded separately by exons 3 and 4. The cortisol-
binding domain is assembled from cxons 5·8, including the 5'-end of exon 9". (Middle, left) The autoradiogram 
allows yisualizatioll of both alleles of the patient obtained by direct sequencing of amplified DNA In exon 5, a 
heterozygous base cbange subsUtutes the wild-type T by A, as indicated by the small arrow. The location of the 
mutation within the gene is shown by the long arrow. The presence of the heterozygous GR gene mutation was 
conflIDlcd in the patient's peripheral white blood cells, EBV·transfornlcd lymphoblast cells, a fibroblast ctlilline and 
in 50% of spcrnl cells. (Middle, right) Sequence analysis of the eDNA rcvealed the prescuce of the wild·type and 
mutant nucleotide at position 1808, eonfuming the expression of both allelcs in the patient's cultured lymphoblasts 
and fibroblasts. The mutation at the second letter of codon 559, CTA to CAA, prcdicts the substitution ofthe wild· 
type amino acid isoleucine (HclI) by asparagine (Asn). (Bottom) The amino acid change is located within the 5'. 
region of the ligand binding domain of the OR protcin. 
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in cells transfected with the non-ligand binding GRp-isoform (Figure 4b). The mutant hGR-
Asn559 thus had lost any ability to bind hormone. Consequently, the mutant Asn-559 receptor 
did not induce expression of a glucocorticoid-responsive luciferase reporter gene (Figure 4c). 
Importantly, as shown in cotransfection studies, the mutant hGR-Asn559 impaired the ability 
of the wild-type GR to activate reporter gene expression, exhibiting a dominant negative effect 
on GR function (Figure 4d). 
Allalysis of Ihe p53 IlIlIIor sllppressor gelle alld proleill 
Immunohistochemical staining using anti-p53 antibodies revealed nuclear accumulation of p53 
protein in a small number of the ACTH-producing pituitary adenoma cells, indicating the 
presence of an oncogenic somatic mutation in the p53 gene of these cells. The attempt to 
amplifY DNA extracted from micro-dissected pituitary tumor tissue for further analysis was 
unsuccessful, despite different primer combinations and short amplicons. Analysis of exons 5-8 
of the p53 gene of DNA from peripheral white blood cells was in accordance with the wild-
type sequence and did not reveal any aberration (19). 
DISCUSSION 
In this study, we report the development of a corticotroph adenoma in a patient with GGR. 
The patient presented initially with hypokalelnia and hypertension. During treatment for GGR 
with pharmacological doses of dexamethasone, but years after the onset of this therapy, the 
patient developed signs and symptoms of Cushing's disease. Despite discontinuation of the 
glucocorticoid substitution, symptoms of Cushing's disease worsened. Eventually, the patient 
underwent bilateral adrenalectomy and subsequently, when a pituitary magnetic resonance 
imaging scan became positive for a tumor, he had TSS to remove a histologically verified 
corticotropinorna. 
Pituitary tumors have not been described in syndromes of complete androgen or thyroid 
hormone resistance. Pituitary gonadotropinomas or thyrotropinomas are rare. Enlargement of 
the sella turcica has been noted in a few patients with longstanding Klinefelter's syndrome, and 
even if this represented gonadotropinoma formation, it would still be exceedingly rare (20). 
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Figure 4. In vitro fransf«:lion studies. (a) Western bioi analysis. Protein ex1racts of COS·? cells transfected with the 
vectors encoding for the eDNA of the mutant GR·Asn559 (lane I) or the ,yild·type OR (lane 2) were analyzed for 
their expression. E",1racls of unfransf«:ted COS-7 cells (lane 3) and HeLa (lane 4) served as negalive or positive 
controls, rcspedively. The 97-kD line indicates the exp«:ted size oflhe human GR. Both lIlulanl GR-Asn559 (lane 
l) and wild· type OR (lane 2) were expressed in the fransf«:tcd COSo? cells and migrated althe same distance as the 
naturally expressed GR of HeLa Cells (lane 4). Interestingly, hyo bands with different migration patterns were 
det«:ted in the untransf«:ted COS-7 cells which might represent nonfunclioning GR (laue 3). These bands were nol 
detectable HeLa cells (Jane 3). (b) Detenuination of rei alive binding affinities of wild· type hORa, and llIutant hOR· 
Asn559. COS-7 cells transfccted with the wild type hGRa, mufant hGR-Asn559 or hGRp expression vcctor, ' .... ere 
incubated with to nM f1HJdexamethasone in the presence of ill creasing concentrations of radio inert (m - to ) 
dexamethasone. Each point represents the average of duplicate samples and is expressed as a percentage of the 
control incubates in the absence of a radioinert competitor. The mutant hOR-Asn559 was unable to bind ligand. 
Expression of wild· type ORa, and mutant hGR·Asn559 was confirmed by Western blot analysis, as sho,,'n in Figure 
4. (e) Transcription activation of LTR-Lue by wild·lype hGRa or mutant hGR-Asn559. COSO? cells were 
Iransfeeted witJl the expression vector for the wild-type OR or the mutant GR-As1l559 aud the reporter plasmid 
pLTRLue. Controltransfectiolls were perfonned by co·transfccti.Ilg the cells with the tnlDcatcd OR isoform GRp 
and the reporter plasmid. Transfected cells were exposed 10 increasing concentrations ofdexamethasolle. The ability 
of expressed wild-type ORa, mutant GR-AsIl559, and the isofornl ORP to stimulate the lucirerase (Luc) gene 
expression was assessed by measuring luciferase activity. Expression of wild-type GRa and mutant hGR -Asn559 
was confmucd by Western blot analysis, as shonD in Figure 4a. (d) Inhibition ofhORa-mediated gene transcription 
by hGR-Asn559. COS· 7 cells were co-transfected with a conslant quantity ofwild·lype hORa (0.051(g; lanes 1-5), 
and iuereasing amounts of the mutant hGR-Asn559 with 0.05.ug (lane 2), O.IJ(g (lane 3). 0.15 Pg (lane 4), and 0.25 
f-Jg (Jane5). The amoWlt of the reporter plasmid pLTR·Luc, as well as the amount of pSV-p-gal as a conlrol of 
tmusfeelion efficacy, remained constant at 1.0 I'g and 0.1 I(g, respectively (Janes 1-5). The tolal amount of DNA 
trallsfected was kept conslant by appropriate addition of plasmid pRSY-erbA, as previously described (33). 
Luciferase activity was assessed after stimulation by 10>7 M dexamethasone. Variations in transfecfion efficiency 
""ere normalized by galactosidase activity. A strong dexamesthasone-dependent dominant-negative effect of the 
mutant hOR on the wild-type OR was seen. Each column represents the mean ± SEM of one out of three 
experiments pcrfonncd inlriplicate. (*p < 0.05, ANOVA followed by Student I test with Bonferroni corrcclioll.) 
One should note that in androgen-resistant patients, increased levels of estrogens, produced by 
peripheral aromatization of androgens, might playa role in suppressing adenoma formation. 
Similarly, patients with primary hypothyroidism rarely develop thyrotropinomas; tlus is true 
also for patients with untreated primary Addison's disease who rarely develop 
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corticotropinomas (21). 
We have previously reported a somatic frame shift mutation of the OR gene in one of four 
patients with Nelson's syndrome (22). The mutation was restricted to pituitary tumor tissue, 
presumably leading to a decrease to half the number of receptors in the aggressively growing 
adenoma. Although we could not directly show a cause and effect between that mutation and 
corticotroph tumorigenesis, those data together with the data from this patient suggest that ex-
posure of the corticotroph to enhanced stimulation by increased production of hypothalamic 
corticotropin releasing hormone and arginine-vasopressin or decreased primary sensitivity of 
the corticotroph to negative glucocorticoid feedback may lead to adenoma formation. 
Analysis of the OR gene of our patient disclosed a novel heterozygous missense mutation (T to 
A) in exon 5 at cDNA position 1808 (17,18). This base change predicted the substitution of 
the neutral and hydrophobic amino acid neu by the neutral and polar Asn at codon 559, in the 
proximal region of the ligand-binding domain. The expression of both wildtype and mutant 
receptors in the patient's tissues was confirmed by sequencing the eDNA transcripts of the 
patient's Iymphoblasts and fibroblasts, which were of both the wild and mutant type. 
Comparison with the corresponding positions in the rat (23), mouse (24), and guinea pig (25) 
OR revealed that neu was conserved in all of them, whereas the related amino acid Leu was 
present in the human mineralocorticoid (26), progeslerone (27), and androgen receptor (28). 
These findings suggest that the presence of neu or Leu at this location has major structural and 
functional significance. Indeed, alignment of the three-dimensional structures of the ligand 
binding domains of the retinoid X receptor (RXR), human retinoic acid receptor (RAR), and 
thyroid hormone receptor (TR) with the unknown arrangement of the hormone binding domain 
of the OR demonstrated that neu 559 is at the beginning of a-helix 3, which is involved in 
forming the entrance of the ligand binding pocket (29-31). 
Ligand-binding studies in peripheral lymphocytes of the patient, performed after TSS, and 
while he was on substitution therapy with 1.5 mg dexamethasone, revealed a normal affinity 
but only half of the expected binding sites. In addition, thymidine incorporation was not 
inhibited by dexamethasone in tlus patient. When OR function was tested in an ill vitro cell 
system, the mutated OR-Asn559 was unable to bind ligand and, in addition, failed to activate 
gene transcription. The location of the mutation at the entrance of the putative ligand-binding 
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pocket suggests that the polar Asn prevents entry of the ligand or, alternatively, abolishes the 
entire cavity fonnation (31). Importantly, as shown in cotransfection studies, the mutated GR-
Asn559 impaired the ability of the wildtype GR to induce gene transcription. This mutation, 
therefore, exhibited a strong dominant-negative effect on the function of the wild-type GR. 
This is the first mutation identified in the GR of a patient with GGR that impairs the action of 
the wild-type receptor. In addition to preventing ligand binding, this mutation might exert its 
dominant-negative effects by potentiating the effects of co-repressors or inhibititing the effects 
of co-activators of the physiological GR encoded by the nonnal allele (32.33). 
Dominant-negative effects of mutated receptors were reported previously in the syndrome of 
thyroid hormone resistance (34). In addition, dominant inhibitory actions of physiologically 
expressed receptor isoforms were demonstrated for the human progesterone receptor-A (35) 
and, recently, for the GR isoform p (36). Actually, our patient's dominant-negative mutant 
receptor appears to be two- to three-fold more potent in its action than the natural GR-p 
isoform. Previously identified mutations of the GR in patients with GGR had no apparent 
dominant-negative effect on the wild-type receptor (4,6). Thus, heterozygotic patients were 
asymptomatic with only mild hypercortisolism (37,38).The degree of the biochemical 
abnormality in these heterozygotes was less than that of members of a family with a 50% 
reduction ofGRs (11,39) owing to nonexpression of one of the GR alleles (5). 
The GR mutation of the patient was not detected in either of his parents or in any of his five 
brothers and two sisters, which agreed with the lack of a clinical or biochemical picture of 
GGR in these subjects. Therefore, this mutation appeared to be a sporadic de novo germ-line 
mutation or a somatic mutation that occurred postzygotically during embryogenesis. That it 
was a de novo genn-line mutation was supported by the lack of mosaicism in the patient's 
tissues and by its presence in 50% of his spenn. Indeed, single-cell PCR amplification 
employing single fibroblasts, Iymphoblasts, or sperm separated by micromanipulation revealed 
that the diploid cells had both the wild-type and the mutant alleles, whereas approximately half 
of the haploid sperm carried the genetic defect. The appearance of a de novo germ-line 
mutation is in accordance with the fact that the patient is the second youngest of eight children, 
whose conception took place when his father was 41 and his mother 38 years old. 
Chronic activation of the HPA axis caused adrenal hyperplasia in the patient and, although not 
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proven by image analysis or pathological examination, might also have resulted in corticotroph 
hyperplasia, similar to that previously observed in patients with untreated Addison's disease 
(21). However, the patient also developed an ACTH-secreting pituitary adenoma, which was 
accompanied by further enlargement of the adrenal glands and development of frank Cushing's 
disease. Chronic exposure of the pituitary to increased concentrations of hypothalamic 
releasing factors might have rendered the corticotroph cells of this patient more susceptible to 
tumor-related genetic changes. Recently, accumulation of the tumor suppressor p53 -gene was 
shown in as many as 60% of spontaneously occurring corticotropinomas, suggesting that a so-
matic mutation of tllis gene had taken place within these tumors (9). Indeed, 
immunohistochemical staining of the chromophobe pituitary adenoma of our patient also 
revealed accumulation of p53 protein, indicating the presence of a putative oncogenic mutation 
in the p53 gene. Our attempt to amplifY DNA extracted from microdissected pituitary tumor 
tissue to examine the potential presence of an oncogenic mutation in the p53 gene was 
noncontributory. Tllis probably was due to the overnight formaldehyde fixation process of the 
pituitary tissue, a procedure often used by pathologists. Therefore, alteration responsible for 
p53 accumulation of the corticotropinoma remained unknown in the patient. Sequencing of 
exons 5-8 of the p53 gene using DNA from peripheral white blood cells revealed identity to the 
wild-type sequence. Consequently, an inherited germ-line p53 mutation, as in the Li-Fraumeni 
syndrome (40), was unlikely in this patient. This was in accordance with the medical history 
and clinical presentation of the family members, who were generally healthy. 
Hence, our investigation provided further pathophysiological insights on glucocorticoid action 
in humans and on the potential role that the GR may play in pituitary corticotroph 
tumorigenesis. It appears that chronic exposure of the pituitary to increased concentrations of 
hypothalamic releasing factors and insufficient suppression by glucocorticoids nlight render the 
corticotroph cells susceptible to tumor-related genetic changes. 
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HUMAN ACTH SECRETING PITUITARY ADENOMAS SHOW 
FREQUENT LOSS OF HETEROZYGOSITY AT THE 
GLUCOCORTICOID RECEPTOR GENE LOCUS. 
Nannette A.T.M. Huizenga, Pieter de Lange, Jan W. Koper, Richard N. Clayton, William E. 
Farrell, Aart Jan van der Lely, Albert O. Brinkmann, Frank H. de Jong and Steven W.J. 
Lamberts 
(Journal o/Clinical Endocrinology and Metabolism, 1998;83:917-921) 
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ABSTRACT 
Objective: Corticotrophinomas are characterized by a relative resistance to the negative 
feedback action of cortisol on ACTH secretion. In this respect there is a similarity with the 
clinical syndrome of cortisol resistance (CR). Since CR can be caused by genetic abnormalities 
in the glucocorticoid receptor (GR) gene, we investigated whether the insensitivity of 
corticotrophinomas to cortisol is also caused by (de novo) mutations in the GR gene. 
Methods: We screened the GR gene in leucocyte- and tumor DNA from 22 patients with 
Cushing's disease for mutations using PCRlSSCP-analysis. In a previous study, we have 
identified 5 polymorphisms in the GR gene in a normal population. These polymorphisms were 
used as markers for the possible occurrence of loss of heterozygosity (LOH) at the GR gene 
locus. 
Results: Except for one silent point-mutation, we did not identity novel mutations in the GR 
gene in leucocytes or corticotrophinomas from these patients. Of the 22 patients, 18 were 
heterozygous for at least one of the polymorphisms. In six of these patients LOH had occurred 
in the tumor DNA. Of21 patients examined for LOH on chr llq13 only one, a corticotroph 
carcinoma, showed allelic deletion. As controls we studied 28 pituitary tumor of other 
subtypes (I I clinically non-functioning, 8 prolactinomas and 9 GH-producing adenomas) and 
found evidence for LOH in only one prolactinoma. 
Conclusions: In 6 patients LOH was found at the GR gene locus (chr 5) in DNA derived from 
adenoma cells. Our observations indicate for the first time that LOH at the GR gene locus is a 
relatively frequent phenomenon in pituitary adenomas of patients with Cushing's disease. This 
might explain the relative resistance of the adenoma cells to the inhibitory feedback action of 
cortisol on ACTH secretion. The specificity of the GR LOH to corticotrophinomas supports 
this concept. Somatic mutations of the GR are not a frequent cause for relative cortisol 
resistance in these cells. 
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INTRODUCTION 
Cushing's disease is caused by an ACTH-secreting pituitary adenoma arising from 
corticotrophic cells, The adenomas are characterized by a relative resistance ofthe tumor cells 
to the feedback inhibition by glucocorticoids (GCs) on ACTH secretion (1,2). The biological 
effects of cortisol (and other GCs) are mediated by the glucocorticoid receptor (GR), a 
member of the family of intracellular hormone receptors (3). These receptors are characterized 
by a three-domain structure: a carboxy- terminal ligand-binding domain with also 
transcriptional activity, a central DNA-binding domain and an N-terminal domain essential for 
transcription activation (3). GC effects can either be the result of DNA binding of the Iigand-
bound receptor, or interactions of the receptor with other proteins within the nucleus (4). 
Mutations in the hormone binding domain of the GR gene have been described as the cause of 
familial glucocorticoid resistance (CR) (5-8). In a recent study, Karl and co-workers (9) 
screened the GR gene in patients who developed Nelson's syndrome after bilateral 
adrenalectomy for Cushing's disease, and found a heterozygous somatic frame shift mutation in 
one out of 4 macroadenomas investigated. 
In the present study, we analysed the GR gene in leucocyte and tumor DNA samples from 22 
patients with Cushing's disease, using PCRlSSCP analysis, to see whether somatic mutations in 
the GR gene in tumor DNA were responsible for the relative cortisol resistance of the 
corticotrophic tumor cells. In a previous study (10), PCRlSSCP screening revealed 5 GR 
polymorphisms in a normal population. Sequence analysis led to the disclosure of point 
mutations in the PCR fragments containing the exons II, IV, V and IX, respectively. In two of 
these polymorphisms (summarised in table I) the variant sequences occur with relatively high 
frequencies (exon V in 31.3% and exon IX in 13.7% of the investigated population). This 
allowed us to use these polymorphisms as markers for the possible occurrence of loss of 
heterozygosity (LOH) at the GR gene locus. The patients investigated were a subgroup of the 
patients studied by Buckley et al (II), who were tested for accumulation ofp53. Since there 
are reports that the MEN-I locus on chromosome IIql3 is potentially involved in the 
pathogenesis of all types of pituitary adenoma (12), we also examined this region of the 
genome for LOH in this unselected cohort of corticotrophinomas (13). 
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PATIENTS AND METHODS 
All 22 patients included in the study had clinical features of Cushing's syndrome and 
biochemical evidence of excessive cortisol production. All failed to suppresss with low dose (4 
x 0.5 mg) dexamethasone. With regard to the differential diagnosis different definitions of 
suppression with high dose (4 x 2 mg) dexamethasone suppression tests were used (e.g. 17-
OHCS, urinary free cortisol and sometimes plasma cortisol values). The high dose 
dexamethasone test does not allow us to distinguish precisely the sensitivity to dexamethasone 
amongst this group of 22 patients with histologically proven ACTH-secreting pituitary 
adenomas. 
Using PCRlSSCP we analysed the GR gene in tumor and leucocyte DNA samples from 22 
patients with pituitary dependent Cushing's syndrome, all due to surgically and histologically 
defined adenomas. All patients were operated on by transsphenoidal selective adenomectomy. 
Tumor samples were fixed in 10% formalin and embedded in paraffin. Tumor DNA was 
extracted from slide material using standard methods (13), with the benefit that the DNA 
originates from histologically defined adenoma tissue, therefore being as homogenous as 
possible. Leucocyte DNA was extracted from peripheral leucocytes using standard methods. 
Tumors were divided into categories according to invasiveness, based on the patients' CT and 
MRI reports as described by Bates et al (13, 14). Grades I and 2 include microadenomas and 
macroadenomas without radiological evidence of invasion, respectively. Grade 3 are 
macroadenomas with local invasion. One patient (no 5) was previously described (15). She had 
a corticotrophic carcinoma, with intracerebral metastases demonstrated on l\1RI scan and at 
autopsy (Grade 4). 
In order to investigate the specificity of the changes in the GR gene in corticotropinomas, we 
also studied 28 other pituitary adenomas (II clinically non-functioning, 8 prolactinomas and 9 
GH-secreting adenomas). 
PCR/SSCP analysis of Ihe glucocorlicoid receplor gene. 
Polymerase chain reaction (PCR) amplification of the GR gene was carried out using primers 
previously described by Koper et a[ (10). Because of the very limited quantity of the DNA 
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samples, PCR amplification was performed in two steps. The first amplification was performed 
in a total volume of 20 flL containing leucocyte or tumor DNA solution, 6 pmol of each 
oligonucleotide from 4 different primer pairs, 200 flM of each dNTP, 3mM MgCI" O.S U 
Ampli Taq (Perkin Elmer), SO mM KCI and 10 ruM Tris (pH 8.3). A 1:300 dilution of the 
primary PCR product was used as a template for a second PCR amplification under the same 
conditions, using one primer pair in each reaction. Single strand conformation polymorphism 
(SSCP) analysis of the PCR products was carried out using O.S x MDE polyacrylamide gels 
(J.T. Baker Chemicals, Deventer, the Netherlands) in the presence or absence of S% glycerol 
at 4 'c as described by Orita et al (16). Each SSCP gel contained samples from controls with 
the normal sequence and from controls with each of the five GR gene polymorphisms 
previously described by Koper et al (10). DNA fragments displaying an abnormal migration 
pattern during SSCP-analysis were amplified with the same primers for direct sequencing using 
a modified Sanger-dideoxynucleotide chain termination method, described in detail by Karl et 
al (7). 
Loss of heterozygosity all chromosome 11 
PCR amplification was performed using primers spanning the microsatellite repeat at the 
PYGM locus (llq13). Primer sequences for the amplification were S'-
GGAATGCTGATTTCCAGGTT-3', and S'-CTGTCAGGTAGCAACTGACATC 3' 
respectively. PCR reaction conditions were: Primer annealing at SO-S4°C for 2 min, primer 
extension at noc for 2 min and denaturation at 94°C for I min and final extension at noc 
for S mins. Leucocyte and tumor PCR products were run adjacently on 8 - 10% non-
denaturing polyacrylamide gels, fixed in 10% methanoVIO% acetic acid and then incubated in 
0.1% aqueous silver nitrate for ISmins. Following two brief washes in distilled water, products 
were visualised by development in an aqueous solution of I.S% sodium hydroxide and 0.1% 
formaldehyde. Allelic loss is identified by a reduction in intensity of >80% or absence of one 
of the expected PCR products (13). Results were reviewed independently by two observers 
and aUelic deletion only recorded if agreed by both. All samples in which LOH was identified 
underwent repeat PCR amplification and gel electrophoresis with identical results. 
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RESULTS 
Age, sex and tumor grading of the 22 patients investigated are shown in Table 1. There were 
20 female and two male patients, ages ranged from 13 to 58 years. There were three invasive 
tumors, four macroadenomas without invasion and 15 microadenomas. Patient 18 showed a 
novel SSCP pattern in exon VI of both tumor and leucocyte DNA. Direct sequence analysis 
showed that the abnonnal pattern was the result of a silent heterozygous point mutation (GCA 
to GCO at codon 618, both coding for an alanine in the receptor protein, data not shown). 
None of the other DNA samples analysed revealed novel SSCP variants in the OR gene. The 
OR PCR fragments containing the polymorphisms as described earlier (10) served as markers 
for possible loss of heterozygosity (LOH) in the present study. The polymorphism in the PCR-
fragment containing exon IV was not present in these 22 patients. In one patient (number 12), 
the polymorphism in PCR fragment exon IIII was present in leucocyte DNA. In the tumor 
DNA of this patient, however, the polymorphism was absent. Tllis suggests that in the tumor 
the variant allele was lost (Table I). The polymorpllism in the 3'-part of exon II (PCR fragment 
exon III5) was present in 2 subjects (2 and 8). The polymorphism was seen in both leucocyte 
and tumor DNA, indicating that there was no LOH in this part of the OR gene in these two 
subjects (Table I). 
Figure I shows the SSCP patterns of the polymorphism in the PCR fragment contahling exon 
V in controls (AA: homozygous for the normal allele; AB: heterozygous; BB: homozygous for 
the variant allele), together with the leucocyte and tumor SSCP patterns from several patients. 
~ JL JL 
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Figure 1. SSCP patterns of the polymorfhisms in the peR fragment oontaining eXOll V in controls (AA, 
homozygous for the Donnal allele; AB, heterozygous; BB, homozygous for the variant allele), together with the 
leukoc)1c and tumor SSCP patterns from several patients. P6 revealed pattern AA in the tumor DNA, \llhich in this 
case represents the presence of one A allele. 
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Table 1. Sex, age, tumor grading, possible loss of heterozygosity at the GR gene locus or chromosome I I, and P53 staining in 
corticotropinomas from 22 patients withpituitary dependent Cushing's disease. 
Glucocorticoid receptor gene peR fragment 
patient no sex age grade Exon ilI1 Exon illS ExonV ExonIX chrom 11 PS3 
F 15 I NT NT retained retained retained nucC 
2 F 50 2 NT retained retained retained retained nucD 
3 F 44 NT NT retained retained retained nucB 
4 F 60 NT NT retained retained retained neg 
5 M 39 3/4 NT NT NT retained LOB cytD 
6 F 50 2 NT NT LOB retained retained neg 
7 F 52 NT NT NT NT retained neg 
8 F 40 3 NT retained NT NT retained neg 
9 F 28 2 NT NT LOB LOB retained nueS 
10 F 48 NT NT LOB retained retained nucD 
II F 13 I NT NT retained NT retained ND 
12 F 25 LOB NT LOB NT retained nucC 
13 F 57 3 NT NT NT NT retained neg 
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14 F 33 NI NI retained NI retained neg 
15 F 58 NI NI NI NI retained neg 
16 F 37 2 NI NI retained NI retained nucA 
17 F 22 NI NI retained NI retained nucA 
18 M 28 NI NI LOB NI retained neg 
19 F 26 NI NI NI NI ND ND 
20 F 32 NI NI retained retained retained neg 
21 F NI NI retained NI retained neg 
22 F 23 NI NI LOB LOB retained cyt C 
Grade: 1. Micro adenoma LOB : loss of heterozygosity P53: nuc: nuclear staining 
2. Macroadenoma, no invasion NI : not informative cyt : cytoplasmic staining 
3. Macroadenorna with invasion ND : not determined A:75-100% B:50-75% 
4. Macroadenoma with intraiextracranial spread retained : informative, no LOB C: 25-50 % D: <25 % 
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Taking patient 6 as an example, a difference in the SSCP pattern in leucocyte and tumor PCR 
products from this patient was observed. Leucocyte DNA shows pattern AB (heterozygous), 
while tumor DNA reveals pattern AA, suggesting that the variant allele was not present in the 
tumor. A total of 16 patients showed SSCP pattern AB in leucocyte DNA, six of whom had an 
AA pattern in their tumor DNA, indicating that in 6 out of the 16 patients who were 
heterozygous for the polymorphism in exon V, LOH occurred at this specific part of the GR. 
Six other patients were homozygous in leucocyte DNA (5 of them showed pattern AA, one 
pattern BB), so the polymorphism was not informative in these patients with respect to LOH 
(Table I). 
With respect to PCR fragment exon IX, ten patients were heterozygous for the polymorphism 
(AB) in leucocyte DNA, two of whom showed LOH in the tumor (SSCP pattern AA, Table I). 
The 12 other patients showed the homozygously normal pattern (AA) in leucocyte DNA not 
allowing a conclusion about a possible LOH in this part of the GR gene could be reached in 
these patients. 
It can be concluded that six patients show LOH at the GR locus. Three of them in PCR 
fragment of exon V (patients 6, 10 and 18) and two of them in both exons V and IX (patients 9 
and 22). Patient 12 shows LOH at the N-terminus of exon II and at exon V. Overall LOH was 
identified in 6 patients, heterozygosity was maintained in 12 patients in sofar as the 
polymorphisms were informative in these patients, and 4 patients were completely 
uninformative. 
Tumor grading in patients in whose tumors LOH for the GR gene was found, showed that 
none of these tumors were invasive (Table I). Only one patient (number 5) showed LOH on 
chromosome II at the PYGM locus. TillS subject had a malignant corticotroph carcinoma and 
has been reported in detail previously (14). All the other Cushing's adenomas examined (n~21) 
retained the PYGM allele at Ilq13. In safar as the data on LOH were informative, tumors 
showing LOH for the GR gene locus do not show LOH on chromosome II. Similarly, for 
chromosome II LOH, heterozygosity in the informative parts of the GR gene was retained. 
Of II clinically non-functioning pituitary adenomas, 6 were heterozygous for the 
polymorphism in exon V (showing the AB phenotype), none of these tumors showed LOH. 
Five were heterozygous for the polymorphism in exon IX, 4 of which also were heterozygous 
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for the exon V polymorphism. The tumors exhibited no LOR for exon IX The polymorphisms 
IIfI and IllS were not present in the DNA from leucocytes and the adenomas. 
OfS prolactinomas, 3 were heterozygous for the polymorphism in exon V; one of these tumors 
showed LOR (the AB pattern was changed into a BB pattern). Two of these tumors were also 
heterozygous for the exon IX polymorphism without showing LOR The 1111 and 1115 
polymorphisms were not present in the DNA from leucocytes and the adenomas. Of 9 GR-
producing adenomas, 2 were heterozygous for the exon V and IX polymorphisms but showed 
no LOR in the tumor, and I was heterozygous for the polymorphism in exon IX without 
showing LOR No 1111 polymorphisms were present in the DNA from leucocytes and the 
adenomas, in one case the 1115 polymorphism was present in the leucocyte DNA and remained 
present in the adenoma DNA. 
In conclusion in 23 of these 2S pituitary tumor types were heterozygous for at least one of the 
polymorphisms investigated, while LOR was detected only in one of them. Statistical analysis 
using the Fisher exact test on LOH in the OR-gene in corticotrophinomas versus pituitary 
adenomas of other origin showed a P-value of <0.02. 
DISCUSSION 
Rypercortisolism in Cushing's disease is caused by semiautonomous ACTR secretion by a 
pituitary corticotrophinoma, in most cases a microadenoma (17). Corticotrophinomas are 
characterized by a decreased sensitivity of the tumor cells to the negative feedback action of 
cortisol on ACTR secretion (1,2), which is mediated by the GR. Hormone-bound GRs regulate 
the expression of glucocorticoid responsive genes, by activating or repressing the transcription 
of glucocorticoid regulated genes by binding to "positive" and "negative" glucocorticoid 
response elements (GRE and nGRE) (IS). The pro-opio-melanocortin (POMC) gene has been 
shown to contain an oGRE. 
With respect to the diminished sensitivity to the inhibitory feedback action of cortisol, 
corticotrophinomas show similarity with the syndrome of cortisol resistance. This syndrome is 
characterized by increased serum concentrations of cortisol due to a decreased inhibitory 
feedback by cortisol on pituitary ACTR production, without clinical stigmata of Cushing's 
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syndrome. The increased ACTH production results in secondary overproduction of adrenal 
androgens and mineralocorticoids (19). It has been demonstrated that mutations in the 
hormone binding domain of the GR gene result in the syndrome of cortisol resistance in man 
(5-8). In the present study we investigated by PCRlSSCP analysis whether somatic mutations 
in the GR gene in ACTH-secreting pituitary adenoma cells might be responsible for the relative 
cortisol resistance observed in these tumors. In only one patient (number 18), a silent point 
mutation in exon VI was identified (both in leucocyte and tumor DNA), indicating that small 
de novo mutations in the GR gene in corticotrophic cells are not frequently involved in the 
relative cortisol resistance of ACTH secreting tumor cells in the pituitary. In a recent paper 
also no point mutations in the GR gene were found in 17 corticotrophinomas, while additional 
studies did not point at a differential relative expression of the two GR isoforms (20). 
We have recently described five polymorphisms in the GR-gene (10). These polymorphisms 
were used as markers for the detection of LOH at the GR locus in these 22 
corticotrophinomas. We found LOH in 6 out of the 18 tumors where at least one of the 
polymorphisms was informative. In four cases no informative polymorphisms were present. 
Our data indicate that the deletions that have occured may be relatively small. Thus, in tumors 
6 and 10, LOH was found with respect to exon V, while for exon IX heterozygosity was 
retained. Moreover, in patient 18, LOH in the tumor was found in exon V, while the silent 
point-mutation in exon VI was present in both leucocyte and tumor DNA.For an adequate GC 
response, all parts of the GR are essential. Deletions such as those observed here will 
undoubtedly inactivate the gene product, if, indeed any is made. Moreover, GR-sensitivity has 
been shown to be gene-dosage dependent. Thus, Karl et al (7) described a family in which 
inactivation of one copy of the GR-gene, through a splice-site mutation, resulted in a reduced 
GR-number and in glucocorticoid resistance. Since the present polymorphisms are located 
within the gene itself and observations such as in tumors 6, 10 and 18 suggest that deletions 
might be relatively small it is unlikely that these results could have been reached using 
extragenic micro-satellite markers. LOH of the GR gene was found in 6 of the 18 informative 
corticotrophinomas studied, and was found in only one of the 23 informative non-functioning 
adenomas, prolactinomas and somatotrophinomas. TIllS does imply some specificity of this 
LOH to corticotrophinomas making it more likely that it contributes to the glucocorticoid 
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resistance ofthis state. 
From the data we obtained so far, it seems that adenomas showing LOH at the GR gene locus 
are non-invasive tumors which show no LOH on chromosome Ilq13. Although this was the 
only allele examined, the finding that the most frequent allelic deletion in pituitary adenomas 
(12,13) was not detected here, further supports the tumor subtype specificity of GR LOH in 
corticotrophinomas. 
It would have been interesting to see if the observed LOH at the GR gene locus is parallelled 
by reductions in the levels of GR-mRNA and GR protein. Unfortunately, the nature (paraffin 
embedded tissues) and quantity of the material makes extensive quantitative studies at the 
protein and mRNA level impossible. Other studies have demonstrated that homozygous point-
mutations in the hormone binding domain of the GR gene cause the clinical syndrome of' 
generalized cortisol resistance in man (5,6). The present data as well as the results from these 
previous studies suggest that there might be a decreased GR fimction in the pituitary tumors 
from the 6 patients in whom LOH was demonstrated. Consequently, these cells are relatively 
resistant to the inhibitory feedback action of cortisol on ACTH secretion, which might explain 
the increased ACTH production by these tumors. 
Hypothesizing on the basis of the present data, the following model can be put forward: in a 
differentiated corticotrophic pituitary cell, a spontaneous genetic alteralion, LOH al Ihe GR 
locus, occurs. Consequently, this cell is relatively insensitive to cortisoL As the mutated 
corticotrophic cell is less sensitive to cortisol, this could be seen as a relative shortage of 
inhibitory hormones, and it provides an advantage for clonal selection, as previously proposed 
by Karl et al (8). A striking example of the enormous clonal expansion due to discontinuation 
of the physiological inhibilory feedback by cortisol is the Nelson tumor which is an aggressive, 
fast growing ACTH-secreting pituitary adenoma. Nelson tumors appear in 10-30% of patients 
who have previously undergone bilateral adrenalectomy for Cushing's disease. In a recent study 
by Karl et al (9), a somatic frame shift mutation in the GR gene was found in one out of 4 
Nelson tumors investigated. It was concluded that the GR defect might have played a 
pathophysiological role in the tumorigenesis of tills corticotrophinoma. Another example in 
favour of the theory that clonal expansion of a single genetically altered corticolrophic cell 
occurs as a result of diminished negative feedback by cortisol is given by a patient described by 
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Karl et al (8). Tills patient had cortisol resistance due to a dominant negative GR gene 
mutation. During the treatment for cortisol resistance with low doses of DEX, the patient 
developed signs and symptoms of Cushing's disease. Despite discontinuation of the DEX 
treatment, the symptoms of Cushing's disease progressed. Eventually, the patient underwent 
bilateral adrenalectomy, and subsequently, when a pituitary magnetic resonance scan became 
positive for a tumor, a corticotrophinoma was removed. It was suggested that in this patient 
the exposure of the corticotroph to enhance stimulation by increased production of 
hypothalamic corticotropin releasing hormone and arginine vasopressine or a decreased 
sensitivity of the corticotroph to the negative feedback by cortisol may have led to adenoma 
formation. 
From the data presented here it can be concluded that simple somatic point mutations in the 
GR gene in corticotropillnomas do not seem to be the cause of the relative cortisol resistance 
in these tumor cells. However, we demonstrate for the first time that there is a frequent loss of 
heterozygosity at the GR gene locus in ACTH secreting pituitary adenomas. As deletions of 
(part of) the GR-gene leads to glucocorticoid resistance, this is a possible explanation for their 
relative resistance to the inhibitory feedback of cortisol on the ACTH secretion. Furthermore 
LOH at the GR gene locus may play a pathophysiological role in the initiation of 
corticotrophinoma forntation, although our data are insufficient to relate this to the size of the 
tumor. 
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ABSTRACT 
Glucocorticoids (GCs) serve a variety of important functions throughout the body. The 
synthesis and secretion of GCs are under the strict influence of the hypothalamo-pituitary-
adrenal axis (HPA-axis). The mechanisms of action of GCs are mediated by the intracellular 
glucocorticoid receptor (GR). Over the years, many studies have been performed concerning 
the regulation of GR expression by GC concentrations. 
In the present study, we determined the characteristics of the GR in peripheral mononuclear 
blood leukocytes (PBML) from thirteen patients with endogenous Cushing's syndrome and 
fifteen controls, using a whole cell dexamethasone binding assay. Furthermore, cortisol 
concentrations were determined in order to investigate a possible relationship between serum 
cortisol levels and receptor characteristics. 
There were no differences in mean receptor number between patients and controls. On the 
other hand, a significantly lower ligand affinity was identified in cells from patients with 
Cushing's syndrome compared to controls. A complete normalisation of the ligand affinity was 
observed after treatment, in the only patient tested in this respect, whereas the receptor number 
was not affected. In patients, there was a statistically significant negative correlation between 
cortisol concentrations and ligand affinity, which was not found in controls. 
Receptor down-regulation does not occur in PBML from patients with endogenous Cushing's 
syndrome. On the other hand, there seems to be a diminished ligand affinity which possibly 
reflects receptor modification in response to exposure to the continuously high cortisol levels 
in patients with Cushing's syndrome. This assumption is substantiated by the fact that in one 
patient a nornlalisation of the ligand affinity after complete remission of the disease was seen. 
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INTRODUCTION 
Glucocorticoids (GCs) serve a variety of important functions throughout the body. GCs affect 
metabolism by maintaining plasma glucose levels. They are important in the regulation of fat 
metabolism, mediate stress response, influence the inunune and central nervous system and 
have numerous effects on development and differentiation (I). The regulation of serum GC 
concentrations is under the influence of the hypothalamo-pituitary-adrenal axis (HP A-axis) (2). 
Hypothalamic corticotropin releasing hormone (CRH) is transported to the pituitary, which, in 
response, secretes corticotrophin (ACTH) into the hypophysial portal system. The adrenal 
gland is stimulated by ACTH to synthesize and secrete cortisol. Cortisol in its turn exerts a 
negative feedback on both the hypothalamic and the pituitary level in order to complete a 
negative feedback loop. In tills way, a perfect balance between cortisol requirement and 
cortisol secretion can be achieved. The HP A-axis is under the influence of many other systems. 
In cases of stress for example, the HP A-axis is activated, resulting in higher concentrations of 
GC (2). 
GCs exert their effects via the cytoplasmic glucocorticoid receptor (GR), willch is a member of 
the family of intracellular steroid hormone receptors to which receptors for vitamin D, retinoic 
acid and thyroid hormone belong as well (3, 4). The structural organisation of the GR is 
characterized by a short and highly conserved cysteine rich central region constituting the 
DNA binding domain, a relatively well conserved carboxy terminal domain which is important 
for both hormone binding and translocation, and a poorly conserved amino terminal region 
containing the transactivation domains responsible for gene activation (5). It is now well 
established that the ability of GCs to exert their biological effects requires the presence of a 
sufficient amount of intact receptor molecules (4, 6). There is evidence that GR undergo 
down-regulation after the exposure to ligand ill vitro, in animals and men (7,8). This receptor 
down-regulation is supposed to be an additional form of negative feedback regulation of GC 
action, apart from the regulation of GC serum levels by the HPA-axis (6). Nevertheless, the 
mechanisms of possible receptor down-regulation are poorly understood, and many 
discrepancies in different studies were reported, Moreover, most studies investigating receptor 
down-regulation were performed ill vitro or, when performed ill vivo, used pharmacological 
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amounts of GCs. In the present study, we investigated GR characteristics in patients with 
endogenous Cushing's syndrome. The aim was to identity whether GR down-regulation in 
peripheral blood mononuclear leukocytes (PBML) from these patients with longterm 
hypercortisolism who lack a diurnal rhythm of semm cortisol concentrations does occur. We 
found no receptor down-regulation, but a statistically significant decrease in ligand affinity for 
the receptor, which appeared to be closely related to the semm cortisol concentrations. 
Furthermore, the ligand affinity returned to normal in a patient after successful treatment for 
Cushing's disease. 
PATIENTS AND METHODS 
Patiellts alld con/roJ subjects. 
Thirteen patients, seven females and six males, with clinical and biochemical Cushing's 
syndrome were included. In all patients 24 hours urinary cortisol excretion was above the 
upper limits of normal. Furthermore, they showed insufficient adrenal cortisol suppression in 
the overnight 1 mg dexamethasone suppression test, and diurnal rhythms of semm cortisol 
concentrations were absent in all patients. Nine of the patients had Cushing's disease, two had 
an adrenal cortisol producing carcinoma, one had ectopic ACTH secretion and one had an 
adrenal cortisol producing adenoma. 
Control subjects were fourteen heaUy volunteers, eight females and six males, without 
Cushing's syndrome or any other endocrine disorder. None of the female volunteers was using 
oral anticonceptive drugs at the time of investigation. 
Peripheral blood 1/I01/Onuc/ear cells. 
40 mI of blood was drawn into heparinized tubes between 8.00h and 9.00h by vena puncture. 
PBMLs were isolated as described previously (9). The blood was diluted twofold with saline 
and layered over Ficoll-Hypaque (Pharmacia, Uppsala, Sweden). The PBML emiched 
interphase was isolated and washed twice with saline. The final cell pellet was resuspended in 
15 mI RPMI-1640 medium (Gibco Europe, Breda, the Netherlands), containing 15 mM Hepes, 
10% charcoal adsorbed fetal calf serum (AmstelstadIFlow, Zwanenburg, the Netherlands), 2 
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mM glutamine, 100 U/m! penicillin, 100 mg/ml streptomycin and 1.5 mg/m! fungizone. The 
cells were incubated for 30 minutes at 37"C in a shaking waterbath in order to remove 
endogenous cortisol. The cell suspension was centrifhged and resuspended in 15 m! medium. 
This procedure was repeated twice more. Finally, the cells were resuspended at a density of 
2.5-10 x 10' cells per ml in the medium. 
Whole cell dexamethasone binding assay. 
The whole cell dexamethasone binding assay was performed as described previously by Molijn 
et al (9). Briefly: incubation was started in a volume of240 III (0.5-2 x 10' cells) containing 'H-
dexamethasone at concentrations of 1.3 to 40 nM without (total binding) and with (specific 
binding) a 400-fold excess of unlabelled dexamethasone. Two tubes whitout labeled 
dexamethasone were incubated under the same conditions for determination of cell number and 
viability at the end of the procedure. The tubes were incubated during I hour at 30 "C in a 
shaking water bath. The incubation was stopped by the addition of 2 ml cold saline, followed 
by centrifugation and two washing steps. Finally, the cells were resuspended in 250 III medium. 
Radioactivity in 200 III of this suspension was counted in a liquid scintillation counter. Specific 
binding was calculated by subtracting non-specific binding from total binding. Receptor 
number and ligand affinity (11K, ) were calculated from the data using the method of Scatchard 
(10). 
Cortisol determinatiolls. 
At the same time blood was drawn for the whole cell dexamethasone binding assay, extra 
blood was drawn for cortisol detenninations. In the patients, two more blood samples were 
taken at 17.00h and 22.00h in order to investigate the circadian rhythm of cortisol 
concentrations. Patients were at basal rest during the day the samples were taken. Serum 
cortisol concentrations were determined using RIA-kits obtained from DPC (Los Angeles, 
CAl. Intra- and interassay variations were below 8.0% and 9.5%. 
Statistical analysis 
The results for serum cortisol concentrations, number of receptors and Kd are reported as mean 
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± SEM. To asses the relationships between cortisol concentrations and number of receptors or 
Kd , linear regression analysis was used. 
RESULTS 
There was a statistically significant higher early morning serum cortisol concentration in 
patients with Cushing's syndrome compared to controls (Table I). Although not all individual 
patients had early morning cortisol concentrations above the upper normal level (800 nmo!!I), 
none of the patients with Cushing's syndrome had a diurnal rhythm of serum cortisol 
concentrations (data not shown). 
Table 1. Differences in semm cortisol concentrations and cortisol receptor characteristics 
between Cushing patients (n~13) and controls (n~14). 
Cushing Controls 
Mean SEM Mean SEM P-value 
serum cortisol (nmol/l) 822 64.S 382 37.6 <0.001' 
number of receptors 6339 417 6184 211 0.72 
per cell 
Kd (nmol/l) 17.4 1.9 9.3 0.5 <0.001* 
Table I also shows that there were no differences in the number of receptors per cell between 
the two groups. On the other hand, there was a statistically significantly higher Kd in the 
patient group compared to controls, indicating a lower affinity of the receptor for its ligand 
As shown in table 2 neither in the patients group nor in the control group, there was a 
statistically significant correlation between number of receptors per cell and serum cortisol 
concentrations. On the other hand, as shown in Figure 1, there was a significant positive 
correlation between Kd and semm cortisol concentrations (so a negative correlation between 
ligand affinity and serum cortisol concentrations) in patients with Cushing's disease, which 
was not present in the control group. 
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Table 2. Correlations between serum cortisol concentrations and cortisol receptor 
characteristics in controls (n~ 14) and patients with Cushing's syndrome (n~ 13) 
number of .. eceptors per cell 
Kd (omolll) 
r 
0.12 
0.59 
Cushing 
P-valu. 
0.68 
0.03* 
• Cushing patients 0 Controls 
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Figure 1. Relationship between serum cortisol concentrations and GR ligand affinity in P13MLs in 13 patients with 
Cushing's syndrome (black dols) and 14 healthy controls (open dots). 
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Figure 2. Whole cell dexamethasone binding assays ofPBm in a patient with Cushing's disease before (triangles) 
and after (dots) succesful treatment. 
Figure 2 shows the results of Scatchard analyses of the GR in one of the patients with pituitary 
dependent Cushing's disease before and after succesfull transsphenoidal adenomectomy ofthe 
ACTH-secreting microadenoma. Although the basal morning serum cortisol concentration 
after remission was not much lower than during disease (704 nmolll versus 510 nmolll, 
respectively), the serum cortisol concentrations after treatment showed a diurnal rhythm in 
contrast to those before treatment. The data in figure 2 indicate that the treatment did not 
influence the number of receptors per cell measured in PBML from this patient, but that the 
ligand affinity normalized after treatment. 
DISCUSSION 
To our knowledge, GR down-regulation in patients with endogenous Cushing's syndrome has 
never been investigated. Therefore, we investigated 13 patients with endogenous Cushing's 
syndrome with respect to GR characteristics. We found no receptor down-regulation, but a 
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significantly lower ligand affinity in patients compared to controls. A possible explanation 
could be that high concentrations of GC influence the outcome of the whole cell 
dexamethasone binding assay. However, a previous study by our group (9) especially 
investigated the effect of exposure to high cortisol concentrations on the number of receptors 
and the ligand affinity in this assay. It was shown that only 3.3% of endogenous cortisol 
remained specifically bound to the receptor. Moreover, incubation in the presence of high 
doses of cortisol affected both receptor number ("down-regulation") and ligand affinity 
("decreased affinity"). In contrast, the results from tills study show an isolated lowering in 
ligand affinity, whithout effects on receptor number. In addition, the absolute cortisol 
concentrations in the patients with Cushing's syndrome were much lower than the 
concentrations administered in the ill vi/ro experiments performed by Molijn et al. Since the 
lowered ligand affinity does not seem to be caused by the presence of cortisol in the whole cell 
dexamethasone binding assay, these results possibly reflect receptor modification in response 
to the exposure to continuously high cortisol levels, as present in patients with Cushing's 
syndrome who lack a normal diurnal rhythm of serum cortisol concentrations. This assumption 
is substantiated by the fact that in one patient a normalisation of the ligand affinity was 
observed after complete remission aftlte disease. 
The ability of GCs to act on target tissues requires the presence of intact and sufficient 
numbers of GRs (3). Many studies investigating GR numbers have been performed, on basis of 
the hypothesis that receptor down-regulation nlight be an additional form of negative feedback, 
protecting against the continued signal elicited by ligand in cases of hypercorticolism or other 
forms of GC excess (6). In several studies a direct correlation between GR number and the 
cell's sensitivity to GCs was found (II, 12). Furthermore, a receptor down-regulation in 
reaction to GC therapy was demonstrated in cell cultures and animals including humans (7,8). 
The possible mechanisms of this receptor down-regulation is poorly understood. There is 
evidence for an enhanced receptor degradation (13,14) ill vitro but nothing is known about 
accelerated OR turnover ill vivo. Furthermore, many investigations were performed on OR 
mRNA expression levels. There is evidence that GC treatment modulates GR expression in a 
number of tissues and cell types, and that down-regulation occurs at both transcriptional, post-
transcriptional and/or post-translational levels (6, 13, IS). Moreover, most of the data available 
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at present concern ill vitro studies or results obtained afler administration of pharmacological 
amounts of exogenously GC. 
Little is known about the physiological actions of OC on receptor number or affinity. An 
elegant example in this respect would be the syndrome of generalized OC resistance. GC 
resistance is a rare disease, in which an extreme insensitivity of the target tissues to GC action 
leads to a clinical syndrome characterized by signs and symptoms of secondary overproduction 
of adrenal androgens and mineralocorticoids. Up till now, in only four kind reds the molecular 
basis of the clinical syndrome has been elucidated. In tbree of these four (l6-IS), different 
mutations in the hormone binding domain of the OR gene were found, while in the fourth 
kindred (19) a heterozygous splice site deletion at the 3' boundary of ex on 6 of the OR gene 
appeared to be the cause of the syndrome. In the latter kindred, the splice site deletion resulted 
in an instable mRNA with only half of the number of receptors on PBMLs as a final result. In 
all of these patients, the HP A-axis was set at a higher level, resulting in higher ACTH and 
cortisol concentrations. None of these patients showed any signs or symptoms mimiking an 
Addisonian clinical picture, meaning that there was a sufficient compensation of cortisol 
concentrations as a result of the increased HP A-activity. In none of the patients receptor up-
regulation was demonstrated, especially not in the patient with only half of the number of 
receptors as a result of the splice site deletion in the OR gene. In these cases, it can be 
concluded that receptor up-regulation is not an additional feedback system in cases of relative 
cortisol shortage. 
On the other hand, one might ask why people treated with GCs develop Cushing's syndrome; 
sufficient receptor down-regulation should protect a patient from developing side-effects of 
GC treatment. Nevertheless, many patients treated with GCs have serious adverse effects. 
It can be concluded that there is no OR down-regulation in patients with endogenous Cushing' 
syndrome, but that a diminished ligand affinity of yet unknown cause might partially protect 
the cells from the high cortisol levels. Nevertheless, this protecting mechanism seems to be 
insufficient, because all patients showed clinical signs and sympoms of GC excess. 
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General Discussion 
In this thesis, studies on several aspects of the variability of the sensitivity to GCs in the normal 
population as well as in disease are described.GCs serve a variety of important functions in 
eukaryotic cells and tissues including mediation of the stress response, induction of 
gluconeogenesis in the liver, regulation of the fat metabolism, influences on the immune and 
central nervous systems as well as the development and function of numerous other organs. In 
man, the major circulating GC is cortisol. Under basal conditions, serum cortisol 
concentrations are under the influence of the HPA-axis. Hypothalamic CRH and A VP are 
secreted into the hypophysial portal system to stimulate the secretion of ACTH by the 
pituitary. ACTH stimulates the adrenal glands to synthesize and secrete cortisol. Cortisol in its 
turn exerts a negative feedback action on the secretion of both hypothalamic CRH and 
pituitary ACTH in order to complete a negative feedback loop. In this way, a perfect balance 
between cortisol requirement and cortisol secretion can be ascertained. The HP A-axis is under 
the influence of a circadian rhythm: because of the diurnal rhythm in the rate of ACTH 
secretion, plasma cortisol levels are higher in the morning than at night. Both negative 
feedback and diurnal rhythm may be overcome by stress which causes increases in CRH, A VP 
and ACTH output resulting in plasma cortisol levels considerably above those found under 
basal conditions. 
Interperson variability versus personal stability of cortisol concentrations. 
Large individual variations in both baseline and stimulated cortisol concentrations have been 
reported in the normal population (I). Little is known concerning the question whether cortisol 
levels are stable within normal subjects. The only studies available wilh this respect are twin 
studies, which indicate that genetic factors may be of importance (2, 3). The variation in 
baseline serum cortisol concentrations belween persons is thought to be a function of many 
influences including the individual feedback sensitivity of the HP A-axis, circadian rhytlun and 
episodic secretion, whereas cortisol binding globulin (CBG) levels also affect cortisol 
concenlrations (3). In chapter 2 of this thesis, a study is described in which early morning 
cortisol concentrations were determined twice in a large group of healthy elderly individuals, at 
an interval of two and a half years. Serum cortisol concentrations showed a wide range 
between subjects but a strong individual stability, indicating that the HPA-axis is sel at a stable 
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and reproducible set point for a given individual. 
The role for the DST in the determination of ditTerences in GC sensitivity 
Another aspect of the study described in chapter 2 was to get an insight in the possible role of 
the 1 mg overnight DST in the determination of differences in sensitivity to GC in the normal 
population. It was shown that 96% of 216 healthy elderly individuals showed a post DEX 
cortisol concentration below the level of 50 nmoVI. However, 20 out of these 216 volunteers 
showed diminished adrenal suppression in reaction to 1 mg of DEX compared to the other 
individuals in the group (post DEX cortisol concentrations above 50 nmoVI). Nevertheless, 
only 5 subjects showed a post DEX cortisol concentration higher than 140 nmolll, which is the 
normal cut-off point in our clinic when the test is used as a screening for endogenous 
Cushing's syndrome. 
As mentioned, the DST is normally used in the screening procedure for patients suspected of 
endogenous Cushing's syndrome (4). It is known that in depressed patients an insufficient 
adrenal suppression in reaction to 1 mg DEX can occur as well (5). Also, many drugs may 
affect the outcome of the 1 mg DST (6) by altering DEX metabolism by the liver. For example 
anti-epileptic drugs induce hepatic enzyme activity, thereby increasing the metabolic clearance 
ofGCs including DEX (7). In a study in psychiatric patients, abnormal results of the DSTwere 
closely associated with low plasma levels of DEX (8). In a study comparing patients with 
endogenous depression and normal controls, it was shown that serum DEX levels were 
significantly lower in non-suppressors than in suppressors (9). Therefore, in the study 
described in Chapter 2, DEX concentrations were detennined in order to get an insight in the 
role of the DEX metabolism as a confounder in the interpretation of the results of the DST if 
used as an indicator for GC sensitivity. Only two out of the five subjects showing a lowered 
adrenal suppression in the 1 mg DST, showed a serum DEX concentration above a level of 2 
nmolll. The other three individuals showed serum DEX levels varying from 0.8 to 1.6 nmoVl, 
which were among the lowest levels measured in the whole group. One of them was using anti-
epileptic drugs. Unfortunately, these three persons did not participate in the 0.25 mg DST (see 
below). The capacity of the liver to metabolize DEX appeared to be related to liver function 
parameters in males and to BMI in females. This influence of liver function disturbances, BMI 
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and several drugs on the metabolism of DEX might therefore contribute to the occurrence of 
false positive or false negative outcomes of the I mg DST in clinical endocrinology. 
However, it is clear that the I mg DST is an accurate test to detect individuals with a lowered 
sensitivity to GCs. On the other hand, it became clear trom these results that a dose of I mg of 
DEX is far too high to detect individuals with an increased sensitivity to GCs, or individuals 
with subtly dintinished sensitivity. 
Therefore, a 0.25 mg DST was performed two and a half years later in the same group of 
healthy volunteers. Post DEX cortisol concentrations showed a much broader range compared 
to those in the I mg DST. Furthermore, a group of individuals with an increased sensitivity to 
GCs could be identified using the results of the 0.25 mg DST (see below). Interestingly, it 
became clear that subjects with the highest baseline cortisol concentrations also showed the 
highest post 0.25 mg DEX cortisol concentrations. This indicates that in a given individual, 
there is a set-point ofHPA-activity which is defined before as well as after a low dose of DE X. 
It can be concluded that the 0.25 mg DST seems to be a more sensitive indicator for subtle 
GC sensitivity differences, whereas the I mg DST still remains the golden standard for 
el<cessive sensitivity changes as in Cushing's disease or CR. 
Effect of age on the HPA-axis activity 
Over the years the effects of age and gender on the function of the HPA-axis axis have been 
extensively investigated. These studies, however, have resulted in contradictory results (10). 
Both circadian patterns of cortisol and ACTH secretion and random morning plasma cortisol 
concentrations were reported to be unaltered in the elderly (11-17). On the other hand, an age-
related trend towards increased levels of evening plasma cortisol was reported (18), and in 
elderly males increased mean cortisol levels derived trom 24-h trequent sampling were found, 
which were not present in elderly females (19). Furthermore, it was reported that aging in 
humans is not accompanied by a significant increase in spontaneous ACTH or cortisol 
secretion or by a decrease in HP A sensitivity to GC feedback suppression (15). In Chapter 2 of 
this thesis, we found no relation between age or gender with baseline cortisol concentrations or 
with post 1.00- or 0.25 rug DEX cortisol concentrations, indicating that neither age nor gender 
has any influence on the activity ofthe HP A-axis. 
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(Lack of) Association between GR gene polymorphism. and glucocorticoid sensitivity. 
The mechanisms of action of steroid hormones, thyroid hormone, vitamin D and retinoic acid 
are mediated specific intracellular receptor proteins (20). Within this superfamily, the GC, 
mineralocorticoid, progesteron and androgen receptors constitute a subfamily (21). These 
receptor proteins regulate expression of specific target genes by ligand-dependent 
transcriptional activation, i.e. ligand-dependent activation of the receptor with subsequent 
dimer formation and DNA-binding. The structure of the GR consists of a poorly conserved 
amino-terminal region containing the transactivation domains responsible for gene activation, a 
highly conserved cysteine-rich central DNA-binding domain, and a relatively well conserved 
carboxy-terminal domain important for hormone binding. It is well established that the ability 
of GC to exert their biological effects ill vivo require the presence of intact receptor molecules 
(21). CR in the cases that have been described previously (22-24), was found to be caused by 
mutations in the hormone binding domain of the GR gene. Thus in "classical CR" the GR 
seems to be the key modulator of GC sensitivity. The results from the studies described in 
Chapter 2 and 3 indicate that biochemical cortisol resistance is probably more common than 
was expected up till now: As mentioned before, 20 subjects out of the 216 individuals that 
participated in the I mg DST showed post DEX cortisol concentrations above the level of 50 
nmoili. Five of them showed post DEX cortisol concentrations above 140 mnolll. However, 
none of these subjects showed signs or symptoms of clinical CR. Using PCR-SSCP analysis, 
five polymorphisms in the GR-gene were identified in this group of healthy elderly individuals. 
None of these polymorphisms was associated with clinical CR in this group of volunteers, nor 
was there an overall association with diminished adrenal suppression. However, one of the 
polymorphisms found in this screening procedure, the double point mutation in codons 22 and 
23 (Figure I), was found several times in patients with obvious clinical and biochemical CR as 
well. In two of the patients described in Chapter 5 of this thesis who showed clear clinical and 
biochemical pictures of CR, the double poin-mutation in codons 22 and 23 was found. From 
one of the patients, a young girl with severe steroid resistant asthma, we screened the family 
with respect to this polymorphism. It appeared that her healthy, unaffected grandmother, 
mother and brother were positive for the mutation as well. In the study described in Chapter 3, 
the double point-mutation was found in the individual with the highest post DEX cortisol 
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concentration (256 nmolll). Moreover, two other "non-suppressors" (post DEX cortisol 
concentration were Ito and 241 nmolll, respectively) were found to carry the mutation. 
However, eight other subjects out of the whole group of volunteers we tested, also showed 
this polymorphism, in combination with a normal cortisol suppression in reaction to I mg of 
DEX. In ill vitro expression experiments, this polymorphism showed no alterations in the 
efficacy of the GR to activate transcription compared to the wild-type receptor (25). Possibly, 
in the non-suppressors we found in this study and in the patients with CR carrying this 
polymorphism, the mutation is linked to another mutation I polymorphism in or near the GR 
gene that was not detected using the PCRlSSCP approach in this study. 
No study mentioned in this thesis so far has distinguished between the two different GR 
isoforms termed GRa and GRp, that are formed by alternative splicing of the human GR pre-
mRNA (26, 27). Recent studies by Bamberger et al (28) however, indicate that the distinction 
between the GRa and GRp form might be more important than previously thought. These two 
protein isoforms have the first 727 amino acids in common, and, thus, both contain the 
transactivation and the DNA-binding domains. GRp differs from GRa only in its C-terminus 
with replacement of the last 50 amino acids of the latter with a unique IS-amino acid sequence 
(26, 27). Because of this difference in the hormone binding domain, GRp was thought to be 
unable to bind GCs and thus to be transcriptionally inactive (29). In a recent study by 
Bamberger et al (28), it was demonstrated that overexpression of GRp could antagonize the 
effect of hormone activated GRa on a GRE gene ill vitro. This dominant negative effect of 
GRp on GRa mediated gene transcription was dose-dependent with overexpression of GRp 
leading up to 90 % reduction of reporter gene activity. GRp mRNA (28) and protein (30) were 
shown to be expressed in many tissues suggesting that this isoform might be physiological 
relavant (20). The existance of at least two GR isoforms that apparantly exert opposite effects 
makes the picture of GR mediated transcription more complex. It demands careful 
reevaluation of previous studies that did not distinguish between the two isoforms. The 
polymorphisms described in Chapter 3 in combination with the observed differences in GC 
sensitivity will be interesting to investigate with respect to these different GR isoforms. 
Another polymorphism described in Chapter 3, an asparagine to serine change in codon 363 as 
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a result of an A to G point mutation in the N-terminal part of the GR gene (Figure I), was 
found in subjects with a normal adrenal suppression in reaction to DEX , rather than in subjects 
with a diminished cortisol suppression. This prompted us to reevaluate the whole study 
population with respect to this polymorphism. We found that in 6% of the individuals tested, 
the polymorphism was present. This mutation has been described before in a family with CR 
(in combination with a splice-site deletion) and in SCLC cell lines DMS097 (31) and COR L24 
(32). In III vitro experiments, no significant difference was observed in the capacity of this 
variant GR relative to the wild type to activate transcription of the CAT gene in an MMTV 
driven reporter construct, after transfection into COS-I cells. Our own results using the more 
sensitive MMTV-LUC system also do not indicate a difference between N363S and wild type 
GR in this respect. Apart from transcriptional activation, GR is also involved in transcriptional 
repression of target genes. It does so either by binding directly to so-called negative 
glucocorticoid responsive elements (nGREs) (33, 34), or via interactions with factors such as 
activating protein-I (AP-I) (35, 36) or nuclear factor (NF)-KB (37-39), thereby preventing 
these factors from activating their target genes. Co-transfection experiments have shown that 
the codon 363 variant has an unaltered capacity to repress target genes via nGREs or via the 
above mentioned transcription factors (40). Nevertheless, by comparing ill vivo indicators for 
an increased sensitivity to GCs between subjects carrying this mutation and controls, it 
appeared that the individuals carrying the mutation showed a statistically significant increased 
adrenal suppression and insulin response in reaction to a low (0.25 mg) dose of DEX as 
indicators of short term CG effects. A dose of I mg of DEX seemed to be too high to detect 
the differences in cortisol suppression. The increased insulin response, however. became 
apparant after both DSTs. Furthermore, an increased BM! and a decreased BMD compared to 
age- and sex-related controls as indicators of long term GC effects were found in tlus group. 
The apparent discrepancy between these ill vivo effects and our inability to confirm this 
increased sensitivity to GCs ill vitro is likely to be due to the broad spectrum of regulatory 
mechanisms in which GCs and their receptors are involved. We showed earlier that GR 
mutations can effect transcriptional activation and -repression differently (25). It could well be 
that COS-I cells lack the transcription factors determining the effect of the N363S mutation ill 
vivo and that the presence of endogenous GR in these cells is an impediment for the study of 
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subtle effects of this mutation ill vitro. Finally, our results may indicate that this polymorphism 
is linked to an additional genetic alteration, as was proposed for the double point mutation in 
co dons 22 and 23. This yet unknown factor might interact with the GR protein to exert its 
effect. However, for diagnostic purposes, the recognition of a point mutation in the GR gene 
linked to a phenotypic difference may prove very useful, irrespective of the fact whether or not 
this may solely, in part or not at all be a consequence of altered GR function. A next step will 
be to investigate whether the codon 363 polymorphism might predict an increased sensitivity to 
the development of early andlor serious side effects during therapy with GCs. If this would be 
true, we might have found an elegant way to predict the appearance of side effects during GC 
therapy. 
(Lack of) Association between clinical CR and GR gene polymorphismslpoint mutations. 
In cases of the extremes of the spectrum of GC sensitivity, these differences in GC sensitivity 
may lead to clinical syndromes like cortisol resistance or the cortisol hyperreactivity syndrome. 
Ever since the first description 1976, only about 30 patients and (asymptomatic) familie 
members with CR have been described. Up tiII now, the molecular basis for CR has been 
described in three patients and affected family members (22-24). In all three cases, mutations in 
the hormone binding domain of the GR gene were responsible for the clinical manifestation of 
CR. Recent reports of a significant prevalence of possible abnormalities in the GR in patients 
attending the endocrine clinic for hypokalemia, hypertension, acne, hirsutism and menstrual 
disorders (40, 41), prompted us to carry out a thourough investigation with respect to GR 
protein and GR gene in many patients attending the endocrine clinic for a broad spectrum of 
complaints suggesting a possible CR. As described in Chapter 5, four of these patients showed, 
characteristics in the GR protein in PBML in concordance with biochemical CR, in 
combination with the suspicious clinical picture. Two of them showed a diminished ligand 
affinity, in one patient only half of the number of receptors in PBML became apparent and in 
two of the patients, an inability to inllibit mitogen induced cell proliferation by DEX in the ill 
vitro bioassay was shown. Moreover, all patients showed an insufficient cortisol suppression in 
the I mg DST. Screening of the GR gene of these patients using PCRlSSCP analysis, however, 
revealed no new point mutations. As mentioned before, two of the patients described carried 
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the double point mutation at codon 22 and 23 that was also found in the general population 
screening described in Chapter 3. Afetr PCRlSSCP analysis, the whole ligand binding domain 
was reevaluated using sequence analysis, but again no alterations in the GR gene were found. 
It is clear that there is a discrepancy between the clinical and biochelnical picture in these 
patients on one side, and the molecular characterization on the other. In order to investigate 
the GR gene more extensively, a next step will be to look at the transcriptional level by 
studying mRNA expression. These investigations are currently under study. 
GR GENE 
GR PROTEIN 
R23K N363S 1659N D641V V7291 
tY::::::::~~[:::::Y::J[~~:IY::::::Y~~::Y::'J" NH2 -I N·1EAM 060 I I HBO I"COOH 
Figure 1. The OR gene with indicatetl aU known mutations / delatiolls in humans 
Analysis of the GR gene of the patient described in Chapter 6 disclosed a novel point mutation 
(T to A) in exon 5 at cDNA position 1808 (26, 27). This base change predicted the 
substitution of the neutral and hydrophobic amino acid isoleucine by the neutral and polar 
asparagine at codon 559 in the proximal region of the hormone binding domain (Figure I). By 
sequencing the cDNA transcripts of the patient's Iymphoblasts and fibroblasts, the expression 
of both wild type and mutant recptor in the patients'S tissues was confirmed. It became 
apparent that this mutant receptor had a dominant negative effect on the wild type receptor. 
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Apart from extreme cases of differences in GC sensitivity which give rise to real clinical 
syndromes, clinical observations show that there is a considerable variability in sensitivity to 
GC therapy as well. Many patients recieve GC therapy for a variety of non-endocrine diseases. 
Some patients show a quick and good response to GCs, while others need higher dosages 
causing only minor responses. One of the biggest disadvantages of GC therapy is the 
unpredictable occurence of side effects. As described above, many studies have been 
performed searching for alterations in the GR gene to explain these differences. Nevertheless, 
up till now, only four point mutations in the hormone binding domain of the GR gene have 
been described, all of which were accompanied with the syndrome of severe CR. Little is 
known about the role of GC metabolism. As described in Chapter 2, there was a very wide 
range between individuals in serum DEX concentrations following the administration of 1.00 
or 0.25 mg of DEX. Moreover, there was a strong intra-individual correlation between the 
serum DEX concentration after 1.00 and 0.25 mg of DEX. As mentioned before, it became 
clear that there is a relationship between liver function parameters, BMI, and administration of 
several drugs on the one hand, and the eventual DEX concentration after oral administration of 
DEX on the other. Also from the literature it is known that a number of factors may alter the 
hepatic metabolism of GCs. The metabolism includes reduction-, oxidation-, hydroxylation-
and conjugation-steps, all of which are catalyzed by different enzymes. It is known that 
hormonal factors (e.g. thyroid hormone affects 5a- and 5p reductase activity) (42), obesity 
(accelerared cortisol turnover) (43), several diseases (e.g. selctive loss of 5a- and 5p 
reductase activity in liver cirrhosis) (44) and many drugs (e.g. phenytoin and rifampicin 
accelerate GC turnover) (45, 46) influence GC metabolism. Therefore it is possible that 
endogenous factors like for example enzyme mutations could influence GC metabolism. It 
might well be that the observed differences in sensitivity to GC therapy are a reflection of 
differences in GC catabolism rather than a reflection of target tissue sensitivity to GCs. In 
order to investigate this assumption, we will have to study a group of healthy volunteers with 
respect to DEX catabolism e.g. after I mg of DE X, and compare DEX concentrations with the 
corresponding cortisol concentrations. In this way, one might get an insight in the role GC 
metabolism plays in the occurence of side effects. 
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GR, CR and Cushing's disease 
In Chapter 6 the development of a corticotroph adenoma in a patient with CR was reported. 
During treatment for CR with high doses of DEX, but many years after the onset of the 
therapy, the patient developed signs and symptoms of Cushing's syndrome. Despite 
discontinuation of the GC therapy, the symptoms of Cushing's syndrome worsened. 
Eventually, the patient underwent bilateral adrenalectomy and subsequently, when a pituitary 
magnetic resonance imaging scan became positive for a tumor, he had transsphenoidal surgery 
in order to remove a histologically verified corticotropinoma. 
Corticotropinomas are characterized by a decreased sensitivity of the tumor cells to the 
negative feedback action of cortisol on ACTH secretion (47, 48), which is mediated by the 
GR. Hormone-bound GRs regulate the expression of glucocorticoid responsive genes, by 
activating or repressing the transcription of glucocorticoid regulated genes after binding to 
"positive" and "negative" glucocorticoid response elements (GRE and nGRE) (34). The pro-
opio-melanocortin (POMe) gene, of which the gene product, the POMC-molecule, is the 
precursor molecule of ACTH, contains an nGRE. 
With respect to the diminished sensitivity to the inhibitory feedback action of cortisol, 
corticotropinomas show similarity with the syndrome of CR. This observation together with 
the development of Cushing's disease in our patient with CR suggested the hypothesis that 
mutations in the GR gene in corticotropinomas might be the cause of the diminished GC 
sensitivity in these tumors. From the study described in Chapter 7, it became apparent that 
somatic mutations do not seem to be the cause of the relative CR in corticotropinomas. On the 
other hand, the polymorphisms in the GR gene described in Chapter 3 could be used as 
markers for the detection ofLOH at the GR gene locus. It was found that LOH at the GR gene 
locus was a common phenomenon in corticotropinomas, in contrast to other pituitary 
adenomas that were investigated as controls in this study. From the data presented here it can 
be concluded that simple somatic point mutations in the GR gene in corticotrophinomas do not 
seem to be the cause of the relative cortisol resistance in these tumor cells. However, we 
demonstrated for the first time that there is a frequent loss of heterozygosity at the GR gene 
locus in ACTH secreting pituitary adenomas. As deletions of (part 01) the GR-gene leads to 
glucocorticoid resistance, this is a possible explanation for their relative resistance to the 
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inhibitory feedback of cortisol on the ACTH secretion. Consequently, these cells are relatively 
resistant to the inhibitory feedback action of cortisol on ACTH secretion, which might explain 
the increased ACTH production by these tumours. 
Studies using X-chromosome inactivation analysis (49) have shown that the majority of 
pituitary adenomas are monoclonal, suggesting that genetic alteration in one single cell is the 
initiating step in the development of these tumours. Faglia (50) proposed a multistage model 
of tumorigenesis of pituitary adenomas involving initiation and promotion. Initiation implies 
pituitary cells undergoing spontaneous or acquired mutations, while promotion assumes the 
expansion of the mutated cell sustained by intrinsic or extrinsic promoting factors. Ifwe apply 
this model to the data obtained from our study, the following hypothesis can be put forward: in 
a differentiated corticotrophic pituitary cell, a spontaneous genetic alteration, LOH at the OR 
locus, occurs. Consequently, this cell is relatively insensitive to cortisol. One of the possible 
promoting influences proposed by Faglia, is a defect in inhibitory hormones. As the mutated 
corticotrophic cell is less sensitive to cortisol, this could be seen as a relative shortage of 
inhibitory hormones, and it provides and advantage for clonal selection. A striking example of 
this is the report by Karl et al on a somatic frame shift mutation in the OR gene in one offour 
patients with a Nelson tumor (51). The mutation was restricted to the pituitary tumor tissue, 
presumably leading to a decrease to half the number of receptors in the aggressively growing 
adenoma. These data, together with the data from our patient described in Chapter 6 and the 
LOH studies from Chapter 7 suggest that decreased sensitivity of the corticotroph to the 
negative feedback of OCs may lead to adenoma formation. It can be concluded that OR 
defects might have played a pathogenetic role in the tumorigenesis of these corticotropinomas. 
The last Chapter of this thesis describes the effect ofhypercortisolism in endogenous Cushing's 
disease on OR number. Many studies investigating OR number have been performed, on basis 
of the hypothesis that receptor down-regulation might be an additional form of negative 
feedback, protecting against the continued signal elicited by the ligand in cases of 
hypereortisolism (52-58). In several studies a direct correlation between OR number and the 
cell's sensitivity to GCs was found (54, 55). Furthermore, a receptor down-regulation in 
reaction to GC therapy was demonstrated in cell cultures and animals including humans (52, 
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53), The possible mechanisms of this receptor down-regulation is poorly understood, There is 
evidence for an enhancement of receptor degradation (56, 57) ill vitro but nothing is known 
about accelerated GR turnover ill vivo. Furthermore, many investigations were performed on 
GR mRNA expression levels, There is evidence that GC treatment modulates GR expression in 
a number of tissues and cell types, and that down-regulation occurs at both transcriptional, 
post-transcriptional and/or post-translational levels (58), Nevertheless, we found no evidence 
for a receptor down-regulation on PBML from patients with endogenous Cushing's syndrome 
compared to controls, We did, however, find a significantly diminished ligand affinity of yet 
unknown cause that might partially protect the cells from the high cortisol levels, Nevertheless, 
this protecting mechanism seems to be inefficient, because all patients showed clinical signs 
and sympoms of GC excess, 
The studies described in this thesis tried to clarity the differences in GC sensitivity in both 
disease and in the normal population, with a central role for the GR, Although several 
questions were answered, also many new questions came up. There are many discrepancies 
between GR alterations and clinical or biochemical CR, Moreover, in only a few cases of 
clinical CR, a GR defect proved to be the direct cause of the clinical syndrome, Further studies 
investigating the GR more extensively will have to clarity whether the GR indeed plays such an 
important role or, if other ways should be chosen in order to elucidate the remaining questions 
about differences in GC sensitivity, 
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GC hormones serve a variety of important functions throughout the body. In man, the major 
circulating GC is cortisol. Under basal conditions, serum cortisol concentrations are under the 
influence of the lIP A-axis to keep a perfect balance between cortisol requirement and cortisol 
secretion. The mechanisms of action of steroid hormones, thyroid hormone. vitamin D and 
retinoic acid are mediated by specific intracellular receptor proteins. These receptor proteins 
regulate expression of specific target genes by ligand-dependent transcriptional activation, i.e. 
ligand-dependent activation of the receptor with subsequent dimer formation and DNA-
binding. The structure of the GR consists of a poorly conserved amino-terminal region 
containing the transactivation domains responsible for gene activation, a highly conserved 
cysteine-rich central DNA-binding domain, and a relatively well conserved carboxy-terminal 
domain important for hormone binding. From clinical observations in patients who are treated 
with GC therapy for non~endocrine diseases, it is known that there is a considerable variation 
in the sensitivity to GC in the normal population. In extreme cases, this variation may lead to 
clinical syndromes like CR or cortisol hypersensitivity. In all cases of CR described so far, 
mutations in the hormone binding domain of the GR gene appeared to be the cause of the 
d.isease. 
In this thesis, studies on several aspects of variability in GC sensitivity in the normal population 
as well as in disease are described. 
Chapler 1 provides a general introduction. It opens with a short description of GC synthesis, 
secretion and effects. As the GR plays a central role in this thesis, an extensive description of 
the structure, function and mechanism of action of the GR is given. Finally, several aspects of 
differences in GC sensitivity in disease and in the normal population are discussed. 
Chapler 2 describes a cohort study in 216 healthy elderly individuals. In these subjects, two 
DSTs with LOO and 0.25 mg of DE X, respectively, were performed at an interval of two and a 
half years. It appeared that serum cortisol concentrations showed a wide range between 
subjects, but a strong individual stability. Moreover, it became clear that subjects with the 
highest baseline cortisol concentrations also showed the highest post 0.25 mg DEX cortisol 
concentrations. This indicates that the lIP A-axis is set at a stable and reproducible set point for 
a given individual. Furthermore, it was concluded that a dose of LOO mg of DE X is too high to 
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detect small differences in GC sensitivity. The 0.25 mg DST gives a much broader range in post 
DEX cortisol concentrations and should be used to detect small differences in GC sensitivity, 
especially when increased sensitivity is suspected. 
Chapter 3 describes the general screening of the GR gene in a subgroup of the study-
population described in Chapter 2. This screening revealed the existence of five polymorphisms 
in the GR gene in the normal population. None of these polymorphisms, however, was 
associated with clinical or biochemical CR. Nevertheless, it became clear that a point mutation 
at cDNA position 1220 resulting in an A to G change in codon 363 might be associated with 
increased sensitivity to GC. This prompted us to re-evaluate the whole study population of216 
healthy elderly individuals with respect to tins polymorplnsm. The mutation was found in 6% 
of the normal population. 
Chaptel" 4 describes that subjects carrying this polymorphism seem to be more sensitive to 
GC, both with respect to short-term effects of exogenously administered GCs (increased 
cortisol suppression and increased insulin response), and with respect to long-term effects of 
endogenous GCs (higher BM!, lower BMD). However, in ill vitro assays, this increased 
sensitivity could not be proven. It could well be that COS-1 cells, which were used in these 
experiments lack the transcription factors determining the effect of the N363S mutation ill viva 
or that the presence of endogenous GR in these cells is an impediment for the study of subtle 
effects of this mutation ill vitro. Another explanation might be that this polymorphism is linked 
to an additional genetic alteration. This yet unknown factor might interact with the GR protein 
to exert its effect. A next step will be to investigate whether the codon 363 polymorplnsm 
might predict an increased sensitivity to the development of early andlor serious side effects 
during therapy with GCs. 
Recent reports of a significant prevalence of possible abnormalities in the GR in patients 
attending the endocrine clinic for hypokalemia, hypertension, acne, hirsutism and menstrual 
disorders, prompted us to carry out a thou rough investigation with respect to the GR protein 
and the GR gene in many patients attending the endocrine clinic for a broad spectrum of 
complaints suggesting a possible CR. 
In Chapter 5 we describe 5 patients who showed a combination of a suspicious clinical 
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picture, together with functional characteristics of the GR protein in PBML which were in 
concordance with biochemical CR. Two of these patients showed a dintinished ligand affinity, 
in one patient the number of receptors in PBML was reduced by 50%, and two of the patients 
showed an inability to inhibit ntitogen induced cell proliferation in an ill vitro bioassay. 
Moreover, all patients showed a decreased cortisol suppression in reaction to 1 mg of DEX. 
Screening the GR gene of these patients using PCR/SSCP analysis, however, revealed no new 
point mutations or any other GR gene alterations. A next step will be to investigate the GR at 
the RNA level. 
Chapter 6 contains the patient history of a man who presented initially with hypokalentia and 
hypertension, which was caused by severe CR. During treatment for CR with high doses of 
DEX, he developed Cushing's disease. Analysis ofthe GR gene of the patient disclosed a novel 
point mutation (T to A) in exon 5 at eDNA position 1808. This base change predicted the 
substitution of the neutral and hydrophobic antino acids isoleucine by the neutral and polar 
asparagine at codon 559 in the proximal region of the homlDne binding domain. By sequencing 
the eDNA transcripts of the patient's lymphoblasts and fibroblasts, the expression of both wild 
type and mutant recptor in the patients's tissues was confirmed. It became apparant that this 
mutant receptor had a dontinant negative effect on the wild type receptor. 
Chapter 7 describes a study concerning the role of the GR in Cushing's disease. Continuing 
along the line provided by Chapter 6, in combination with the observation that 
corticotropinomas show a strong resemblance to CR with respect to the diminished sensitivity 
to GCs, it was hypothesized that mutations in the GR gene in corticotropinomas ntight be the 
cause of the decreased GC sensitivity in these tumors. However, it became apparent that 
somatic mutations did not cause the relative CR in corticotropinomas. On the other hand, the 
polymorphisms in the GR gene described in Chapter 3 could be used as markers for the 
detection of LOH at the GR gene locus. It was found that LOH at the GR gene locus is a 
common phenomenon in corticotropinomas, in contrast to other pituitary adenomas that were 
investigated as controls in this study. Furthennore, it was concluded that the GR defect might 
have played a pathogenetic role in the tumorigenesis of these corticotropinomas. 
Chapter 8 describes the effect of hypercortisolism in endogenous Cushing's disease on GR 
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number. Many studies investigating GR number have been performed, on basis of the 
hypothesis that receptor down-regulation might be an additional form of negative feedback, 
protecting the cell against the continued signal elicited by ligand in cases ofhypercorticolism or 
other forms of GC excess. We found, however, a diminished ligand affinity rather than a 
receptor down-regulation in PBMLs from patients with endogenous Cushing's syndrome. This 
diminished ligand affinity of yet unknown cause might partially protect the cells from the high 
cortisol levels. Nevertheless, this protecting mechanism seems to be insufficient, because all 
patients showed clinical signs and sympoms of GC excess. 
Chapter 9 is a general discussion ofthe results described in Chapters 2-8. 
It is concluded that the studies described in Chapter 2-8 further clarified the role of the GR in 
the complex problem of differences in GC sensitivity in both the normal population and 
disease. 
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Glucocorticoiden (GCn) zijn steroid hormonen die naast androgenen en mineralocorticoiden 
geproduceerd worden door de bijnierschors. Cortisol, de belangrijkste glucocorticoid bij de 
mens, vervult vele belangrijke functies in het lichaam zoals de regulatie van de glucose 
huishouding, het behouden van de homeostase en in mind ere mate de regulatie van de water en 
zout huishouding. Daamaast is cortisol een krachtige regulator van de immuunrespons. Onder 
normale omstandigheden wordt de concentratie van het serum cortisol gereguleerd door de 
hypothalamus-hypoJ:yse-bijnier-as (HPA-as), waardoor een perfecte balans bestaat tussen de 
cortisol behoefte van het lichaam en de cortisol secretie door de bijnieren. 
Cortisol oefent zijn werking uit door zich speciliek te binden aan de glucocorticoid receptor 
(GR), een eiwit dat tot expressie komt in vrijwel aile cellen van het Iichaam. De GR is, evenals 
de receptoren voor andere steroid hormonen, zoals onder andere de geslachtshormonen, lid 
van de familie van intracellulaire ligand athankelijke transcriptie regulatoren. Deze eiwitten zijn 
zijn structured verwant en bevatten een aantal functionele domeinen, waaronder een N-
terminaal transactivatie domein, een centraal gelegen DNA-bindend domein, en een C-
terminaal hormoon bind end domein. De GR is in afWezigheid van hormoon in het cytoplasma 
aanwezig als onderdeel van een complex, dat naast het receptor eiwit onder meer bestaat uit 
"heat-shock" eiwitten, Binding van cortisol aan de receptor resulteert onder andere in 
dissociatie van dit complex, dimerisatie van hormoon gebonden receptoren en verplaatsing van 
dit hormoon-receptor complex naar de celkern. Het cortisol-GR complex is daar in staat zich 
te binden aan specilieke DNA gedeelten, de zogenaamde glucocorticoid respons elementen 
(GREs), die gelokaliseerd zijn in promotor gebieden van doe/wit genen. Via deze DNA binding 
en interactie met andere eiwitten in de celkern reguleert het cortisol-GRcomplex de modulatie 
van de expressie van deze genen, 
Het is bekend uit k1inische observaties dat er binnen patienten groepen die worden behandeld 
met GCn in verband met zeer uiteen/opende aandoeningen, er een aanzien/ijke variatie bestaat 
in de gevoeligheid voor deze middelen. In extreme gevallen kunnen deze verschillen in 
gevoeligheid zelfs leiden tot op zichzelf staande ziektebeelden, zoals het syndoom van de 
gegeneraliseerde cortisol resistentie (CR), of het cortisol hypersensitiviteit syndroom. CR is 
een zeldzaam ziektebeeld dat wordt gekenmerkt door een gegeneraliseerde verminderde 
gevoeligheid voor cortisol, hetgeen gecompenseerd wordt door een hogere cortisol produktie 
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door de bijnieren len gevolge van een hogere activiteit van de HP A-as. In aUe gevaUen van CR 
die tot nu toe in de Iiteratuur beschreven zijn, bleek de verminderde gevoeligheid voor cortisol 
te berusten op mutaties in het hormoon bindende domein van de GR. 
Dit proefschrift beschrijft een aantal studies over de verschillen in gevoeligheid voor cortisol 
zoals die gezien worden binnen de normale populatie. Daarnaast wordt aandacht besteed aan 
sensitiviteits verschiUen voor GCn in bepaalde zieklebeelden. Hierbij wordt met name 
onderzocht welke rol de GR speelt in het ontstaan van deze verschillen in gevoeligheid. 
Hoofd.luk 1 is een algemene inIeiding over de synthese, secretie en werking van GCn. Omdat 
de GR een centrale rol speelt in dit proefschrift, wordt een uitgebreide beschrijving gegeven 
van de structuur, de functie en hel werkingsmechanisme van de GR. Tenslotte worden een 
aantal aspecten van de variabiliteit in GC gevoeligheid beschreven, zowel binnen de normale 
populatie als bij bepaalde zieklebeelden. 
Hoofdsluk 2 van dit proefschrift beschrijft een studie naar de variatie in gevoeligheid voor 
GCn binnen de normale oudere bevolking. In een groep van 216 gezonde proetjJersonen van 
55 jaar en ouder werden, met een inlerval van 2.5 jaar twee dexamethason (DEX) suppressie 
testen (DST) verricht, met respectievelijk 1.00 en 0.25 mg DEX. Er bleek een aanzienlijke 
variabilileit te bestaan in de basale serum cortisol concentraties van de verschillende 
proefpersonen. Er was echter een duidelijke stabiliteit te zien in serum cortisol concentraties 
binnen proetjJersonen over het interval van 2.5 jaar. Daarnaast bleek dat proetjJersonen mel de 
hoogste serum cortisol concentraties voor DEX, ook de hoogste cortisol concenlraties 
vertoonden na de toediening van 0.25 mg DEX. Dit duidt erop dat de HP A-as van een persoon 
is afgesteld op een individueel, stabiel "set point". 
Een andere conclusie uit dit hoofdstuk is dat een DST waarbij gebruik gemaakl wordt van 1.00 
mg DEX geen goede lesl is voor het aanlonen van verschiUen in gevoeligheid voor GCn 
binnen de nonnale populatie; 96% van aUe proefpersonen vertoonde een bijna totale 
onderdrukking van de HPA-as. Een dosering van 0.25 mg DEX loonde een veel grotere 
spreiding in post-DEX cortisol concentraties, omdat bij deze dosering de HPA-as niet voUedig 
onderdrukt blijkt te worden. Deze test is dan ook te prefereren voor het detecteren van 
verschiUen in cortisol gevoeligheid binnen de normale populatie, met name indien een 
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verhoogde gevoeligheid verwacht wordt. 
Hoofd,tuk 3 be,chrijf\ de screening op mutaties in het gen dat codeert voor de GR in een deel· 
van de populatie zoals die werd beschreven in hoofdstuk 2. Bij deze screening, waarbij gebruik 
werd gemaakt van PCRlSSCP-analyse, werden binnen de normale populatie vijf verschillende 
polymorphismen aangetoond in het GR gen. Echter, geen van deze polymorphismen bleek te 
zijn geassocieerd met een klinische of biochemische CR Wei kon worden aangetoond dat Mn 
van de polymorphismen, veroorzaakt door een puntmutatie op eDNA positie 1220, resulterend 
in een A naar G verandering in codon 363 (N363S), geassocieerd lijkt met een verhoogde 
gevoeligheid voor Gen. Derhalve werd de gehele groep van 216 proefjJersonen gescreend op 
het bestaan van dit polymorphisme. Bij 13 mensen uit de groep (6%) werd de mutatie 
gevonden. 
In Hoofd,tuk 4 wordt beschreven dat personen die drager zijll van deze mutatie een 
verhoogde gevoeligheid voor GCn lijken te bezitten. Dit geldt zowel voor de korte termijn 
effecten van exogeen toegediende Gen (waardoor een toegenomen cortisol suppressie en 
insuline respons), als voor de lange tennijn effecten van endogeen cortisol (hogere body mass 
index, lagere bot mineraal dichtheid). Echter, deze verhoogde gevoeligheid kon il1 vitro, 
waarbij gebruik werd gemaakt van transfectie studies in COS-I cellen, niet worden 
aangetoond. Een mogelijke verklaring hiervoor is dat in COS-I cellen de transcriptie factoren 
ontbreken die voor het effect van de N363S mutatie il1 vivo verantwoordelijk zijn, of dat de 
aanwezigheid van endogeen GR in de cellen het onmogelijk maakt subtiele effecten van de 
mutatie aan te tonen. Een andere verklaring kan zijn dat de N363S mutatie geassocieerd is met 
een andere, nog niet gedetermineerde genetische verandering. Nader onderzoek zal in de 
toekomst moeten aantonen of de N363S mutatie in verband gebracht kan worden met het 
ontstaan van snel optredende enlof ernstige bijwerkingen van Ge therapie. 
De afgelopen jaren is een aantal publicaties verschenen over mogelijke afwijkingen in de GR bij 
patienten die gezien worden op de polikliniek endocrinologie met een hypokaliemie, een 
hypertensie, klachten van acne, hirsutisme en menstruatie stoornissen. Daarom weed bij een 
aantal van deze patienten met klachten die zouden kunnen duiden op het bestaan van een 
mogelijke CR onderzoek verricht met betrekking tot het GR eiwit en het GR gen. 
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In Hoofdsluk 5 worden vijf patienten beschreven bij wie een klinisch beeld verdacht voor CR 
werd gezien, in combinatie mel afWijkingen in hel GR eiwil zoals bepaald bij bindingsstudies in 
perifere mononucleaire leukocyten. Bij twee van de patienten werd een verminderde ligand 
binding gevonden. Leukocyten van een andere patient toonden slechls de helft van het normale 
aanlal GRn. De leukocyten van de twee laatste patienlen loonden een onvermogen tot inhibitie 
van mitogeen gernduceerde eel proliferatie in een in vitro bioassay. Daarnaast vertoonden aile 
patienlen een verminderde suppressie van cortisol in een I mg DST. Echter, bij analyse van het 
GR gen met behulp van PCR/SSCP/sequentie analyse kon bij geen van deze patienten een 
afWijking worden aangetoond. Daarom zal bij volgend onderzoek bekeken worden of er 
afWijkingen zijn op RNA niveau. 
In Hoofdsluk 6 wordt de casus beschreven van een patient die zich aanvankelijk presenteerde 
met een zeer ernstige hypokalientie en hypertensie, hetgeen bleek te berusten op CR. Tijdens 
behandeling voor CR met hoge doseringen GCn ontwikkelde hij de ziekte van Cushing. 
Analyse van het GR gen van deze patient toonde een punt mutatie (T naar A) in exon 5 op 
cDNA positie 1808. Deze verandering is verantwoordelijk voor de vervanging van het neutrale 
en hydrofobe aminozuur isoleucine door het neutrale en polaire asparagine in codon 559, aan 
het begin van het hormoon bindende domein van de GR. Met behulp van sequentie analyse van 
het cDNA uit Iymphoblasten en fibroblasten van de patient konden zowel het wild typeals de 
gemuteerde receptor worden aangetoond. Nadere ill vitro analyse met co-transfectie studies 
bracht een dominant negatief effeci van de gemuteerde receptor op het wild type receptor aan 
het licht, hetgeen een goede verklaring kan zijn voor het zeer ernstige klinische beeld van de 
patient. 
Hoofdsluk 7 beschrijft een studie naar de rol die de GR speelt in de ziekte van Cushing. De 
casus zoals beschreven in hoofdstuk 6 heeft voor de eerste maal heeft aangetoond dat 
palienten met een gegeneraliseerde CR de ziekte van Cushing kunnen ontwikkelen. Daarnaast 
vertonen ACTH producerende hypolYse adenomen een sterke gelijkenis met CR voor wat 
betreft de verminderde gevoeligheid voor cortisol. De werkhypothese was derhalve dal 
mutaties in het GR gen in ACTH producerende hypolYse adenomen de oorzaak zouden kunnen 
zijn van de verntinderde gevoeligheid voor de negatieve feed back van cortisol in deze 
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tumoren, Het bleek echter dat somatische mutaties niet de oorzaak zijn voor de CR van ACTH 
producerende hypofyse adenomen, In deze stu die werden tevens de polymorphismen, zoals 
beschreven in hoofdstuk 3, gebruikt als markers voor het optreden van "loss of 
heterozygosity" (LOR) in deze tumoren, Het werd duidelijk dat LOR ter plaatse van het GR 
gen een frequent voorkomend fenomeen is in ACTH producerende hypofyse adenomen, Dit in 
tegenstelling tot andere hypofyse tumoren die als controle preparaten werden gebruikt in deze 
studie, Er kan worden geconcludeerd dat het defect in de GR een mogelijke pathogenetische 
rol kan spelen in het ontstaan van deze tumoren, 
Hoofdstuk 8 beschrijft een studie naar het effect van hypercortisolisme op het GR aantal in 
perifere leukocyten bij patienten met een endogeen syndroom van Cushing, Er zijn reeds vele 
studies verricht naar GR aantal in geval van hypercortisolisme op basis van de hypothese dat 
receptor down regulatie een extra vorm van negatieve feedback kan bieden ter beschenning 
van de cel tegen de continue cortisol druk, Echter, deze studie heeft aangetoond dat in geval 
van hypercortisolisme in het syndroom van Cushing geen receptor down regulatie ontstaat, 
maar dat de affiniteit van de receptor voor het hornlOon aanzienlijk daalt, Het is mogelijk dat 
deze venninderde hormoon affiniteit, waarvan het mechanisme nog onduidelijk is, de eel een 
extra bescherollng tegen cortisol bied!. Als dit het geval zou zijn, dan zou dat bescherollngs 
mechanisme echter onvoldoende zijn, aangezien aile onderzochte patienten duidelijke k1inische 
symptomen van hypercortisolisme vertoonden, 
Hoofdstuk 9 tenslotte is de algemene discussie over wat in hoofdstukken 2-8 beschreven is, 
Concluderend wordt in dit proefschrift beschreven welke rol de GR speelt in de verschillen in 
gevoeligheid voor GCn zoals die gezien worden in de normale bevolking, in geval van cortisol 
resistentie en in het syndroom van Cushing, 
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Het is een goede gewoonte te benadrukken dat het schrijven van een proefschrift nooit een 
individuele zaak is maar het gevolg is van intensieve samenwerking. Tijdens het schrijven van 
dit boekje wist ik mij gesteund door velen, enkele van hen wil ik hier met name bedanken. 
Prof. dr S. W.J Lamberts, beste Steven, bedankt voor je enthousiasme, je creativiteit en het in 
mij gestelde vertouwen. Als ik even stuk zat hoefde ik maar een paar minuten met je te 
ovedeggen en ik kon er weer helemaal tegen aan. 
Prof. dr F.H. de Jong, beste Frank, dank voor je heldere analyses en opbouwende kritiek. Jij 
kortwiekte mijn wollige schrijfstijl, zonder jou was dit boekje minstens 300 pagina's dik 
geworden. 
Dr J. W. Koper, beste Jan WilIem, jou wil ik bedanken voor aUe tijd die je eraan hebt besteed 
een dokter te leren pipetteren, PCR-en, SSCP-en, en ga zo maar door. Daarnaast bedankt voor 
het delen van Bd-277, het razendsneUe bijschaven van mijn manuscripten, en aile gezeUigheid. 
Dr P. de Lange, beste Pieter, samen hebben we honderden gels gegoten, vele luchtbellen 
gevangen, en menig biertje gedronken. Bedankt voor een prima tijd op het lab. 
Prof. dr. H.A.P. Pols, beste Huib, als inspirator van ERGO legde je de basis voor een groot 
deel van het in dit boekje beschreven onderzoek. Hartelijk dank voor je interesse en het 
corrigeren van de manuscripten. 
Prof. dr D.E. Grobbee en Prof. dr H.C. Hoogsteden dank ik voor het kritisch doorlezen van 
mijn proefschrift. 
AIle overige collega's van het Hypotyse Lab, Leo Hofland, Marlijn Waaijers, Diana Mooy, 
Joke Zuyderwijk, Piet Uitterlinden, Joop Janssen, Elgin Lichtenauer en Peter van Koetsveld 
bedank ik voor de prettige samenwerking. Mijn collega's van het Steroid Lab wil ik danken 
voor het bepalen van de enorme hoeveelheid cortisolen. Ook aile overige medewerkers van het 
lab Interne III; Bedankt voor de gezelligheidl 
Dr W. W. de Herder, beste Wouter, jij wist mij als eerste te interesseren voor harige vrouwen. 
Bedankt dat je me gei"ntroduceerd hebt bij de Interne III. 
Dr A.J. van der Lely, beste Aart Jan, ook ik heb ervan mogen profiteren dat jij zo goed met 
computers overweg kan. 
Drs P. van Biezen, lieve Paula, jij bent het beste wat een beginnende arts-assistent kan 
overkomen! Jij hebt mij doen realiseren dat ook bij wetenschappelijk onderzoek het welzijn 
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van de patient centraal behoort te staan. 
Mijn ouders wil ik bedanken voor 31 jaar onvoorwaardelijke lief de, zorg, toewijding, geduld 
en vertrouwen. Esther, Tip en Ellen, ik kan me geen betere zus, broer en schoonzus wensenl 
Mijn paranimfen Leontine van Campen en Anouk van Heeren dank ik voor hun jarenlange 
vriendschap. Jullie zorgden ervoor dat ik ook eens achter mijn computer vandaan kwam. Ook 
de rest van de Binnenweg en aile bijbehorende meubelstukken; Bedankt voor vele Goede 
Tijdenl 
Andre den Hartog, bedankt voor het schilderen van de voorkant van dit boekje. 
Tenslotte ik wil Pim bedanken. Lieve Pim, zonder jou was het ook best gelukt, maar met jou 
was het een stuk leuker. 
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